#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Similarities and differences of functional connectivity in drug-naïve, first-episode adolescent and young adult with major depressive disorder and schizophrenia
#Text=Major depressive disorder (MDD) and schizophrenia (SZ) are considered two distinct psychiatric disorders.
1-1	0-12	Similarities	_
1-2	13-16	and	_
1-3	17-28	differences	_
1-4	29-31	of	_
1-5	32-42	functional	_
1-6	43-55	connectivity	_
1-7	56-58	in	_
1-8	59-69	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
1-9	69-70	,	_
1-10	71-84	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-11	85-95	adolescent	_
1-12	96-99	and	_
1-13	100-105	young	_
1-14	106-111	adult	_
1-15	112-116	with	_
1-16	117-122	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[1]
1-17	123-133	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[1]
1-18	134-142	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[1]
1-19	143-146	and	_
1-20	147-160	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-21	161-166	Major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
1-22	167-177	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
1-23	178-186	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]
1-24	187-188	(	_
1-25	188-191	MDD	_
1-26	191-192	)	_
1-27	193-196	and	_
1-28	197-210	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-29	211-212	(	_
1-30	212-214	SZ	_
1-31	214-215	)	_
1-32	216-219	are	_
1-33	220-230	considered	_
1-34	231-234	two	_
1-35	235-243	distinct	_
1-36	244-255	psychiatric	_
1-37	256-265	disorders	_
1-38	265-266	.	_

#Text=Yet, they have considerable overlap in symptomatology and clinical features, particularly in the initial phases of illness.
2-1	267-270	Yet	_
2-2	270-271	,	_
2-3	272-276	they	_
2-4	277-281	have	_
2-5	282-294	considerable	_
2-6	295-302	overlap	_
2-7	303-305	in	_
2-8	306-320	symptomatology	_
2-9	321-324	and	_
2-10	325-333	clinical	_
2-11	334-342	features	_
2-12	342-343	,	_
2-13	344-356	particularly	_
2-14	357-359	in	_
2-15	360-363	the	_
2-16	364-371	initial	_
2-17	372-378	phases	_
2-18	379-381	of	_
2-19	382-389	illness	_
2-20	389-390	.	_

#Text=The amygdala and prefrontal cortex (PFC) appear to have critical roles in these disorders; however, abnormalities appear to manifest differently.
3-1	391-394	The	_
3-2	395-403	amygdala	_
3-3	404-407	and	_
3-4	408-418	prefrontal	_
3-5	419-425	cortex	_
3-6	426-427	(	_
3-7	427-430	PFC	_
3-8	430-431	)	_
3-9	432-438	appear	_
3-10	439-441	to	_
3-11	442-446	have	_
3-12	447-455	critical	_
3-13	456-461	roles	_
3-14	462-464	in	_
3-15	465-470	these	_
3-16	471-480	disorders	_
3-17	480-481	;	_
3-18	482-489	however	_
3-19	489-490	,	_
3-20	491-504	abnormalities	_
3-21	505-511	appear	_
3-22	512-514	to	_
3-23	515-523	manifest	_
3-24	524-535	differently	_
3-25	535-536	.	_

#Text=In our study forty-nine drug-naïve, first-episode MDD, 45 drug-naïve, first-episode SZ, and 50 healthy control (HC) participants from 13 to 30 years old underwent resting-state functional magnetic resonance imaging.
4-1	537-539	In	_
4-2	540-543	our	_
4-3	544-549	study	_
4-4	550-560	forty-nine	_
4-5	561-571	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[3]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[4]
4-6	571-572	,	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[3]
4-7	573-586	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[3]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[5]
4-8	587-590	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[3]
4-9	590-591	,	_
4-10	592-594	45	_
4-11	595-605	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[7]
4-12	605-606	,	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
4-13	607-620	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[8]
4-14	621-623	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]
4-15	623-624	,	_
4-16	625-628	and	_
4-17	629-631	50	_
4-18	632-639	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
4-19	640-647	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
4-20	648-649	(	_
4-21	649-651	HC	_
4-22	651-652	)	_
4-23	653-665	participants	_
4-24	666-670	from	_
4-25	671-673	13	_
4-26	674-676	to	_
4-27	677-679	30	_
4-28	680-685	years	_
4-29	686-689	old	_
4-30	690-699	underwent	_
4-31	700-713	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]
4-32	714-724	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]
4-33	725-733	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]
4-34	734-743	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]
4-35	744-751	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]
4-36	751-752	.	_

#Text=Functional connectivity (FC) between the amygdala and PFC was compared among the three groups.
5-1	753-763	Functional	_
5-2	764-776	connectivity	_
5-3	777-778	(	_
5-4	778-780	FC	_
5-5	780-781	)	_
5-6	782-789	between	_
5-7	790-793	the	_
5-8	794-802	amygdala	_
5-9	803-806	and	_
5-10	807-810	PFC	_
5-11	811-814	was	_
5-12	815-823	compared	_
5-13	824-829	among	_
5-14	830-833	the	_
5-15	834-839	three	_
5-16	840-846	groups	_
5-17	846-847	.	_

#Text=Significant differences in FC were observed between the amygdala and ventral PFC (VPFC), dorsolateral PFC (DLPFC), and dorsal anterior cingulated cortex (dACC) among the three groups.
6-1	848-859	Significant	_
6-2	860-871	differences	_
6-3	872-874	in	_
6-4	875-877	FC	_
6-5	878-882	were	_
6-6	883-891	observed	_
6-7	892-899	between	_
6-8	900-903	the	_
6-9	904-912	amygdala	_
6-10	913-916	and	_
6-11	917-924	ventral	_
6-12	925-928	PFC	_
6-13	929-930	(	_
6-14	930-934	VPFC	_
6-15	934-935	)	_
6-16	935-936	,	_
6-17	937-949	dorsolateral	_
6-18	950-953	PFC	_
6-19	954-955	(	_
6-20	955-960	DLPFC	_
6-21	960-961	)	_
6-22	961-962	,	_
6-23	963-966	and	_
6-24	967-973	dorsal	_
6-25	974-982	anterior	_
6-26	983-993	cingulated	_
6-27	994-1000	cortex	_
6-28	1001-1002	(	_
6-29	1002-1006	dACC	_
6-30	1006-1007	)	_
6-31	1008-1013	among	_
6-32	1014-1017	the	_
6-33	1018-1023	three	_
6-34	1024-1030	groups	_
6-35	1030-1031	.	_

#Text=Further analyses demonstrated that MDD showed decreased amygdala-VPFC FC and SZ had reductions in amygdala-dACC FC.
7-1	1032-1039	Further	_
7-2	1040-1048	analyses	_
7-3	1049-1061	demonstrated	_
7-4	1062-1066	that	_
7-5	1067-1070	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
7-6	1071-1077	showed	_
7-7	1078-1087	decreased	_
7-8	1088-1101	amygdala-VPFC	_
7-9	1102-1104	FC	_
7-10	1105-1108	and	_
7-11	1109-1111	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-12	1112-1115	had	_
7-13	1116-1126	reductions	_
7-14	1127-1129	in	_
7-15	1130-1143	amygdala-dACC	_
7-16	1144-1146	FC	_
7-17	1146-1147	.	_

#Text=Both the diagnostic groups had significantly decreased amygdala-DLPFC FC.
8-1	1148-1152	Both	_
8-2	1153-1156	the	_
8-3	1157-1167	diagnostic	_
8-4	1168-1174	groups	_
8-5	1175-1178	had	_
8-6	1179-1192	significantly	_
8-7	1193-1202	decreased	_
8-8	1203-1217	amygdala-DLPFC	_
8-9	1218-1220	FC	_
8-10	1220-1221	.	_

#Text=These indicate abnormalities in amygdala-PFC FC and further support the importance of the interaction between the amygdala and PFC in adolescents and young adults with these disorders.
9-1	1222-1227	These	_
9-2	1228-1236	indicate	_
9-3	1237-1250	abnormalities	_
9-4	1251-1253	in	_
9-5	1254-1266	amygdala-PFC	_
9-6	1267-1269	FC	_
9-7	1270-1273	and	_
9-8	1274-1281	further	_
9-9	1282-1289	support	_
9-10	1290-1293	the	_
9-11	1294-1304	importance	_
9-12	1305-1307	of	_
9-13	1308-1311	the	_
9-14	1312-1323	interaction	_
9-15	1324-1331	between	_
9-16	1332-1335	the	_
9-17	1336-1344	amygdala	_
9-18	1345-1348	and	_
9-19	1349-1352	PFC	_
9-20	1353-1355	in	_
9-21	1356-1367	adolescents	_
9-22	1368-1371	and	_
9-23	1372-1377	young	_
9-24	1378-1384	adults	_
9-25	1385-1389	with	_
9-26	1390-1395	these	_
9-27	1396-1405	disorders	_
9-28	1405-1406	.	_

#Text=Additionally, the alterations in amygdala-PFC FC may underlie the initial similarities observed between MDD and SZ and suggest potential markers of differentiation between the disorders at first onset.
10-1	1407-1419	Additionally	_
10-2	1419-1420	,	_
10-3	1421-1424	the	_
10-4	1425-1436	alterations	_
10-5	1437-1439	in	_
10-6	1440-1452	amygdala-PFC	_
10-7	1453-1455	FC	_
10-8	1456-1459	may	_
10-9	1460-1468	underlie	_
10-10	1469-1472	the	_
10-11	1473-1480	initial	_
10-12	1481-1493	similarities	_
10-13	1494-1502	observed	_
10-14	1503-1510	between	_
10-15	1511-1514	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
10-16	1515-1518	and	_
10-17	1519-1521	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-18	1522-1525	and	_
10-19	1526-1533	suggest	_
10-20	1534-1543	potential	_
10-21	1544-1551	markers	_
10-22	1552-1554	of	_
10-23	1555-1570	differentiation	_
10-24	1571-1578	between	_
10-25	1579-1582	the	_
10-26	1583-1592	disorders	_
10-27	1593-1595	at	_
10-28	1596-1601	first	_
10-29	1602-1607	onset	_
10-30	1607-1608	.	_

#Text=Psychiatric diagnosis is challenging, particularly during the initial phases of illness.
11-1	1609-1620	Psychiatric	_
11-2	1621-1630	diagnosis	_
11-3	1631-1633	is	_
11-4	1634-1645	challenging	_
11-5	1645-1646	,	_
11-6	1647-1659	particularly	_
11-7	1660-1666	during	_
11-8	1667-1670	the	_
11-9	1671-1678	initial	_
11-10	1679-1685	phases	_
11-11	1686-1688	of	_
11-12	1689-1696	illness	_
11-13	1696-1697	.	_

#Text=As a field, we still rely heavily on longitudinal observation for definitive diagnosis, often resulting in considerable delay in appropriate diagnosis and treatment.
12-1	1698-1700	As	_
12-2	1701-1702	a	_
12-3	1703-1708	field	_
12-4	1708-1709	,	_
12-5	1710-1712	we	_
12-6	1713-1718	still	_
12-7	1719-1723	rely	_
12-8	1724-1731	heavily	_
12-9	1732-1734	on	_
12-10	1735-1747	longitudinal	_
12-11	1748-1759	observation	_
12-12	1760-1763	for	_
12-13	1764-1774	definitive	_
12-14	1775-1784	diagnosis	_
12-15	1784-1785	,	_
12-16	1786-1791	often	_
12-17	1792-1801	resulting	_
12-18	1802-1804	in	_
12-19	1805-1817	considerable	_
12-20	1818-1823	delay	_
12-21	1824-1826	in	_
12-22	1827-1838	appropriate	_
12-23	1839-1848	diagnosis	_
12-24	1849-1852	and	_
12-25	1853-1862	treatment	_
12-26	1862-1863	.	_

#Text=With converging evidence of significant neural abnormalities by the time of illness onset, early identification and intervention is increasingly critical in efforts to substantially alter the trajectory of psychiatric illnesses such as schizophrenia (SZ) and major depressive disorder (MDD).
13-1	1864-1868	With	_
13-2	1869-1879	converging	_
13-3	1880-1888	evidence	_
13-4	1889-1891	of	_
13-5	1892-1903	significant	_
13-6	1904-1910	neural	_
13-7	1911-1924	abnormalities	_
13-8	1925-1927	by	_
13-9	1928-1931	the	_
13-10	1932-1936	time	_
13-11	1937-1939	of	_
13-12	1940-1947	illness	_
13-13	1948-1953	onset	_
13-14	1953-1954	,	_
13-15	1955-1960	early	_
13-16	1961-1975	identification	_
13-17	1976-1979	and	_
13-18	1980-1992	intervention	_
13-19	1993-1995	is	_
13-20	1996-2008	increasingly	_
13-21	2009-2017	critical	_
13-22	2018-2020	in	_
13-23	2021-2028	efforts	_
13-24	2029-2031	to	_
13-25	2032-2045	substantially	_
13-26	2046-2051	alter	_
13-27	2052-2055	the	_
13-28	2056-2066	trajectory	_
13-29	2067-2069	of	_
13-30	2070-2081	psychiatric	_
13-31	2082-2091	illnesses	_
13-32	2092-2096	such	_
13-33	2097-2099	as	_
13-34	2100-2113	schizophrenia	_
13-35	2114-2115	(	_
13-36	2115-2117	SZ	_
13-37	2117-2118	)	_
13-38	2119-2122	and	_
13-39	2123-2128	major	_
13-40	2129-2139	depressive	_
13-41	2140-2148	disorder	_
13-42	2149-2150	(	_
13-43	2150-2153	MDD	_
13-44	2153-2154	)	_
13-45	2154-2155	.	_

#Text=MDD and SZ are severely disabling psychiatric disorders that have long been conceptualized as two distinct illnesses.
14-1	2156-2159	MDD	_
14-2	2160-2163	and	_
14-3	2164-2166	SZ	_
14-4	2167-2170	are	_
14-5	2171-2179	severely	_
14-6	2180-2189	disabling	_
14-7	2190-2201	psychiatric	_
14-8	2202-2211	disorders	_
14-9	2212-2216	that	_
14-10	2217-2221	have	_
14-11	2222-2226	long	_
14-12	2227-2231	been	_
14-13	2232-2246	conceptualized	_
14-14	2247-2249	as	_
14-15	2250-2253	two	_
14-16	2254-2262	distinct	_
14-17	2263-2272	illnesses	_
14-18	2272-2273	.	_

#Text=However, MDD and SZ have considerable overlap in behavioral manifestations and impairments in emotional processing and cognitive functioning, particularly during their initial phases.
15-1	2274-2281	However	_
15-2	2281-2282	,	_
15-3	2283-2286	MDD	_
15-4	2287-2290	and	_
15-5	2291-2293	SZ	_
15-6	2294-2298	have	_
15-7	2299-2311	considerable	_
15-8	2312-2319	overlap	_
15-9	2320-2322	in	_
15-10	2323-2333	behavioral	_
15-11	2334-2348	manifestations	_
15-12	2349-2352	and	_
15-13	2353-2364	impairments	_
15-14	2365-2367	in	_
15-15	2368-2377	emotional	_
15-16	2378-2388	processing	_
15-17	2389-2392	and	_
15-18	2393-2402	cognitive	_
15-19	2403-2414	functioning	_
15-20	2414-2415	,	_
15-21	2416-2428	particularly	_
15-22	2429-2435	during	_
15-23	2436-2441	their	_
15-24	2442-2449	initial	_
15-25	2450-2456	phases	_
15-26	2456-2457	.	_

#Text=Frequently, prodromal SZ resembles a major depressive episode and psychotic symptoms are present in first episode MDD, complicating differentiation between the two disorders at initial onset.
16-1	2458-2468	Frequently	_
16-2	2468-2469	,	_
16-3	2470-2479	prodromal	_
16-4	2480-2482	SZ	_
16-5	2483-2492	resembles	_
16-6	2493-2494	a	_
16-7	2495-2500	major	_
16-8	2501-2511	depressive	_
16-9	2512-2519	episode	_
16-10	2520-2523	and	_
16-11	2524-2533	psychotic	_
16-12	2534-2542	symptoms	_
16-13	2543-2546	are	_
16-14	2547-2554	present	_
16-15	2555-2557	in	_
16-16	2558-2563	first	_
16-17	2564-2571	episode	_
16-18	2572-2575	MDD	_
16-19	2575-2576	,	_
16-20	2577-2589	complicating	_
16-21	2590-2605	differentiation	_
16-22	2606-2613	between	_
16-23	2614-2617	the	_
16-24	2618-2621	two	_
16-25	2622-2631	disorders	_
16-26	2632-2634	at	_
16-27	2635-2642	initial	_
16-28	2643-2648	onset	_
16-29	2648-2649	.	_

#Text=In first episode psychosis, significant negative symptoms, which traditionally has been viewed as hallmarks of SZ, have been observed in both SZ and MDD, as well as depressive symptoms in first episode SZ.
17-1	2650-2652	In	_
17-2	2653-2658	first	_
17-3	2659-2666	episode	_
17-4	2667-2676	psychosis	_
17-5	2676-2677	,	_
17-6	2678-2689	significant	_
17-7	2690-2698	negative	_
17-8	2699-2707	symptoms	_
17-9	2707-2708	,	_
17-10	2709-2714	which	_
17-11	2715-2728	traditionally	_
17-12	2729-2732	has	_
17-13	2733-2737	been	_
17-14	2738-2744	viewed	_
17-15	2745-2747	as	_
17-16	2748-2757	hallmarks	_
17-17	2758-2760	of	_
17-18	2761-2763	SZ	_
17-19	2763-2764	,	_
17-20	2765-2769	have	_
17-21	2770-2774	been	_
17-22	2775-2783	observed	_
17-23	2784-2786	in	_
17-24	2787-2791	both	_
17-25	2792-2794	SZ	_
17-26	2795-2798	and	_
17-27	2799-2802	MDD	_
17-28	2802-2803	,	_
17-29	2804-2806	as	_
17-30	2807-2811	well	_
17-31	2812-2814	as	_
17-32	2815-2825	depressive	_
17-33	2826-2834	symptoms	_
17-34	2835-2837	in	_
17-35	2838-2843	first	_
17-36	2844-2851	episode	_
17-37	2852-2854	SZ	_
17-38	2854-2855	.	_

#Text=These overlaps in presentation at initial onset challenge effective treatment interventions during the early course of these disorders and ultimately the potential for marked improvement in clinical outcomes.
18-1	2856-2861	These	_
18-2	2862-2870	overlaps	_
18-3	2871-2873	in	_
18-4	2874-2886	presentation	_
18-5	2887-2889	at	_
18-6	2890-2897	initial	_
18-7	2898-2903	onset	_
18-8	2904-2913	challenge	_
18-9	2914-2923	effective	_
18-10	2924-2933	treatment	_
18-11	2934-2947	interventions	_
18-12	2948-2954	during	_
18-13	2955-2958	the	_
18-14	2959-2964	early	_
18-15	2965-2971	course	_
18-16	2972-2974	of	_
18-17	2975-2980	these	_
18-18	2981-2990	disorders	_
18-19	2991-2994	and	_
18-20	2995-3005	ultimately	_
18-21	3006-3009	the	_
18-22	3010-3019	potential	_
18-23	3020-3023	for	_
18-24	3024-3030	marked	_
18-25	3031-3042	improvement	_
18-26	3043-3045	in	_
18-27	3046-3054	clinical	_
18-28	3055-3063	outcomes	_
18-29	3063-3064	.	_

#Text=Treatment approaches toward MDD and SZ differ in targets, pharmacologic agents, use of somatic therapy, and duration of treatment, and hence accurate diagnosis is important in determining appropriate treatment for individuals with these disorders.
19-1	3065-3074	Treatment	_
19-2	3075-3085	approaches	_
19-3	3086-3092	toward	_
19-4	3093-3096	MDD	_
19-5	3097-3100	and	_
19-6	3101-3103	SZ	_
19-7	3104-3110	differ	_
19-8	3111-3113	in	_
19-9	3114-3121	targets	_
19-10	3121-3122	,	_
19-11	3123-3136	pharmacologic	_
19-12	3137-3143	agents	_
19-13	3143-3144	,	_
19-14	3145-3148	use	_
19-15	3149-3151	of	_
19-16	3152-3159	somatic	_
19-17	3160-3167	therapy	_
19-18	3167-3168	,	_
19-19	3169-3172	and	_
19-20	3173-3181	duration	_
19-21	3182-3184	of	_
19-22	3185-3194	treatment	_
19-23	3194-3195	,	_
19-24	3196-3199	and	_
19-25	3200-3205	hence	_
19-26	3206-3214	accurate	_
19-27	3215-3224	diagnosis	_
19-28	3225-3227	is	_
19-29	3228-3237	important	_
19-30	3238-3240	in	_
19-31	3241-3252	determining	_
19-32	3253-3264	appropriate	_
19-33	3265-3274	treatment	_
19-34	3275-3278	for	_
19-35	3279-3290	individuals	_
19-36	3291-3295	with	_
19-37	3296-3301	these	_
19-38	3302-3311	disorders	_
19-39	3311-3312	.	_

#Text=Neural biomarkers could vastly improve differentiation between psychiatric disorders such as MDD and SZ, especially at first onset.
20-1	3313-3319	Neural	_
20-2	3320-3330	biomarkers	_
20-3	3331-3336	could	_
20-4	3337-3343	vastly	_
20-5	3344-3351	improve	_
20-6	3352-3367	differentiation	_
20-7	3368-3375	between	_
20-8	3376-3387	psychiatric	_
20-9	3388-3397	disorders	_
20-10	3398-3402	such	_
20-11	3403-3405	as	_
20-12	3406-3409	MDD	_
20-13	3410-3413	and	_
20-14	3414-3416	SZ	_
20-15	3416-3417	,	_
20-16	3418-3428	especially	_
20-17	3429-3431	at	_
20-18	3432-3437	first	_
20-19	3438-3443	onset	_
20-20	3443-3444	.	_

#Text=However studies comparing first-episode MDD and SZ are very limited.
21-1	3445-3452	However	_
21-2	3453-3460	studies	_
21-3	3461-3470	comparing	_
21-4	3471-3484	first-episode	_
21-5	3485-3488	MDD	_
21-6	3489-3492	and	_
21-7	3493-3495	SZ	_
21-8	3496-3499	are	_
21-9	3500-3504	very	_
21-10	3505-3512	limited	_
21-11	3512-3513	.	_

#Text=Recent reviews of the literature indicate similar and different expression of structural and functional brain abnormalities in MDD and SZ.
22-1	3514-3520	Recent	_
22-2	3521-3528	reviews	_
22-3	3529-3531	of	_
22-4	3532-3535	the	_
22-5	3536-3546	literature	_
22-6	3547-3555	indicate	_
22-7	3556-3563	similar	_
22-8	3564-3567	and	_
22-9	3568-3577	different	_
22-10	3578-3588	expression	_
22-11	3589-3591	of	_
22-12	3592-3602	structural	_
22-13	3603-3606	and	_
22-14	3607-3617	functional	_
22-15	3618-3623	brain	_
22-16	3624-3637	abnormalities	_
22-17	3638-3640	in	_
22-18	3641-3644	MDD	_
22-19	3645-3648	and	_
22-20	3649-3651	SZ	_
22-21	3651-3652	.	_

#Text=In particular, two key brain regions involved in emotional and cognitive processing, the amygdala and prefrontal cortex (PFC), have been strongly implicated in both MDD and SZ.
23-1	3653-3655	In	_
23-2	3656-3666	particular	_
23-3	3666-3667	,	_
23-4	3668-3671	two	_
23-5	3672-3675	key	_
23-6	3676-3681	brain	_
23-7	3682-3689	regions	_
23-8	3690-3698	involved	_
23-9	3699-3701	in	_
23-10	3702-3711	emotional	_
23-11	3712-3715	and	_
23-12	3716-3725	cognitive	_
23-13	3726-3736	processing	_
23-14	3736-3737	,	_
23-15	3738-3741	the	_
23-16	3742-3750	amygdala	_
23-17	3751-3754	and	_
23-18	3755-3765	prefrontal	_
23-19	3766-3772	cortex	_
23-20	3773-3774	(	_
23-21	3774-3777	PFC	_
23-22	3777-3778	)	_
23-23	3778-3779	,	_
23-24	3780-3784	have	_
23-25	3785-3789	been	_
23-26	3790-3798	strongly	_
23-27	3799-3809	implicated	_
23-28	3810-3812	in	_
23-29	3813-3817	both	_
23-30	3818-3821	MDD	_
23-31	3822-3825	and	_
23-32	3826-3828	SZ	_
23-33	3828-3829	.	_

#Text=[In this article, the PFC is defined as the dorsal lateral PFC (DLPFC), critically engaged in cognitive regulation of emotion and working memory task; the dorsal medial PFC including the dorsal anterior cingulated cortex (dACC) and its anterior section of frontal cortices– closely linked with conflict monitoring and reward processing and cognitive-motor functions; and the ventral PFC (VPFC) including the orbitofrontal cortex (OFC), the inferior and rostral frontal cortices, ventral and rostral components of the ACC, mainly associated with emotional and hedonic processing].
24-1	3830-3831	[	_
24-2	3831-3833	In	_
24-3	3834-3838	this	_
24-4	3839-3846	article	_
24-5	3846-3847	,	_
24-6	3848-3851	the	_
24-7	3852-3855	PFC	_
24-8	3856-3858	is	_
24-9	3859-3866	defined	_
24-10	3867-3869	as	_
24-11	3870-3873	the	_
24-12	3874-3880	dorsal	_
24-13	3881-3888	lateral	_
24-14	3889-3892	PFC	_
24-15	3893-3894	(	_
24-16	3894-3899	DLPFC	_
24-17	3899-3900	)	_
24-18	3900-3901	,	_
24-19	3902-3912	critically	_
24-20	3913-3920	engaged	_
24-21	3921-3923	in	_
24-22	3924-3933	cognitive	_
24-23	3934-3944	regulation	_
24-24	3945-3947	of	_
24-25	3948-3955	emotion	_
24-26	3956-3959	and	_
24-27	3960-3967	working	_
24-28	3968-3974	memory	_
24-29	3975-3979	task	_
24-30	3979-3980	;	_
24-31	3981-3984	the	_
24-32	3985-3991	dorsal	_
24-33	3992-3998	medial	_
24-34	3999-4002	PFC	_
24-35	4003-4012	including	_
24-36	4013-4016	the	_
24-37	4017-4023	dorsal	_
24-38	4024-4032	anterior	_
24-39	4033-4043	cingulated	_
24-40	4044-4050	cortex	_
24-41	4051-4052	(	_
24-42	4052-4056	dACC	_
24-43	4056-4057	)	_
24-44	4058-4061	and	_
24-45	4062-4065	its	_
24-46	4066-4074	anterior	_
24-47	4075-4082	section	_
24-48	4083-4085	of	_
24-49	4086-4093	frontal	_
24-50	4094-4102	cortices	_
24-51	4102-4103	–	_
24-52	4104-4111	closely	_
24-53	4112-4118	linked	_
24-54	4119-4123	with	_
24-55	4124-4132	conflict	_
24-56	4133-4143	monitoring	_
24-57	4144-4147	and	_
24-58	4148-4154	reward	_
24-59	4155-4165	processing	_
24-60	4166-4169	and	_
24-61	4170-4185	cognitive-motor	_
24-62	4186-4195	functions	_
24-63	4195-4196	;	_
24-64	4197-4200	and	_
24-65	4201-4204	the	_
24-66	4205-4212	ventral	_
24-67	4213-4216	PFC	_
24-68	4217-4218	(	_
24-69	4218-4222	VPFC	_
24-70	4222-4223	)	_
24-71	4224-4233	including	_
24-72	4234-4237	the	_
24-73	4238-4251	orbitofrontal	_
24-74	4252-4258	cortex	_
24-75	4259-4260	(	_
24-76	4260-4263	OFC	_
24-77	4263-4264	)	_
24-78	4264-4265	,	_
24-79	4266-4269	the	_
24-80	4270-4278	inferior	_
24-81	4279-4282	and	_
24-82	4283-4290	rostral	_
24-83	4291-4298	frontal	_
24-84	4299-4307	cortices	_
24-85	4307-4308	,	_
24-86	4309-4316	ventral	_
24-87	4317-4320	and	_
24-88	4321-4328	rostral	_
24-89	4329-4339	components	_
24-90	4340-4342	of	_
24-91	4343-4346	the	_
24-92	4347-4350	ACC	_
24-93	4350-4351	,	_
24-94	4352-4358	mainly	_
24-95	4359-4369	associated	_
24-96	4370-4374	with	_
24-97	4375-4384	emotional	_
24-98	4385-4388	and	_
24-99	4389-4396	hedonic	_
24-100	4397-4407	processing	_
24-101	4407-4408	]	_
24-102	4408-4409	.	_

#Text=Postmortem histological studies indicated volume/cell munbers, levels of neurotransmitter receptors and gene expression in both the amygdala and PFC in MDD and SZ.
25-1	4410-4420	Postmortem	_
25-2	4421-4433	histological	_
25-3	4434-4441	studies	_
25-4	4442-4451	indicated	_
25-5	4452-4458	volume	_
25-6	4458-4459	/	_
25-7	4459-4463	cell	_
25-8	4464-4471	munbers	_
25-9	4471-4472	,	_
25-10	4473-4479	levels	_
25-11	4480-4482	of	_
25-12	4483-4499	neurotransmitter	_
25-13	4500-4509	receptors	_
25-14	4510-4513	and	_
25-15	4514-4518	gene	_
25-16	4519-4529	expression	_
25-17	4530-4532	in	_
25-18	4533-4537	both	_
25-19	4538-4541	the	_
25-20	4542-4550	amygdala	_
25-21	4551-4554	and	_
25-22	4555-4558	PFC	_
25-23	4559-4561	in	_
25-24	4562-4565	MDD	_
25-25	4566-4569	and	_
25-26	4570-4572	SZ	_
25-27	4572-4573	.	_

#Text=Structural and functional magnetic resonance imaging (MRI) studies demonstrate amygdala abnormalities in MDD and SZ with respect to size, density and activation.
26-1	4574-4584	Structural	_
26-2	4585-4588	and	_
26-3	4589-4599	functional	_
26-4	4600-4608	magnetic	_
26-5	4609-4618	resonance	_
26-6	4619-4626	imaging	_
26-7	4627-4628	(	_
26-8	4628-4631	MRI	_
26-9	4631-4632	)	_
26-10	4633-4640	studies	_
26-11	4641-4652	demonstrate	_
26-12	4653-4661	amygdala	_
26-13	4662-4675	abnormalities	_
26-14	4676-4678	in	_
26-15	4679-4682	MDD	_
26-16	4683-4686	and	_
26-17	4687-4689	SZ	_
26-18	4690-4694	with	_
26-19	4695-4702	respect	_
26-20	4703-4705	to	_
26-21	4706-4710	size	_
26-22	4710-4711	,	_
26-23	4712-4719	density	_
26-24	4720-4723	and	_
26-25	4724-4734	activation	_
26-26	4734-4735	.	_

#Text=Previous structural MRI studies provided support MDD enlarged amygdala volume or reduced amygdala volume and decreased amygdala gray matter (GM) concentration and SZ reported decreased amygdala volume and GM density.
27-1	4736-4744	Previous	_
27-2	4745-4755	structural	_
27-3	4756-4759	MRI	_
27-4	4760-4767	studies	_
27-5	4768-4776	provided	_
27-6	4777-4784	support	_
27-7	4785-4788	MDD	_
27-8	4789-4797	enlarged	_
27-9	4798-4806	amygdala	_
27-10	4807-4813	volume	_
27-11	4814-4816	or	_
27-12	4817-4824	reduced	_
27-13	4825-4833	amygdala	_
27-14	4834-4840	volume	_
27-15	4841-4844	and	_
27-16	4845-4854	decreased	_
27-17	4855-4863	amygdala	_
27-18	4864-4868	gray	_
27-19	4869-4875	matter	_
27-20	4876-4877	(	_
27-21	4877-4879	GM	_
27-22	4879-4880	)	_
27-23	4881-4894	concentration	_
27-24	4895-4898	and	_
27-25	4899-4901	SZ	_
27-26	4902-4910	reported	_
27-27	4911-4920	decreased	_
27-28	4921-4929	amygdala	_
27-29	4930-4936	volume	_
27-30	4937-4940	and	_
27-31	4941-4943	GM	_
27-32	4944-4951	density	_
27-33	4951-4952	.	_

#Text=Functional MRI MDD demonstrated increased activation in the amygdala and SZ altered functional activation in amygdala.
28-1	4953-4963	Functional	_
28-2	4964-4967	MRI	_
28-3	4968-4971	MDD	_
28-4	4972-4984	demonstrated	_
28-5	4985-4994	increased	_
28-6	4995-5005	activation	_
28-7	5006-5008	in	_
28-8	5009-5012	the	_
28-9	5013-5021	amygdala	_
28-10	5022-5025	and	_
28-11	5026-5028	SZ	_
28-12	5029-5036	altered	_
28-13	5037-5047	functional	_
28-14	5048-5058	activation	_
28-15	5059-5061	in	_
28-16	5062-5070	amygdala	_
28-17	5070-5071	.	_

#Text=Most interestingly, in the PFC, MDD and SZ appear to have some differential involvement of PFC subregions based on other MRI studies.
29-1	5072-5076	Most	_
29-2	5077-5090	interestingly	_
29-3	5090-5091	,	_
29-4	5092-5094	in	_
29-5	5095-5098	the	_
29-6	5099-5102	PFC	_
29-7	5102-5103	,	_
29-8	5104-5107	MDD	_
29-9	5108-5111	and	_
29-10	5112-5114	SZ	_
29-11	5115-5121	appear	_
29-12	5122-5124	to	_
29-13	5125-5129	have	_
29-14	5130-5134	some	_
29-15	5135-5147	differential	_
29-16	5148-5159	involvement	_
29-17	5160-5162	of	_
29-18	5163-5166	PFC	_
29-19	5167-5177	subregions	_
29-20	5178-5183	based	_
29-21	5184-5186	on	_
29-22	5187-5192	other	_
29-23	5193-5196	MRI	_
29-24	5197-5204	studies	_
29-25	5204-5205	.	_

#Text=Morphological and functional alterations have been shown primarily in the DLPFC and VPFC in MDD, though dACC deficits have also been observed, whereas the majority of the MRI studies report abnormalities in the DLPFC and dACC in SZ, as well as the dorsomedial PFC (DMPFC).
30-1	5206-5219	Morphological	_
30-2	5220-5223	and	_
30-3	5224-5234	functional	_
30-4	5235-5246	alterations	_
30-5	5247-5251	have	_
30-6	5252-5256	been	_
30-7	5257-5262	shown	_
30-8	5263-5272	primarily	_
30-9	5273-5275	in	_
30-10	5276-5279	the	_
30-11	5280-5285	DLPFC	_
30-12	5286-5289	and	_
30-13	5290-5294	VPFC	_
30-14	5295-5297	in	_
30-15	5298-5301	MDD	_
30-16	5301-5302	,	_
30-17	5303-5309	though	_
30-18	5310-5314	dACC	_
30-19	5315-5323	deficits	_
30-20	5324-5328	have	_
30-21	5329-5333	also	_
30-22	5334-5338	been	_
30-23	5339-5347	observed	_
30-24	5347-5348	,	_
30-25	5349-5356	whereas	_
30-26	5357-5360	the	_
30-27	5361-5369	majority	_
30-28	5370-5372	of	_
30-29	5373-5376	the	_
30-30	5377-5380	MRI	_
30-31	5381-5388	studies	_
30-32	5389-5395	report	_
30-33	5396-5409	abnormalities	_
30-34	5410-5412	in	_
30-35	5413-5416	the	_
30-36	5417-5422	DLPFC	_
30-37	5423-5426	and	_
30-38	5427-5431	dACC	_
30-39	5432-5434	in	_
30-40	5435-5437	SZ	_
30-41	5437-5438	,	_
30-42	5439-5441	as	_
30-43	5442-5446	well	_
30-44	5447-5449	as	_
30-45	5450-5453	the	_
30-46	5454-5465	dorsomedial	_
30-47	5466-5469	PFC	_
30-48	5470-5471	(	_
30-49	5471-5476	DMPFC	_
30-50	5476-5477	)	_
30-51	5477-5478	.	_

#Text=Connectivity studies have found abnormalities in PFC-amygdala functional connectivity (FC) in both MDD and SZ, including altered FC between the DLPFC and amygdala and the VPFC and amygdala in MDD, and abnormalities in DLPFC-amygdala FC in SZ.
31-1	5479-5491	Connectivity	_
31-2	5492-5499	studies	_
31-3	5500-5504	have	_
31-4	5505-5510	found	_
31-5	5511-5524	abnormalities	_
31-6	5525-5527	in	_
31-7	5528-5540	PFC-amygdala	_
31-8	5541-5551	functional	_
31-9	5552-5564	connectivity	_
31-10	5565-5566	(	_
31-11	5566-5568	FC	_
31-12	5568-5569	)	_
31-13	5570-5572	in	_
31-14	5573-5577	both	_
31-15	5578-5581	MDD	_
31-16	5582-5585	and	_
31-17	5586-5588	SZ	_
31-18	5588-5589	,	_
31-19	5590-5599	including	_
31-20	5600-5607	altered	_
31-21	5608-5610	FC	_
31-22	5611-5618	between	_
31-23	5619-5622	the	_
31-24	5623-5628	DLPFC	_
31-25	5629-5632	and	_
31-26	5633-5641	amygdala	_
31-27	5642-5645	and	_
31-28	5646-5649	the	_
31-29	5650-5654	VPFC	_
31-30	5655-5658	and	_
31-31	5659-5667	amygdala	_
31-32	5668-5670	in	_
31-33	5671-5674	MDD	_
31-34	5674-5675	,	_
31-35	5676-5679	and	_
31-36	5680-5693	abnormalities	_
31-37	5694-5696	in	_
31-38	5697-5711	DLPFC-amygdala	_
31-39	5712-5714	FC	_
31-40	5715-5717	in	_
31-41	5718-5720	SZ	_
31-42	5720-5721	.	_

#Text=We are not aware of any study directly comparing the resting-state FC (rsFC) between the amygdala and PFC in drug-naïve, first-episode MDD and SZ.
32-1	5722-5724	We	_
32-2	5725-5728	are	_
32-3	5729-5732	not	_
32-4	5733-5738	aware	_
32-5	5739-5741	of	_
32-6	5742-5745	any	_
32-7	5746-5751	study	_
32-8	5752-5760	directly	_
32-9	5761-5770	comparing	_
32-10	5771-5774	the	_
32-11	5775-5788	resting-state	_
32-12	5789-5791	FC	_
32-13	5792-5793	(	_
32-14	5793-5797	rsFC	_
32-15	5797-5798	)	_
32-16	5799-5806	between	_
32-17	5807-5810	the	_
32-18	5811-5819	amygdala	_
32-19	5820-5823	and	_
32-20	5824-5827	PFC	_
32-21	5828-5830	in	_
32-22	5831-5841	drug-naïve	_
32-23	5841-5842	,	_
32-24	5843-5856	first-episode	_
32-25	5857-5860	MDD	_
32-26	5861-5864	and	_
32-27	5865-5867	SZ	_
32-28	5867-5868	.	_

#Text=Studies of drug naïve, first episode populations minimize confounding factors of medication effects and illness chronicity in understanding the development of psychiatric disorders.
33-1	5869-5876	Studies	_
33-2	5877-5879	of	_
33-3	5880-5884	drug	_
33-4	5885-5890	naïve	_
33-5	5890-5891	,	_
33-6	5892-5897	first	_
33-7	5898-5905	episode	_
33-8	5906-5917	populations	_
33-9	5918-5926	minimize	_
33-10	5927-5938	confounding	_
33-11	5939-5946	factors	_
33-12	5947-5949	of	_
33-13	5950-5960	medication	_
33-14	5961-5968	effects	_
33-15	5969-5972	and	_
33-16	5973-5980	illness	_
33-17	5981-5991	chronicity	_
33-18	5992-5994	in	_
33-19	5995-6008	understanding	_
33-20	6009-6012	the	_
33-21	6013-6024	development	_
33-22	6025-6027	of	_
33-23	6028-6039	psychiatric	_
33-24	6040-6049	disorders	_
33-25	6049-6050	.	_

#Text=In this study, we performed a seed-based analysis of rsFC between the amygdala and PFC in first-episode, drug-naïve MDD and SZ, and healthy control (HC) participants aged 13 to 30 years.
34-1	6051-6053	In	_
34-2	6054-6058	this	_
34-3	6059-6064	study	_
34-4	6064-6065	,	_
34-5	6066-6068	we	_
34-6	6069-6078	performed	_
34-7	6079-6080	a	_
34-8	6081-6091	seed-based	_
34-9	6092-6100	analysis	_
34-10	6101-6103	of	_
34-11	6104-6108	rsFC	_
34-12	6109-6116	between	_
34-13	6117-6120	the	_
34-14	6121-6129	amygdala	_
34-15	6130-6133	and	_
34-16	6134-6137	PFC	_
34-17	6138-6140	in	_
34-18	6141-6154	first-episode	_
34-19	6154-6155	,	_
34-20	6156-6166	drug-naïve	_
34-21	6167-6170	MDD	_
34-22	6171-6174	and	_
34-23	6175-6177	SZ	_
34-24	6177-6178	,	_
34-25	6179-6182	and	_
34-26	6183-6190	healthy	_
34-27	6191-6198	control	_
34-28	6199-6200	(	_
34-29	6200-6202	HC	_
34-30	6202-6203	)	_
34-31	6204-6216	participants	_
34-32	6217-6221	aged	_
34-33	6222-6224	13	_
34-34	6225-6227	to	_
34-35	6228-6230	30	_
34-36	6231-6236	years	_
34-37	6236-6237	.	_

#Text=We selected this specific age range due to the critical brain changes that occurs during this period in the development of MDD and SZ.
35-1	6238-6240	We	_
35-2	6241-6249	selected	_
35-3	6250-6254	this	_
35-4	6255-6263	specific	_
35-5	6264-6267	age	_
35-6	6268-6273	range	_
35-7	6274-6277	due	_
35-8	6278-6280	to	_
35-9	6281-6284	the	_
35-10	6285-6293	critical	_
35-11	6294-6299	brain	_
35-12	6300-6307	changes	_
35-13	6308-6312	that	_
35-14	6313-6319	occurs	_
35-15	6320-6326	during	_
35-16	6327-6331	this	_
35-17	6332-6338	period	_
35-18	6339-6341	in	_
35-19	6342-6345	the	_
35-20	6346-6357	development	_
35-21	6358-6360	of	_
35-22	6361-6364	MDD	_
35-23	6365-6368	and	_
35-24	6369-6371	SZ	_
35-25	6371-6372	.	_

#Text=Consistent with previous MRI studies in MDD or SZ, we hypothesized that (1) amygdala-PFC rsFC would be altered in the MDD and SZ groups, compared to the HC group, (2) there would be similarities in amygdala-DLPFC rsFC abnormalities between the MDD and SZ group, (3) there would be differences in amygdala to other regions of PFC rsFC abnormalities between the MDD and SZ group, for example, amygdala-VPFC rsFC abnormalities in MDD and amygdala-dACC rsFC alterations in SZ.
36-1	6373-6383	Consistent	_
36-2	6384-6388	with	_
36-3	6389-6397	previous	_
36-4	6398-6401	MRI	_
36-5	6402-6409	studies	_
36-6	6410-6412	in	_
36-7	6413-6416	MDD	_
36-8	6417-6419	or	_
36-9	6420-6422	SZ	_
36-10	6422-6423	,	_
36-11	6424-6426	we	_
36-12	6427-6439	hypothesized	_
36-13	6440-6444	that	_
36-14	6445-6446	(	_
36-15	6446-6447	1	_
36-16	6447-6448	)	_
36-17	6449-6461	amygdala-PFC	_
36-18	6462-6466	rsFC	_
36-19	6467-6472	would	_
36-20	6473-6475	be	_
36-21	6476-6483	altered	_
36-22	6484-6486	in	_
36-23	6487-6490	the	_
36-24	6491-6494	MDD	_
36-25	6495-6498	and	_
36-26	6499-6501	SZ	_
36-27	6502-6508	groups	_
36-28	6508-6509	,	_
36-29	6510-6518	compared	_
36-30	6519-6521	to	_
36-31	6522-6525	the	_
36-32	6526-6528	HC	_
36-33	6529-6534	group	_
36-34	6534-6535	,	_
36-35	6536-6537	(	_
36-36	6537-6538	2	_
36-37	6538-6539	)	_
36-38	6540-6545	there	_
36-39	6546-6551	would	_
36-40	6552-6554	be	_
36-41	6555-6567	similarities	_
36-42	6568-6570	in	_
36-43	6571-6585	amygdala-DLPFC	_
36-44	6586-6590	rsFC	_
36-45	6591-6604	abnormalities	_
36-46	6605-6612	between	_
36-47	6613-6616	the	_
36-48	6617-6620	MDD	_
36-49	6621-6624	and	_
36-50	6625-6627	SZ	_
36-51	6628-6633	group	_
36-52	6633-6634	,	_
36-53	6635-6636	(	_
36-54	6636-6637	3	_
36-55	6637-6638	)	_
36-56	6639-6644	there	_
36-57	6645-6650	would	_
36-58	6651-6653	be	_
36-59	6654-6665	differences	_
36-60	6666-6668	in	_
36-61	6669-6677	amygdala	_
36-62	6678-6680	to	_
36-63	6681-6686	other	_
36-64	6687-6694	regions	_
36-65	6695-6697	of	_
36-66	6698-6701	PFC	_
36-67	6702-6706	rsFC	_
36-68	6707-6720	abnormalities	_
36-69	6721-6728	between	_
36-70	6729-6732	the	_
36-71	6733-6736	MDD	_
36-72	6737-6740	and	_
36-73	6741-6743	SZ	_
36-74	6744-6749	group	_
36-75	6749-6750	,	_
36-76	6751-6754	for	_
36-77	6755-6762	example	_
36-78	6762-6763	,	_
36-79	6764-6777	amygdala-VPFC	_
36-80	6778-6782	rsFC	_
36-81	6783-6796	abnormalities	_
36-82	6797-6799	in	_
36-83	6800-6803	MDD	_
36-84	6804-6807	and	_
36-85	6808-6821	amygdala-dACC	_
36-86	6822-6826	rsFC	_
36-87	6827-6838	alterations	_
36-88	6839-6841	in	_
36-89	6842-6844	SZ	_
36-90	6844-6845	.	_

#Text=Methods
#Text=Subjects
#Text=This study totally recruited 94 drug naïve, first episode MDD and SZ aged from 13 to 30 years.
37-1	6846-6853	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
37-2	6854-6862	Subjects	_
37-3	6863-6867	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-4	6868-6873	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-5	6874-6881	totally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-6	6882-6891	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-7	6892-6894	94	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-8	6895-6899	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[13]
37-9	6900-6905	naïve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[13]
37-10	6905-6906	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]
37-11	6907-6912	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[14]
37-12	6913-6920	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[14]
37-13	6921-6924	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[12]
37-14	6925-6928	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-15	6929-6931	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[15]
37-16	6932-6936	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-17	6937-6941	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-18	6942-6944	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-19	6945-6947	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-20	6948-6950	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-21	6951-6956	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-22	6956-6957	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=Participants included 49 drug-naïve, first episode MDD (mean age 19.35 ± 6.03 years, 32 females), 45 drug-naïve, first episode SZ (mean age 18.42 ± 3.84 years, 26 females), and 50 HC individuals (mean age 18.18 ± 3.92 years, 33 females).
38-1	6958-6970	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-2	6971-6979	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-3	6980-6982	49	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-4	6983-6993	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[17]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[18]
38-5	6993-6994	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[17]
38-6	6995-7000	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[17]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]
38-7	7001-7008	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[17]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[19]
38-8	7009-7012	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[17]
38-9	7013-7014	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-10	7014-7018	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-11	7019-7022	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-12	7023-7028	19.35	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-13	7029-7030	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-14	7031-7035	6.03	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-15	7036-7041	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-16	7041-7042	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-17	7043-7045	32	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-18	7046-7053	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-19	7053-7054	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-20	7054-7055	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-21	7056-7058	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-22	7059-7069	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]|http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated[21]
38-23	7069-7070	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]
38-24	7071-7076	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]
38-25	7077-7084	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]
38-26	7085-7087	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[20]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[22]
38-27	7088-7089	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-28	7089-7093	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-29	7094-7097	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-30	7098-7103	18.42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-31	7104-7105	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-32	7106-7110	3.84	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-33	7111-7116	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-34	7116-7117	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-35	7118-7120	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-36	7121-7128	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-37	7128-7129	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-38	7129-7130	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-39	7131-7134	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-40	7135-7137	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-41	7138-7140	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
38-42	7141-7152	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-43	7153-7154	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-44	7154-7158	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-45	7159-7162	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-46	7163-7168	18.18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-47	7169-7170	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-48	7171-7175	3.92	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-49	7176-7181	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-50	7181-7182	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-51	7183-7185	33	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-52	7186-7193	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-53	7193-7194	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
38-54	7194-7195	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=MDD and SZ participants were recruited from the outpatient clinics at the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shengyang China.
39-1	7196-7199	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[25]
39-2	7200-7203	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-3	7204-7206	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[26]
39-4	7207-7219	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-5	7220-7224	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-6	7225-7234	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-7	7235-7239	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-8	7240-7243	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-9	7244-7254	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-10	7255-7262	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-11	7263-7265	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-12	7266-7269	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-13	7270-7280	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-14	7281-7283	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-15	7284-7294	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-16	7294-7295	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-17	7296-7301	First	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-18	7302-7312	Affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-19	7313-7321	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-20	7322-7324	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-21	7325-7330	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-22	7331-7338	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-23	7339-7349	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-24	7349-7350	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-25	7351-7360	Shengyang	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-26	7361-7366	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-27	7366-7367	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]

#Text=HC participants were recruited from Shengyang, China using community advertisement.
40-1	7368-7370	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
40-2	7371-7383	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-3	7384-7388	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-4	7389-7398	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-5	7399-7403	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-6	7404-7413	Shengyang	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-7	7413-7414	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-8	7415-7420	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-9	7421-7426	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-10	7427-7436	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-11	7437-7450	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-12	7450-7451	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]

#Text=The presence or absence of Axis I diagnoses were independently determined by two trained psychiatrists using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) in participants ≥18 years old and the Schedule for Affective Disorders and Schizophrenia for School-Age Children-present and Lifetime Version (K-SADS-PL) in participants younger than 18 years old.
41-1	7452-7455	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-2	7456-7464	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-3	7465-7467	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-4	7468-7475	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-5	7476-7478	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-6	7479-7483	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-7	7484-7485	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-8	7486-7495	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-9	7496-7500	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-10	7501-7514	independently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-11	7515-7525	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-12	7526-7528	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-13	7529-7532	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-14	7533-7540	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-15	7541-7554	psychiatrists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-16	7555-7560	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-17	7561-7564	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-18	7565-7575	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-19	7576-7584	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-20	7585-7594	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-21	7595-7598	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-22	7599-7605	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-23	7606-7610	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-24	7611-7612	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-25	7613-7622	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-26	7623-7624	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-27	7624-7628	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-28	7628-7629	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[30]
41-29	7630-7632	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-30	7633-7645	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-31	7646-7647	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-32	7647-7649	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-33	7650-7655	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-34	7656-7659	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-35	7660-7663	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-36	7664-7667	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-37	7668-7676	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-38	7677-7680	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-39	7681-7690	Affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-40	7691-7700	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-41	7701-7704	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-42	7705-7718	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-43	7719-7722	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-44	7723-7733	School-Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-45	7734-7750	Children-present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-46	7751-7754	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-47	7755-7763	Lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-48	7764-7771	Version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-49	7772-7773	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-50	7773-7782	K-SADS-PL	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-51	7782-7783	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[31]
41-52	7784-7786	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-53	7787-7799	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-54	7800-7807	younger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-55	7808-7812	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-56	7813-7815	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-57	7816-7821	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-58	7822-7825	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
41-59	7825-7826	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=MDD and SZ participants respectively met the DSM-IV criteria for MDD or SZ without any other current or lifetime Axis I disorders, including substance abuse and dependence.
42-1	7827-7830	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[33]
42-2	7831-7834	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-3	7835-7837	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[34]
42-4	7838-7850	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-5	7851-7863	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-6	7864-7867	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-7	7868-7871	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-8	7872-7878	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-9	7879-7887	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-10	7888-7891	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-11	7892-7895	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[35]
42-12	7896-7898	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-13	7899-7901	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[36]
42-14	7902-7909	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-15	7910-7913	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-16	7914-7919	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-17	7920-7927	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-18	7928-7930	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-19	7931-7939	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-20	7940-7944	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-21	7945-7946	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-22	7947-7956	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-23	7956-7957	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-24	7958-7967	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-25	7968-7977	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-26	7978-7983	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-27	7984-7987	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-28	7988-7998	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
42-29	7998-7999	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]

#Text=Efforts were made to follow-up on subjects and confirm their diagnosis, particularly those in the early course of illness.
43-1	8000-8007	Efforts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-2	8008-8012	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-3	8013-8017	made	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-4	8018-8020	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-5	8021-8030	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-6	8031-8033	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-7	8034-8042	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-8	8043-8046	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-9	8047-8054	confirm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-10	8055-8060	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-11	8061-8070	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-12	8070-8071	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-13	8072-8084	particularly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-14	8085-8090	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-15	8091-8093	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-16	8094-8097	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-17	8098-8103	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-18	8104-8110	course	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-19	8111-8113	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-20	8114-8121	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
43-21	8121-8122	.	_

#Text=Of the 45 subjects with SZ, 37 were within the first year of initial symptom onset and DSM-IV criteria for SZ.
44-1	8123-8125	Of	_
44-2	8126-8129	the	_
44-3	8130-8132	45	_
44-4	8133-8141	subjects	_
44-5	8142-8146	with	_
44-6	8147-8149	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-7	8149-8150	,	_
44-8	8151-8153	37	_
44-9	8154-8158	were	_
44-10	8159-8165	within	_
44-11	8166-8169	the	_
44-12	8170-8175	first	_
44-13	8176-8180	year	_
44-14	8181-8183	of	_
44-15	8184-8191	initial	_
44-16	8192-8199	symptom	_
44-17	8200-8205	onset	_
44-18	8206-8209	and	_
44-19	8210-8216	DSM-IV	_
44-20	8217-8225	criteria	_
44-21	8226-8229	for	_
44-22	8230-8232	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-23	8232-8233	.	_

#Text=At one year follow-up, these subjects continued to meet DSM-IV criteria for SZ.
45-1	8234-8236	At	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-2	8237-8240	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-3	8241-8245	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-4	8246-8255	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-5	8255-8256	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-6	8257-8262	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-7	8263-8271	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-8	8272-8281	continued	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-9	8282-8284	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-10	8285-8289	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-11	8290-8296	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-12	8297-8305	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-13	8306-8309	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
45-14	8310-8312	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[39]
45-15	8312-8313	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]

#Text=Of the total 49 MDD subjects in this study, 44 remain as MDD at two year follow-up, and 5 remain as MDD at one year follow-up.
46-1	8314-8316	Of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-2	8317-8320	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-3	8321-8326	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-4	8327-8329	49	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-5	8330-8333	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[41]
46-6	8334-8342	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-7	8343-8345	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-8	8346-8350	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-9	8351-8356	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-10	8356-8357	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-11	8358-8360	44	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-12	8361-8367	remain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-13	8368-8370	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-14	8371-8374	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[42]
46-15	8375-8377	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-16	8378-8381	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-17	8382-8386	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-18	8387-8396	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-19	8396-8397	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-20	8398-8401	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-21	8402-8403	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-22	8404-8410	remain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-23	8411-8413	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-24	8414-8417	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[43]
46-25	8418-8420	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-26	8421-8424	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-27	8425-8429	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-28	8430-8439	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-29	8439-8440	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]

#Text=HC participants did not have any first-degree relatives with Axis I disorders.
47-1	8441-8443	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[44]
47-2	8444-8456	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-3	8457-8460	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-4	8461-8464	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-5	8465-8469	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-6	8470-8473	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-7	8474-8486	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-8	8487-8496	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-9	8497-8501	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-10	8502-8506	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-11	8507-8508	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-12	8509-8518	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
47-13	8518-8519	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]

#Text=For all three groups, individuals were excluded if any of the following were present: (1) any MRI contraindications; (2) history of head trauma with loss of consciousness 5 or more minutes or any neurological disorder; and (3) any concomitant major medical disorder.
48-1	8520-8523	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-2	8524-8527	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-3	8528-8533	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-4	8534-8540	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-5	8540-8541	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-6	8542-8553	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-7	8554-8558	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-8	8559-8567	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-9	8568-8570	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-10	8571-8574	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-11	8575-8577	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-12	8578-8581	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-13	8582-8591	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-14	8592-8596	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-15	8597-8604	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-16	8604-8605	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-17	8606-8607	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-18	8607-8608	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-19	8608-8609	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-20	8610-8613	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-21	8614-8617	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-22	8618-8635	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-23	8635-8636	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-24	8637-8638	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-25	8638-8639	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-26	8639-8640	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-27	8641-8648	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-28	8649-8651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-29	8652-8656	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-30	8657-8663	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-31	8664-8668	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-32	8669-8673	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-33	8674-8676	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-34	8677-8690	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-35	8691-8692	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-36	8693-8695	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-37	8696-8700	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-38	8701-8708	minutes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-39	8709-8711	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-40	8712-8715	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-41	8716-8728	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-42	8729-8737	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-43	8737-8738	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-44	8739-8742	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-45	8743-8744	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-46	8744-8745	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-47	8745-8746	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-48	8747-8750	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-49	8751-8762	concomitant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-50	8763-8768	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-51	8769-8776	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-52	8777-8785	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-53	8785-8786	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]

#Text=All participants were right handed and scanned within 24 hours of initial contact with the research team.
49-1	8787-8790	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-2	8791-8803	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-3	8804-8808	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-4	8809-8814	right	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-5	8815-8821	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-6	8822-8825	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-7	8826-8833	scanned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-8	8834-8840	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-9	8841-8843	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-10	8844-8849	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-11	8850-8852	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-12	8853-8860	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-13	8861-8868	contact	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-14	8869-8873	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-15	8874-8877	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-16	8878-8886	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-17	8887-8891	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]
49-18	8891-8892	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[46]

#Text=All participants provided written informed consent after detailed description of the study.
50-1	8893-8896	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-2	8897-8909	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-3	8910-8918	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-4	8919-8926	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-5	8927-8935	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-6	8936-8943	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-7	8944-8949	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-8	8950-8958	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-9	8959-8970	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-10	8971-8973	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-11	8974-8977	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-12	8978-8983	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-13	8983-8984	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=If participants were younger than 18 years old, participants gave written informed assent, and their parent/legal guardian provided written informed consent after receiving a detailed description of the study.
51-1	8985-8987	If	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-2	8988-9000	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-3	9001-9005	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-4	9006-9013	younger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-5	9014-9018	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-6	9019-9021	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-7	9022-9027	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-8	9028-9031	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-9	9031-9032	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-10	9033-9045	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-11	9046-9050	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-12	9051-9058	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-13	9059-9067	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-14	9068-9074	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-15	9074-9075	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-16	9076-9079	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-17	9080-9085	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-18	9086-9092	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-19	9092-9093	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-20	9093-9098	legal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-21	9099-9107	guardian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-22	9108-9116	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-23	9117-9124	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-24	9125-9133	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-25	9134-9141	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-26	9142-9147	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-27	9148-9157	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-28	9158-9159	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-29	9160-9168	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-30	9169-9180	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-31	9181-9183	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-32	9184-9187	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-33	9188-9193	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]
51-34	9193-9194	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[48]

#Text=The study was approved by the Institutional Review Board of China Medical University.
52-1	9195-9198	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-2	9199-9204	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-3	9205-9208	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-4	9209-9217	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-5	9218-9220	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-6	9221-9224	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-7	9225-9238	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-8	9239-9245	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-9	9246-9251	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-10	9252-9254	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-11	9255-9260	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-12	9261-9268	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-13	9269-9279	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]
52-14	9279-9280	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[49]

#Text=Symptom measures using the Hamilton Depression Rating Scale (HAMD), the Brief Psychiatric Rating Scale (BPRS) and Hamilton Anxiety Rating Scale (HAMA) and neuropsychological function using the Wisconsin Card Sorting Test (WCST) were obtained in all three groups.
53-1	9281-9288	Symptom	_
53-2	9289-9297	measures	_
53-3	9298-9303	using	_
53-4	9304-9307	the	_
53-5	9308-9316	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-6	9317-9327	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-7	9328-9334	Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-8	9335-9340	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-9	9341-9342	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-10	9342-9346	HAMD	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-11	9346-9347	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale[50]
53-12	9347-9348	,	_
53-13	9349-9352	the	*[51]
53-14	9353-9358	Brief	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-15	9359-9370	Psychiatric	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-16	9371-9377	Rating	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-17	9378-9383	Scale	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-18	9384-9385	(	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-19	9385-9389	BPRS	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-20	9389-9390	)	*[51]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[52]
53-21	9391-9394	and	*[51]
53-22	9395-9403	Hamilton	*[51]
53-23	9404-9411	Anxiety	*[51]
53-24	9412-9418	Rating	*[51]
53-25	9419-9424	Scale	*[51]
53-26	9425-9426	(	_
53-27	9426-9430	HAMA	_
53-28	9430-9431	)	_
53-29	9432-9435	and	_
53-30	9436-9454	neuropsychological	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-31	9455-9463	function	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-32	9464-9469	using	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-33	9470-9473	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-34	9474-9483	Wisconsin	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-35	9484-9488	Card	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-36	9489-9496	Sorting	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-37	9497-9501	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-38	9502-9503	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-39	9503-9507	WCST	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-40	9507-9508	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[53]
53-41	9509-9513	were	_
53-42	9514-9522	obtained	_
53-43	9523-9525	in	_
53-44	9526-9529	all	_
53-45	9530-9535	three	_
53-46	9536-9542	groups	_
53-47	9542-9543	.	_

#Text=MRI data acquisition
#Text=MRI data was acquired using a GE MR Signa HDX 3.0 T MRI scanner at the First Affiliated Hospital, China Medical University, Shenyang, China.
54-1	9544-9547	MRI	_
54-2	9548-9552	data	_
54-3	9553-9564	acquisition	_
54-4	9565-9568	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
54-5	9569-9573	data	_
54-6	9574-9577	was	_
54-7	9578-9586	acquired	_
54-8	9587-9592	using	_
54-9	9593-9594	a	_
54-10	9595-9597	GE	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-11	9598-9600	MR	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-12	9601-9606	Signa	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-13	9607-9610	HDX	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-14	9611-9614	3.0	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-15	9615-9616	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-16	9617-9620	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-17	9621-9628	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[54]
54-18	9629-9631	at	_
54-19	9632-9635	the	_
54-20	9636-9641	First	_
54-21	9642-9652	Affiliated	_
54-22	9653-9661	Hospital	_
54-23	9661-9662	,	_
54-24	9663-9668	China	_
54-25	9669-9676	Medical	_
54-26	9677-9687	University	_
54-27	9687-9688	,	_
54-28	9689-9697	Shenyang	_
54-29	9697-9698	,	_
54-30	9699-9704	China	_
54-31	9704-9705	.	_

#Text=Head motion was minimized with restraining foam pads.
55-1	9706-9710	Head	_
55-2	9711-9717	motion	_
55-3	9718-9721	was	_
55-4	9722-9731	minimized	_
55-5	9732-9736	with	_
55-6	9737-9748	restraining	_
55-7	9749-9753	foam	_
55-8	9754-9758	pads	_
55-9	9758-9759	.	_

#Text=A standard head coil was used for radio frequency transmission and reception of the nuclear magnetic resonance signal.
56-1	9760-9761	A	_
56-2	9762-9770	standard	_
56-3	9771-9775	head	_
56-4	9776-9780	coil	_
56-5	9781-9784	was	_
56-6	9785-9789	used	_
56-7	9790-9793	for	_
56-8	9794-9799	radio	_
56-9	9800-9809	frequency	_
56-10	9810-9822	transmission	_
56-11	9823-9826	and	_
56-12	9827-9836	reception	_
56-13	9837-9839	of	_
56-14	9840-9843	the	_
56-15	9844-9851	nuclear	_
56-16	9852-9860	magnetic	_
56-17	9861-9870	resonance	_
56-18	9871-9877	signal	_
56-19	9877-9878	.	_

#Text=The participants were asked to keep their eyes closed but remain awake during the scan.
57-1	9879-9882	The	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-2	9883-9895	participants	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-3	9896-9900	were	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-4	9901-9906	asked	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-5	9907-9909	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-6	9910-9914	keep	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-7	9915-9920	their	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-8	9921-9925	eyes	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-9	9926-9932	closed	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-10	9933-9936	but	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-11	9937-9943	remain	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-12	9944-9949	awake	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-13	9950-9956	during	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-14	9957-9960	the	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-15	9961-9965	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[55]
57-16	9965-9966	.	_

#Text=FMRI images were acquired using a spin echo planar imaging (EPI) sequence, parallel to the anterior–posterior commissure (AC–PC) plane with the following scan parameters: repetition time (TR) = 2000 ms; echo time (TE) = 40 ms; image matrix = 64 × 64; field of view (FOV) = 24 × 24 cm2; 35 contiguous slices of 3 mm and without gap; scan time 6 min 40 s.
58-1	9967-9971	FMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
58-2	9972-9978	images	_
58-3	9979-9983	were	_
58-4	9984-9992	acquired	_
58-5	9993-9998	using	_
58-6	9999-10000	a	_
58-7	10001-10005	spin	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-8	10006-10010	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-9	10011-10017	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-10	10018-10025	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-11	10026-10027	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-12	10027-10030	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-13	10030-10031	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-14	10032-10040	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-15	10040-10041	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[56]
58-16	10042-10050	parallel	_
58-17	10051-10053	to	_
58-18	10054-10057	the	_
58-19	10058-10076	anterior–posterior	_
58-20	10077-10087	commissure	_
58-21	10088-10089	(	_
58-22	10089-10094	AC–PC	_
58-23	10094-10095	)	_
58-24	10096-10101	plane	_
58-25	10102-10106	with	_
58-26	10107-10110	the	_
58-27	10111-10120	following	_
58-28	10121-10125	scan	_
58-29	10126-10136	parameters	_
58-30	10136-10137	:	_
58-31	10138-10148	repetition	_
58-32	10149-10153	time	_
58-33	10154-10155	(	_
58-34	10155-10157	TR	_
58-35	10157-10158	)	_
58-36	10159-10160	=	_
58-37	10161-10165	2000	_
58-38	10166-10168	ms	_
58-39	10168-10169	;	_
58-40	10170-10174	echo	_
58-41	10175-10179	time	_
58-42	10180-10181	(	_
58-43	10181-10183	TE	_
58-44	10183-10184	)	_
58-45	10185-10186	=	_
58-46	10187-10189	40	_
58-47	10190-10192	ms	_
58-48	10192-10193	;	_
58-49	10194-10199	image	_
58-50	10200-10206	matrix	_
58-51	10207-10208	=	_
58-52	10209-10211	64	_
58-53	10212-10213	×	_
58-54	10214-10216	64	_
58-55	10216-10217	;	_
58-56	10218-10223	field	_
58-57	10224-10226	of	_
58-58	10227-10231	view	_
58-59	10232-10233	(	_
58-60	10233-10236	FOV	_
58-61	10236-10237	)	_
58-62	10238-10239	=	_
58-63	10240-10242	24	_
58-64	10243-10244	×	_
58-65	10245-10247	24	_
58-66	10248-10251	cm2	_
58-67	10251-10252	;	_
58-68	10253-10255	35	_
58-69	10256-10266	contiguous	_
58-70	10267-10273	slices	_
58-71	10274-10276	of	_
58-72	10277-10278	3	_
58-73	10279-10281	mm	_
58-74	10282-10285	and	_
58-75	10286-10293	without	_
58-76	10294-10297	gap	_
58-77	10297-10298	;	_
58-78	10299-10303	scan	_
58-79	10304-10308	time	_
58-80	10309-10310	6	_
58-81	10311-10314	min	_
58-82	10315-10317	40	_
58-83	10318-10319	s	_
58-84	10319-10320	.	_

#Text=Data processing
#Text=The resting-state fMRI data preprocessing was carried out by using SPM8 (www.fil.ion.ucl.ac.uk/spm/software/spm8) and the Resting-State fMRI Data Analysis Toolkit (REST) (www.restfmri.net).
59-1	10321-10325	Data	_
59-2	10326-10336	processing	_
59-3	10337-10340	The	_
59-4	10341-10354	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[57]
59-5	10355-10359	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[57]
59-6	10360-10364	data	_
59-7	10365-10378	preprocessing	_
59-8	10379-10382	was	_
59-9	10383-10390	carried	_
59-10	10391-10394	out	_
59-11	10395-10397	by	_
59-12	10398-10403	using	_
59-13	10404-10408	SPM8	_
59-14	10409-10410	(	_
59-15	10410-10431	www.fil.ion.ucl.ac.uk	_
59-16	10431-10432	/	_
59-17	10432-10435	spm	_
59-18	10435-10436	/	_
59-19	10436-10444	software	_
59-20	10444-10445	/	_
59-21	10445-10449	spm8	_
59-22	10449-10450	)	_
59-23	10451-10454	and	_
59-24	10455-10458	the	_
59-25	10459-10472	Resting-State	_
59-26	10473-10477	fMRI	_
59-27	10478-10482	Data	_
59-28	10483-10491	Analysis	_
59-29	10492-10499	Toolkit	_
59-30	10500-10501	(	_
59-31	10501-10505	REST	_
59-32	10505-10506	)	_
59-33	10507-10508	(	_
59-34	10508-10524	www.restfmri.net	_
59-35	10524-10525	)	_
59-36	10525-10526	.	_

#Text=The first 10 images were deleted, and then the data underwent further preprocessing, including slice timing correction, head motion correction, spatial normalization and smoothing.
60-1	10527-10530	The	_
60-2	10531-10536	first	_
60-3	10537-10539	10	_
60-4	10540-10546	images	_
60-5	10547-10551	were	_
60-6	10552-10559	deleted	_
60-7	10559-10560	,	_
60-8	10561-10564	and	_
60-9	10565-10569	then	_
60-10	10570-10573	the	_
60-11	10574-10578	data	_
60-12	10579-10588	underwent	_
60-13	10589-10596	further	_
60-14	10597-10610	preprocessing	_
60-15	10610-10611	,	_
60-16	10612-10621	including	_
60-17	10622-10627	slice	_
60-18	10628-10634	timing	_
60-19	10635-10645	correction	_
60-20	10645-10646	,	_
60-21	10647-10651	head	_
60-22	10652-10658	motion	_
60-23	10659-10669	correction	_
60-24	10669-10670	,	_
60-25	10671-10678	spatial	_
60-26	10679-10692	normalization	_
60-27	10693-10696	and	_
60-28	10697-10706	smoothing	_
60-29	10706-10707	.	_

#Text=Head motion parameters were computed by estimating translation in each direction and the angular rotation about each axis for each volume.
61-1	10708-10712	Head	_
61-2	10713-10719	motion	_
61-3	10720-10730	parameters	_
61-4	10731-10735	were	_
61-5	10736-10744	computed	_
61-6	10745-10747	by	_
61-7	10748-10758	estimating	_
61-8	10759-10770	translation	_
61-9	10771-10773	in	_
61-10	10774-10778	each	_
61-11	10779-10788	direction	_
61-12	10789-10792	and	_
61-13	10793-10796	the	_
61-14	10797-10804	angular	_
61-15	10805-10813	rotation	_
61-16	10814-10819	about	_
61-17	10820-10824	each	_
61-18	10825-10829	axis	_
61-19	10830-10833	for	_
61-20	10834-10838	each	_
61-21	10839-10845	volume	_
61-22	10845-10846	.	_

#Text=Datasets were excluded if head motion was >3 mm maximum displacement in any of the x, y or z directions or 3° of any angular motion throughout the course of the scan.
62-1	10847-10855	Datasets	_
62-2	10856-10860	were	_
62-3	10861-10869	excluded	_
62-4	10870-10872	if	_
62-5	10873-10877	head	_
62-6	10878-10884	motion	_
62-7	10885-10888	was	_
62-8	10889-10890	>	_
62-9	10890-10891	3	_
62-10	10892-10894	mm	_
62-11	10895-10902	maximum	_
62-12	10903-10915	displacement	_
62-13	10916-10918	in	_
62-14	10919-10922	any	_
62-15	10923-10925	of	_
62-16	10926-10929	the	_
62-17	10930-10931	x	_
62-18	10931-10932	,	_
62-19	10933-10934	y	_
62-20	10935-10937	or	_
62-21	10938-10939	z	_
62-22	10940-10950	directions	_
62-23	10951-10953	or	_
62-24	10954-10955	3	_
62-25	10955-10956	°	_
62-26	10957-10959	of	_
62-27	10960-10963	any	_
62-28	10964-10971	angular	_
62-29	10972-10978	motion	_
62-30	10979-10989	throughout	_
62-31	10990-10993	the	_
62-32	10994-11000	course	_
62-33	11001-11003	of	_
62-34	11004-11007	the	_
62-35	11008-11012	scan	_
62-36	11012-11013	.	_

#Text=To access head motion confounder, we compared the mean framewise displacement among three groups, the result showed no significant differences in head motion when comparing the three groups (p = 0.81).
63-1	11014-11016	To	_
63-2	11017-11023	access	_
63-3	11024-11028	head	_
63-4	11029-11035	motion	_
63-5	11036-11046	confounder	_
63-6	11046-11047	,	_
63-7	11048-11050	we	_
63-8	11051-11059	compared	_
63-9	11060-11063	the	_
63-10	11064-11068	mean	_
63-11	11069-11078	framewise	_
63-12	11079-11091	displacement	_
63-13	11092-11097	among	_
63-14	11098-11103	three	_
63-15	11104-11110	groups	_
63-16	11110-11111	,	_
63-17	11112-11115	the	_
63-18	11116-11122	result	_
63-19	11123-11129	showed	_
63-20	11130-11132	no	_
63-21	11133-11144	significant	_
63-22	11145-11156	differences	_
63-23	11157-11159	in	_
63-24	11160-11164	head	_
63-25	11165-11171	motion	_
63-26	11172-11176	when	_
63-27	11177-11186	comparing	_
63-28	11187-11190	the	_
63-29	11191-11196	three	_
63-30	11197-11203	groups	_
63-31	11204-11205	(	_
63-32	11205-11206	p	_
63-33	11207-11208	=	_
63-34	11209-11213	0.81	_
63-35	11213-11214	)	_
63-36	11214-11215	.	_

#Text=Spatial normalization was performed using a standard EPI template from the Montreal Neurological Institute (MNI).
64-1	11216-11223	Spatial	_
64-2	11224-11237	normalization	_
64-3	11238-11241	was	_
64-4	11242-11251	performed	_
64-5	11252-11257	using	_
64-6	11258-11259	a	_
64-7	11260-11268	standard	_
64-8	11269-11272	EPI	_
64-9	11273-11281	template	_
64-10	11282-11286	from	_
64-11	11287-11290	the	_
64-12	11291-11299	Montreal	_
64-13	11300-11312	Neurological	_
64-14	11313-11322	Institute	_
64-15	11323-11324	(	_
64-16	11324-11327	MNI	_
64-17	11327-11328	)	_
64-18	11328-11329	.	_

#Text=The voxel size was resampled to 3 × 3 × 3 mm3.
65-1	11330-11333	The	_
65-2	11334-11339	voxel	_
65-3	11340-11344	size	_
65-4	11345-11348	was	_
65-5	11349-11358	resampled	_
65-6	11359-11361	to	_
65-7	11362-11363	3	_
65-8	11364-11365	×	_
65-9	11366-11367	3	_
65-10	11368-11369	×	_
65-11	11370-11371	3	_
65-12	11372-11375	mm3	_
65-13	11375-11376	.	_

#Text=Spatial smoothing was performed with an 8-mm full-width at half maximum (FWHM) Gaussian filter.
66-1	11377-11384	Spatial	_
66-2	11385-11394	smoothing	_
66-3	11395-11398	was	_
66-4	11399-11408	performed	_
66-5	11409-11413	with	_
66-6	11414-11416	an	_
66-7	11417-11418	8	_
66-8	11418-11419	-	_
66-9	11419-11421	mm	_
66-10	11422-11432	full-width	_
66-11	11433-11435	at	_
66-12	11436-11440	half	_
66-13	11441-11448	maximum	_
66-14	11449-11450	(	_
66-15	11450-11454	FWHM	_
66-16	11454-11455	)	_
66-17	11456-11464	Gaussian	_
66-18	11465-11471	filter	_
66-19	11471-11472	.	_

#Text=Linear detrending and temporal bandpass (0.01–0.08 Hz) filtering were performed to remove low-frequency drifts and physiological high-frequency noise.
67-1	11473-11479	Linear	_
67-2	11480-11490	detrending	_
67-3	11491-11494	and	_
67-4	11495-11503	temporal	_
67-5	11504-11512	bandpass	_
67-6	11513-11514	(	_
67-7	11514-11518	0.01	_
67-8	11518-11519	–	_
67-9	11519-11523	0.08	_
67-10	11524-11526	Hz	_
67-11	11526-11527	)	_
67-12	11528-11537	filtering	_
67-13	11538-11542	were	_
67-14	11543-11552	performed	_
67-15	11553-11555	to	_
67-16	11556-11562	remove	_
67-17	11563-11576	low-frequency	_
67-18	11577-11583	drifts	_
67-19	11584-11587	and	_
67-20	11588-11601	physiological	_
67-21	11602-11616	high-frequency	_
67-22	11617-11622	noise	_
67-23	11622-11623	.	_

#Text=Linear regression of head motion parameters, global mean signal, white matter signal and cerebrospinal fluid signal were performed to remove the effects of the nuisance covariates.
68-1	11624-11630	Linear	_
68-2	11631-11641	regression	_
68-3	11642-11644	of	_
68-4	11645-11649	head	_
68-5	11650-11656	motion	_
68-6	11657-11667	parameters	_
68-7	11667-11668	,	_
68-8	11669-11675	global	_
68-9	11676-11680	mean	_
68-10	11681-11687	signal	_
68-11	11687-11688	,	_
68-12	11689-11694	white	_
68-13	11695-11701	matter	_
68-14	11702-11708	signal	_
68-15	11709-11712	and	_
68-16	11713-11726	cerebrospinal	_
68-17	11727-11732	fluid	_
68-18	11733-11739	signal	_
68-19	11740-11744	were	_
68-20	11745-11754	performed	_
68-21	11755-11757	to	_
68-22	11758-11764	remove	_
68-23	11765-11768	the	_
68-24	11769-11776	effects	_
68-25	11777-11779	of	_
68-26	11780-11783	the	_
68-27	11784-11792	nuisance	_
68-28	11793-11803	covariates	_
68-29	11803-11804	.	_

#Text=Functional connectivity analysis
#Text=Functional connectivity analysis was performed using correlation analysis between the seed amygdala ROI and PFC mask in a voxel-wise manner using REST.
69-1	11805-11815	Functional	_
69-2	11816-11828	connectivity	_
69-3	11829-11837	analysis	_
69-4	11838-11848	Functional	_
69-5	11849-11861	connectivity	_
69-6	11862-11870	analysis	_
69-7	11871-11874	was	_
69-8	11875-11884	performed	_
69-9	11885-11890	using	_
69-10	11891-11902	correlation	_
69-11	11903-11911	analysis	_
69-12	11912-11919	between	_
69-13	11920-11923	the	_
69-14	11924-11928	seed	_
69-15	11929-11937	amygdala	_
69-16	11938-11941	ROI	_
69-17	11942-11945	and	_
69-18	11946-11949	PFC	_
69-19	11950-11954	mask	_
69-20	11955-11957	in	_
69-21	11958-11959	a	_
69-22	11960-11970	voxel-wise	_
69-23	11971-11977	manner	_
69-24	11978-11983	using	_
69-25	11984-11988	REST	_
69-26	11988-11989	.	_

#Text=The correlation coefficients were then transformed to Z-values using the Fisher r-to-z transformation.
70-1	11990-11993	The	_
70-2	11994-12005	correlation	_
70-3	12006-12018	coefficients	_
70-4	12019-12023	were	_
70-5	12024-12028	then	_
70-6	12029-12040	transformed	_
70-7	12041-12043	to	_
70-8	12044-12052	Z-values	_
70-9	12053-12058	using	_
70-10	12059-12062	the	_
70-11	12063-12069	Fisher	_
70-12	12070-12076	r-to-z	_
70-13	12077-12091	transformation	_
70-14	12091-12092	.	_

#Text=The amygdala was selected as the region-of-interest (ROI).
71-1	12093-12096	The	_
71-2	12097-12105	amygdala	_
71-3	12106-12109	was	_
71-4	12110-12118	selected	_
71-5	12119-12121	as	_
71-6	12122-12125	the	_
71-7	12126-12144	region-of-interest	_
71-8	12145-12146	(	_
71-9	12146-12149	ROI	_
71-10	12149-12150	)	_
71-11	12150-12151	.	_

#Text=The bilateral amygdala ROI was defined according to the automated anatomical labeling (AAL) template contained in REST, which has been resampled to 3 × 3 × 3 mm3.
72-1	12152-12155	The	_
72-2	12156-12165	bilateral	_
72-3	12166-12174	amygdala	_
72-4	12175-12178	ROI	_
72-5	12179-12182	was	_
72-6	12183-12190	defined	_
72-7	12191-12200	according	_
72-8	12201-12203	to	_
72-9	12204-12207	the	_
72-10	12208-12217	automated	_
72-11	12218-12228	anatomical	_
72-12	12229-12237	labeling	_
72-13	12238-12239	(	_
72-14	12239-12242	AAL	_
72-15	12242-12243	)	_
72-16	12244-12252	template	_
72-17	12253-12262	contained	_
72-18	12263-12265	in	_
72-19	12266-12270	REST	_
72-20	12270-12271	,	_
72-21	12272-12277	which	_
72-22	12278-12281	has	_
72-23	12282-12286	been	_
72-24	12287-12296	resampled	_
72-25	12297-12299	to	_
72-26	12300-12301	3	_
72-27	12302-12303	×	_
72-28	12304-12305	3	_
72-29	12306-12307	×	_
72-30	12308-12309	3	_
72-31	12310-12313	mm3	_
72-32	12313-12314	.	_

#Text=The BOLD time series of the voxels within the ROI were averaged to generate the reference time series for the ROI.
73-1	12315-12318	The	_
73-2	12319-12323	BOLD	_
73-3	12324-12328	time	_
73-4	12329-12335	series	_
73-5	12336-12338	of	_
73-6	12339-12342	the	_
73-7	12343-12349	voxels	_
73-8	12350-12356	within	_
73-9	12357-12360	the	_
73-10	12361-12364	ROI	_
73-11	12365-12369	were	_
73-12	12370-12378	averaged	_
73-13	12379-12381	to	_
73-14	12382-12390	generate	_
73-15	12391-12394	the	_
73-16	12395-12404	reference	_
73-17	12405-12409	time	_
73-18	12410-12416	series	_
73-19	12417-12420	for	_
73-20	12421-12424	the	_
73-21	12425-12428	ROI	_
73-22	12428-12429	.	_

#Text=A PFC mask was created using the normalized T1-weighted high-resolution images of all participants, which were skull-stripped using BrainSuite2 (http://brainsuite.usc.edu).
74-1	12430-12431	A	_
74-2	12432-12435	PFC	_
74-3	12436-12440	mask	_
74-4	12441-12444	was	_
74-5	12445-12452	created	_
74-6	12453-12458	using	_
74-7	12459-12462	the	_
74-8	12463-12473	normalized	_
74-9	12474-12476	T1	_
74-10	12476-12477	-	_
74-11	12477-12485	weighted	_
74-12	12486-12501	high-resolution	_
74-13	12502-12508	images	_
74-14	12509-12511	of	_
74-15	12512-12515	all	_
74-16	12516-12528	participants	_
74-17	12528-12529	,	_
74-18	12530-12535	which	_
74-19	12536-12540	were	_
74-20	12541-12555	skull-stripped	_
74-21	12556-12561	using	_
74-22	12562-12573	BrainSuite2	_
74-23	12574-12575	(	_
74-24	12575-12579	http	_
74-25	12579-12580	:	_
74-26	12580-12581	/	_
74-27	12581-12582	/	_
74-28	12582-12600	brainsuite.usc.edu	_
74-29	12600-12601	)	_
74-30	12601-12602	.	_

#Text=The PFC mask included Brodmann areas (BA) 9–12, 24, 25, 32, and 44–47.
75-1	12603-12606	The	_
75-2	12607-12610	PFC	_
75-3	12611-12615	mask	_
75-4	12616-12624	included	_
75-5	12625-12633	Brodmann	_
75-6	12634-12639	areas	_
75-7	12640-12641	(	_
75-8	12641-12643	BA	_
75-9	12643-12644	)	_
75-10	12645-12646	9	_
75-11	12646-12647	–	_
75-12	12647-12649	12	_
75-13	12649-12650	,	_
75-14	12651-12653	24	_
75-15	12653-12654	,	_
75-16	12655-12657	25	_
75-17	12657-12658	,	_
75-18	12659-12661	32	_
75-19	12661-12662	,	_
75-20	12663-12666	and	_
75-21	12667-12669	44	_
75-22	12669-12670	–	_
75-23	12670-12672	47	_
75-24	12672-12673	.	_

#Text=Only voxels within this mask were further analyzed.
76-1	12674-12678	Only	_
76-2	12679-12685	voxels	_
76-3	12686-12692	within	_
76-4	12693-12697	this	_
76-5	12698-12702	mask	_
76-6	12703-12707	were	_
76-7	12708-12715	further	_
76-8	12716-12724	analyzed	_
76-9	12724-12725	.	_

#Text=Statistical analysis
#Text=Demographic and clinical characteristics were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, NY, USA).
77-1	12726-12737	Statistical	_
77-2	12738-12746	analysis	_
77-3	12747-12758	Demographic	_
77-4	12759-12762	and	_
77-5	12763-12771	clinical	_
77-6	12772-12787	characteristics	_
77-7	12788-12792	were	_
77-8	12793-12801	analyzed	_
77-9	12802-12807	using	_
77-10	12808-12811	IBM	_
77-11	12812-12816	SPSS	_
77-12	12817-12827	Statistics	_
77-13	12828-12831	for	_
77-14	12832-12839	Windows	_
77-15	12839-12840	,	_
77-16	12841-12848	Version	_
77-17	12849-12853	21.0	_
77-18	12854-12855	(	_
77-19	12855-12861	Armonk	_
77-20	12861-12862	,	_
77-21	12863-12865	NY	_
77-22	12865-12866	,	_
77-23	12867-12870	USA	_
77-24	12870-12871	)	_
77-25	12871-12872	.	_

#Text=A one-way ANOVA was used to compare rsFC among the three groups.
78-1	12873-12874	A	_
78-2	12875-12882	one-way	_
78-3	12883-12888	ANOVA	_
78-4	12889-12892	was	_
78-5	12893-12897	used	_
78-6	12898-12900	to	_
78-7	12901-12908	compare	_
78-8	12909-12913	rsFC	_
78-9	12914-12919	among	_
78-10	12920-12923	the	_
78-11	12924-12929	three	_
78-12	12930-12936	groups	_
78-13	12936-12937	.	_

#Text=The contrast map threshold was set at p < 0.05 for each voxel with a cluster size of at least 40 voxels (1080 mm3), corrected for multiple comparison as determined by AlphaSim (see program AlphaSim by B.D.
79-1	12938-12941	The	_
79-2	12942-12950	contrast	_
79-3	12951-12954	map	_
79-4	12955-12964	threshold	_
79-5	12965-12968	was	_
79-6	12969-12972	set	_
79-7	12973-12975	at	_
79-8	12976-12977	p	_
79-9	12978-12979	<	_
79-10	12980-12984	0.05	_
79-11	12985-12988	for	_
79-12	12989-12993	each	_
79-13	12994-12999	voxel	_
79-14	13000-13004	with	_
79-15	13005-13006	a	_
79-16	13007-13014	cluster	_
79-17	13015-13019	size	_
79-18	13020-13022	of	_
79-19	13023-13025	at	_
79-20	13026-13031	least	_
79-21	13032-13034	40	_
79-22	13035-13041	voxels	_
79-23	13042-13043	(	_
79-24	13043-13047	1080	_
79-25	13048-13051	mm3	_
79-26	13051-13052	)	_
79-27	13052-13053	,	_
79-28	13054-13063	corrected	_
79-29	13064-13067	for	_
79-30	13068-13076	multiple	_
79-31	13077-13087	comparison	_
79-32	13088-13090	as	_
79-33	13091-13101	determined	_
79-34	13102-13104	by	_
79-35	13105-13113	AlphaSim	_
79-36	13114-13115	(	_
79-37	13115-13118	see	_
79-38	13119-13126	program	_
79-39	13127-13135	AlphaSim	_
79-40	13136-13138	by	_
79-41	13139-13142	B.D	_
79-42	13142-13143	.	_

#Text=Ward in AFNI software. http://afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf).
80-1	13144-13148	Ward	_
80-2	13149-13151	in	_
80-3	13152-13156	AFNI	_
80-4	13157-13165	software	_
80-5	13165-13166	.	_
80-6	13167-13171	http	_
80-7	13171-13172	:	_
80-8	13172-13173	/	_
80-9	13173-13174	/	_
80-10	13174-13191	afni.nimh.nih.gov	_
80-11	13191-13192	/	_
80-12	13192-13195	pub	_
80-13	13195-13196	/	_
80-14	13196-13200	dist	_
80-15	13200-13201	/	_
80-16	13201-13204	doc	_
80-17	13204-13205	/	_
80-18	13205-13211	manual	_
80-19	13211-13212	/	_
80-20	13212-13224	AlphaSim.pdf	_
80-21	13224-13225	)	_
80-22	13225-13226	.	_

#Text=Z-values were extracted from the PFC regions showing significant differences among the three groups.
81-1	13227-13235	Z-values	_
81-2	13236-13240	were	_
81-3	13241-13250	extracted	_
81-4	13251-13255	from	_
81-5	13256-13259	the	_
81-6	13260-13263	PFC	_
81-7	13264-13271	regions	_
81-8	13272-13279	showing	_
81-9	13280-13291	significant	_
81-10	13292-13303	differences	_
81-11	13304-13309	among	_
81-12	13310-13313	the	_
81-13	13314-13319	three	_
81-14	13320-13326	groups	_
81-15	13326-13327	.	_

#Text=Post hoc two-sample t-test of the Z-values between each pair group (HC vs.
82-1	13328-13332	Post	_
82-2	13333-13336	hoc	_
82-3	13337-13347	two-sample	_
82-4	13348-13354	t-test	_
82-5	13355-13357	of	_
82-6	13358-13361	the	_
82-7	13362-13370	Z-values	_
82-8	13371-13378	between	_
82-9	13379-13383	each	_
82-10	13384-13388	pair	_
82-11	13389-13394	group	_
82-12	13395-13396	(	_
82-13	13396-13398	HC	_
82-14	13399-13401	vs	_
82-15	13401-13402	.	_

#Text=MDD, HC vs.
83-1	13403-13406	MDD	_
83-2	13406-13407	,	_
83-3	13408-13410	HC	_
83-4	13411-13413	vs	_
83-5	13413-13414	.	_

#Text=SZ, MDD vs.
84-1	13415-13417	SZ	_
84-2	13417-13418	,	_
84-3	13419-13422	MDD	_
84-4	13423-13425	vs	_
84-5	13425-13426	.	_

#Text=SZ) were performed using SPSS.
85-1	13427-13429	SZ	_
85-2	13429-13430	)	_
85-3	13431-13435	were	_
85-4	13436-13445	performed	_
85-5	13446-13451	using	_
85-6	13452-13456	SPSS	_
85-7	13456-13457	.	_

#Text=Statistical significance was determined by p < 0.05.
86-1	13458-13469	Statistical	_
86-2	13470-13482	significance	_
86-3	13483-13486	was	_
86-4	13487-13497	determined	_
86-5	13498-13500	by	_
86-6	13501-13502	p	_
86-7	13503-13504	<	_
86-8	13505-13509	0.05	_
86-9	13509-13510	.	_

#Text=Results
#Text=Demographics, clinical characteristics and cognitive function
#Text=Demographics, clinical characteristics and cognitive function of participants are shown in Table 1.
87-1	13511-13518	Results	_
87-2	13519-13531	Demographics	_
87-3	13531-13532	,	_
87-4	13533-13541	clinical	_
87-5	13542-13557	characteristics	_
87-6	13558-13561	and	_
87-7	13562-13571	cognitive	_
87-8	13572-13580	function	_
87-9	13581-13593	Demographics	_
87-10	13593-13594	,	_
87-11	13595-13603	clinical	_
87-12	13604-13619	characteristics	_
87-13	13620-13623	and	_
87-14	13624-13633	cognitive	_
87-15	13634-13642	function	_
87-16	13643-13645	of	_
87-17	13646-13658	participants	_
87-18	13659-13662	are	_
87-19	13663-13668	shown	_
87-20	13669-13671	in	_
87-21	13672-13677	Table	_
87-22	13678-13679	1	_
87-23	13679-13680	.	_

#Text=There were no significant differences in age or gender (p > 0.6), or education (p = 0.05) among the three groups.
88-1	13681-13686	There	_
88-2	13687-13691	were	_
88-3	13692-13694	no	_
88-4	13695-13706	significant	_
88-5	13707-13718	differences	_
88-6	13719-13721	in	_
88-7	13722-13725	age	_
88-8	13726-13728	or	_
88-9	13729-13735	gender	_
88-10	13736-13737	(	_
88-11	13737-13738	p	_
88-12	13739-13740	>	_
88-13	13741-13744	0.6	_
88-14	13744-13745	)	_
88-15	13745-13746	,	_
88-16	13747-13749	or	_
88-17	13750-13759	education	_
88-18	13760-13761	(	_
88-19	13761-13762	p	_
88-20	13763-13764	=	_
88-21	13765-13769	0.05	_
88-22	13769-13770	)	_
88-23	13771-13776	among	_
88-24	13777-13780	the	_
88-25	13781-13786	three	_
88-26	13787-13793	groups	_
88-27	13793-13794	.	_

#Text=And there was also no significant difference in duration of illness between MDD and SZ groups (p = 0.88).
89-1	13795-13798	And	_
89-2	13799-13804	there	_
89-3	13805-13808	was	_
89-4	13809-13813	also	_
89-5	13814-13816	no	_
89-6	13817-13828	significant	_
89-7	13829-13839	difference	_
89-8	13840-13842	in	_
89-9	13843-13851	duration	_
89-10	13852-13854	of	_
89-11	13855-13862	illness	_
89-12	13863-13870	between	_
89-13	13871-13874	MDD	_
89-14	13875-13878	and	_
89-15	13879-13881	SZ	_
89-16	13882-13888	groups	_
89-17	13889-13890	(	_
89-18	13890-13891	p	_
89-19	13892-13893	=	_
89-20	13894-13898	0.88	_
89-21	13898-13899	)	_
89-22	13899-13900	.	_

#Text=Significant differences in HAMD, HAMA, and BPRS scores (p < 0.01) were observed among the three groups.
90-1	13901-13912	Significant	_
90-2	13913-13924	differences	_
90-3	13925-13927	in	_
90-4	13928-13932	HAMD	_
90-5	13932-13933	,	_
90-6	13934-13938	HAMA	_
90-7	13938-13939	,	_
90-8	13940-13943	and	_
90-9	13944-13948	BPRS	_
90-10	13949-13955	scores	_
90-11	13956-13957	(	_
90-12	13957-13958	p	_
90-13	13959-13960	<	_
90-14	13961-13965	0.01	_
90-15	13965-13966	)	_
90-16	13967-13971	were	_
90-17	13972-13980	observed	_
90-18	13981-13986	among	_
90-19	13987-13990	the	_
90-20	13991-13996	three	_
90-21	13997-14003	groups	_
90-22	14003-14004	.	_

#Text=Post-hoc analyses showed higher HAMD and HAMA scores in the MDD group compared to the SZ and HC group and in the SZ group compared to the HC group.
91-1	14005-14013	Post-hoc	_
91-2	14014-14022	analyses	_
91-3	14023-14029	showed	_
91-4	14030-14036	higher	_
91-5	14037-14041	HAMD	_
91-6	14042-14045	and	_
91-7	14046-14050	HAMA	_
91-8	14051-14057	scores	_
91-9	14058-14060	in	_
91-10	14061-14064	the	_
91-11	14065-14068	MDD	_
91-12	14069-14074	group	_
91-13	14075-14083	compared	_
91-14	14084-14086	to	_
91-15	14087-14090	the	_
91-16	14091-14093	SZ	_
91-17	14094-14097	and	_
91-18	14098-14100	HC	_
91-19	14101-14106	group	_
91-20	14107-14110	and	_
91-21	14111-14113	in	_
91-22	14114-14117	the	_
91-23	14118-14120	SZ	_
91-24	14121-14126	group	_
91-25	14127-14135	compared	_
91-26	14136-14138	to	_
91-27	14139-14142	the	_
91-28	14143-14145	HC	_
91-29	14146-14151	group	_
91-30	14151-14152	.	_

#Text=BPRS scores were significantly higher in the SZ group when compared to the MDD and HC groups.
92-1	14153-14157	BPRS	_
92-2	14158-14164	scores	_
92-3	14165-14169	were	_
92-4	14170-14183	significantly	_
92-5	14184-14190	higher	_
92-6	14191-14193	in	_
92-7	14194-14197	the	_
92-8	14198-14200	SZ	_
92-9	14201-14206	group	_
92-10	14207-14211	when	_
92-11	14212-14220	compared	_
92-12	14221-14223	to	_
92-13	14224-14227	the	_
92-14	14228-14231	MDD	_
92-15	14232-14235	and	_
92-16	14236-14238	HC	_
92-17	14239-14245	groups	_
92-18	14245-14246	.	_

#Text=Significant differences were also observed in WCST-correct responses, WCST-categories completed and WCST-total errors scores among the three groups (p < 0.05).
93-1	14247-14258	Significant	_
93-2	14259-14270	differences	_
93-3	14271-14275	were	_
93-4	14276-14280	also	_
93-5	14281-14289	observed	_
93-6	14290-14292	in	_
93-7	14293-14305	WCST-correct	_
93-8	14306-14315	responses	_
93-9	14315-14316	,	_
93-10	14317-14332	WCST-categories	_
93-11	14333-14342	completed	_
93-12	14343-14346	and	_
93-13	14347-14357	WCST-total	_
93-14	14358-14364	errors	_
93-15	14365-14371	scores	_
93-16	14372-14377	among	_
93-17	14378-14381	the	_
93-18	14382-14387	three	_
93-19	14388-14394	groups	_
93-20	14395-14396	(	_
93-21	14396-14397	p	_
93-22	14398-14399	<	_
93-23	14400-14404	0.05	_
93-24	14404-14405	)	_
93-25	14405-14406	.	_

#Text=Post-hoc analyses showed lower WCST-correct responses, WCST-categories completed and WCST-total errors scores in the SZ group compared to the MDD and HC group.
94-1	14407-14415	Post-hoc	_
94-2	14416-14424	analyses	_
94-3	14425-14431	showed	_
94-4	14432-14437	lower	_
94-5	14438-14450	WCST-correct	_
94-6	14451-14460	responses	_
94-7	14460-14461	,	_
94-8	14462-14477	WCST-categories	_
94-9	14478-14487	completed	_
94-10	14488-14491	and	_
94-11	14492-14502	WCST-total	_
94-12	14503-14509	errors	_
94-13	14510-14516	scores	_
94-14	14517-14519	in	_
94-15	14520-14523	the	_
94-16	14524-14526	SZ	_
94-17	14527-14532	group	_
94-18	14533-14541	compared	_
94-19	14542-14544	to	_
94-20	14545-14548	the	_
94-21	14549-14552	MDD	_
94-22	14553-14556	and	_
94-23	14557-14559	HC	_
94-24	14560-14565	group	_
94-25	14565-14566	.	_

#Text=Amygdala-PFC Connectivity
#Text=There were significant differences in amygdala- VPFC, amygdala-DLPFC and amygdala- dorsal ACC (dACC) rsFC in the three group comparison (p < 0.05, corrected) (Table 2; Fig. 1).
95-1	14567-14579	Amygdala-PFC	_
95-2	14580-14592	Connectivity	_
95-3	14593-14598	There	_
95-4	14599-14603	were	_
95-5	14604-14615	significant	_
95-6	14616-14627	differences	_
95-7	14628-14630	in	_
95-8	14631-14639	amygdala	_
95-9	14639-14640	-	_
95-10	14641-14645	VPFC	_
95-11	14645-14646	,	_
95-12	14647-14661	amygdala-DLPFC	_
95-13	14662-14665	and	_
95-14	14666-14674	amygdala	_
95-15	14674-14675	-	_
95-16	14676-14682	dorsal	_
95-17	14683-14686	ACC	_
95-18	14687-14688	(	_
95-19	14688-14692	dACC	_
95-20	14692-14693	)	_
95-21	14694-14698	rsFC	_
95-22	14699-14701	in	_
95-23	14702-14705	the	_
95-24	14706-14711	three	_
95-25	14712-14717	group	_
95-26	14718-14728	comparison	_
95-27	14729-14730	(	_
95-28	14730-14731	p	_
95-29	14732-14733	<	_
95-30	14734-14738	0.05	_
95-31	14738-14739	,	_
95-32	14740-14749	corrected	_
95-33	14749-14750	)	_
95-34	14751-14752	(	_
95-35	14752-14757	Table	_
95-36	14758-14759	2	_
95-37	14759-14760	;	_
95-38	14761-14764	Fig	_
95-39	14764-14765	.	_
95-40	14766-14767	1	_
95-41	14767-14768	)	_
95-42	14768-14769	.	_

#Text=Post hoc pairwise comparisons found significantly decreased rsFC between the amygdala and VPFC in the MDD group, when compared with the HC and SZ groups (p < 0.05, corrected).
96-1	14770-14774	Post	_
96-2	14775-14778	hoc	_
96-3	14779-14787	pairwise	_
96-4	14788-14799	comparisons	_
96-5	14800-14805	found	_
96-6	14806-14819	significantly	_
96-7	14820-14829	decreased	_
96-8	14830-14834	rsFC	_
96-9	14835-14842	between	_
96-10	14843-14846	the	_
96-11	14847-14855	amygdala	_
96-12	14856-14859	and	_
96-13	14860-14864	VPFC	_
96-14	14865-14867	in	_
96-15	14868-14871	the	_
96-16	14872-14875	MDD	_
96-17	14876-14881	group	_
96-18	14881-14882	,	_
96-19	14883-14887	when	_
96-20	14888-14896	compared	_
96-21	14897-14901	with	_
96-22	14902-14905	the	_
96-23	14906-14908	HC	_
96-24	14909-14912	and	_
96-25	14913-14915	SZ	_
96-26	14916-14922	groups	_
96-27	14923-14924	(	_
96-28	14924-14925	p	_
96-29	14926-14927	<	_
96-30	14928-14932	0.05	_
96-31	14932-14933	,	_
96-32	14934-14943	corrected	_
96-33	14943-14944	)	_
96-34	14944-14945	.	_

#Text=No significant difference in amygdala-VPFC rsFC was observed between the HC and SZ groups.
97-1	14946-14948	No	_
97-2	14949-14960	significant	_
97-3	14961-14971	difference	_
97-4	14972-14974	in	_
97-5	14975-14988	amygdala-VPFC	_
97-6	14989-14993	rsFC	_
97-7	14994-14997	was	_
97-8	14998-15006	observed	_
97-9	15007-15014	between	_
97-10	15015-15018	the	_
97-11	15019-15021	HC	_
97-12	15022-15025	and	_
97-13	15026-15028	SZ	_
97-14	15029-15035	groups	_
97-15	15035-15036	.	_

#Text=Amygdala-DLPFC rsFC was significantly decreased in the MDD and SZ groups, compared to the HC group (p < 0.05, corrected).
98-1	15037-15051	Amygdala-DLPFC	_
98-2	15052-15056	rsFC	_
98-3	15057-15060	was	_
98-4	15061-15074	significantly	_
98-5	15075-15084	decreased	_
98-6	15085-15087	in	_
98-7	15088-15091	the	_
98-8	15092-15095	MDD	_
98-9	15096-15099	and	_
98-10	15100-15102	SZ	_
98-11	15103-15109	groups	_
98-12	15109-15110	,	_
98-13	15111-15119	compared	_
98-14	15120-15122	to	_
98-15	15123-15126	the	_
98-16	15127-15129	HC	_
98-17	15130-15135	group	_
98-18	15136-15137	(	_
98-19	15137-15138	p	_
98-20	15139-15140	<	_
98-21	15141-15145	0.05	_
98-22	15145-15146	,	_
98-23	15147-15156	corrected	_
98-24	15156-15157	)	_
98-25	15157-15158	.	_

#Text=Significantly decreased rsFC between the amygdala and dACC was found in the SZ group, compared to the HC group.
99-1	15159-15172	Significantly	_
99-2	15173-15182	decreased	_
99-3	15183-15187	rsFC	_
99-4	15188-15195	between	_
99-5	15196-15199	the	_
99-6	15200-15208	amygdala	_
99-7	15209-15212	and	_
99-8	15213-15217	dACC	_
99-9	15218-15221	was	_
99-10	15222-15227	found	_
99-11	15228-15230	in	_
99-12	15231-15234	the	_
99-13	15235-15237	SZ	_
99-14	15238-15243	group	_
99-15	15243-15244	,	_
99-16	15245-15253	compared	_
99-17	15254-15256	to	_
99-18	15257-15260	the	_
99-19	15261-15263	HC	_
99-20	15264-15269	group	_
99-21	15269-15270	.	_

#Text=No significant differences were shown in amygdala-dACC rsFC in the MDD group when compared to the HC and SZ groups (p < 0.05, corrected) (Fig. 2).
100-1	15271-15273	No	_
100-2	15274-15285	significant	_
100-3	15286-15297	differences	_
100-4	15298-15302	were	_
100-5	15303-15308	shown	_
100-6	15309-15311	in	_
100-7	15312-15325	amygdala-dACC	_
100-8	15326-15330	rsFC	_
100-9	15331-15333	in	_
100-10	15334-15337	the	_
100-11	15338-15341	MDD	_
100-12	15342-15347	group	_
100-13	15348-15352	when	_
100-14	15353-15361	compared	_
100-15	15362-15364	to	_
100-16	15365-15368	the	_
100-17	15369-15371	HC	_
100-18	15372-15375	and	_
100-19	15376-15378	SZ	_
100-20	15379-15385	groups	_
100-21	15386-15387	(	_
100-22	15387-15388	p	_
100-23	15389-15390	<	_
100-24	15391-15395	0.05	_
100-25	15395-15396	,	_
100-26	15397-15406	corrected	_
100-27	15406-15407	)	_
100-28	15408-15409	(	_
100-29	15409-15412	Fig	_
100-30	15412-15413	.	_
100-31	15414-15415	2	_
100-32	15415-15416	)	_
100-33	15416-15417	.	_

#Text=Clinical variables
#Text=Exploratory analyses did not reveal any significant correlations between rsFC in regions showing significant group differences and HAMD, BPRS, HAMA scores, and WCST in the MDD and SZ groups.
101-1	15418-15426	Clinical	_
101-2	15427-15436	variables	_
101-3	15437-15448	Exploratory	_
101-4	15449-15457	analyses	_
101-5	15458-15461	did	_
101-6	15462-15465	not	_
101-7	15466-15472	reveal	_
101-8	15473-15476	any	_
101-9	15477-15488	significant	_
101-10	15489-15501	correlations	_
101-11	15502-15509	between	_
101-12	15510-15514	rsFC	_
101-13	15515-15517	in	_
101-14	15518-15525	regions	_
101-15	15526-15533	showing	_
101-16	15534-15545	significant	_
101-17	15546-15551	group	_
101-18	15552-15563	differences	_
101-19	15564-15567	and	_
101-20	15568-15572	HAMD	_
101-21	15572-15573	,	_
101-22	15574-15578	BPRS	_
101-23	15578-15579	,	_
101-24	15580-15584	HAMA	_
101-25	15585-15591	scores	_
101-26	15591-15592	,	_
101-27	15593-15596	and	_
101-28	15597-15601	WCST	_
101-29	15602-15604	in	_
101-30	15605-15608	the	_
101-31	15609-15612	MDD	_
101-32	15613-15616	and	_
101-33	15617-15619	SZ	_
101-34	15620-15626	groups	_
101-35	15626-15627	.	_

#Text=Discussion
#Text=As far as we are aware, this is the first study to investigate rsFC abnormalities between the amygdala and PFC in drug-naïve, first-episode adolescents and young adults with MDD and SZ.
102-1	15628-15638	Discussion	_
102-2	15639-15641	As	_
102-3	15642-15645	far	_
102-4	15646-15648	as	_
102-5	15649-15651	we	_
102-6	15652-15655	are	_
102-7	15656-15661	aware	_
102-8	15661-15662	,	_
102-9	15663-15667	this	_
102-10	15668-15670	is	_
102-11	15671-15674	the	_
102-12	15675-15680	first	_
102-13	15681-15686	study	_
102-14	15687-15689	to	_
102-15	15690-15701	investigate	_
102-16	15702-15706	rsFC	_
102-17	15707-15720	abnormalities	_
102-18	15721-15728	between	_
102-19	15729-15732	the	_
102-20	15733-15741	amygdala	_
102-21	15742-15745	and	_
102-22	15746-15749	PFC	_
102-23	15750-15752	in	_
102-24	15753-15763	drug-naïve	_
102-25	15763-15764	,	_
102-26	15765-15778	first-episode	_
102-27	15779-15790	adolescents	_
102-28	15791-15794	and	_
102-29	15795-15800	young	_
102-30	15801-15807	adults	_
102-31	15808-15812	with	_
102-32	15813-15816	MDD	_
102-33	15817-15820	and	_
102-34	15821-15823	SZ	_
102-35	15823-15824	.	_

#Text=Our findings support similarities and differences in amygdala-PFC rsFC abnormalities between drug-naïve, first episode adolescents and young adults with MDD and SZ.
103-1	15825-15828	Our	_
103-2	15829-15837	findings	_
103-3	15838-15845	support	_
103-4	15846-15858	similarities	_
103-5	15859-15862	and	_
103-6	15863-15874	differences	_
103-7	15875-15877	in	_
103-8	15878-15890	amygdala-PFC	_
103-9	15891-15895	rsFC	_
103-10	15896-15909	abnormalities	_
103-11	15910-15917	between	_
103-12	15918-15928	drug-naïve	_
103-13	15928-15929	,	_
103-14	15930-15935	first	_
103-15	15936-15943	episode	_
103-16	15944-15955	adolescents	_
103-17	15956-15959	and	_
103-18	15960-15965	young	_
103-19	15966-15972	adults	_
103-20	15973-15977	with	_
103-21	15978-15981	MDD	_
103-22	15982-15985	and	_
103-23	15986-15988	SZ	_
103-24	15988-15989	.	_

#Text=Consistent with our previous hypotheses in this study, significant differences were found in rsFC between the amygdala and the VPFC, DLPFC, and dACC in the three group comparison (MDD, SZ, and HC).
104-1	15990-16000	Consistent	_
104-2	16001-16005	with	_
104-3	16006-16009	our	_
104-4	16010-16018	previous	_
104-5	16019-16029	hypotheses	_
104-6	16030-16032	in	_
104-7	16033-16037	this	_
104-8	16038-16043	study	_
104-9	16043-16044	,	_
104-10	16045-16056	significant	_
104-11	16057-16068	differences	_
104-12	16069-16073	were	_
104-13	16074-16079	found	_
104-14	16080-16082	in	_
104-15	16083-16087	rsFC	_
104-16	16088-16095	between	_
104-17	16096-16099	the	_
104-18	16100-16108	amygdala	_
104-19	16109-16112	and	_
104-20	16113-16116	the	_
104-21	16117-16121	VPFC	_
104-22	16121-16122	,	_
104-23	16123-16128	DLPFC	_
104-24	16128-16129	,	_
104-25	16130-16133	and	_
104-26	16134-16138	dACC	_
104-27	16139-16141	in	_
104-28	16142-16145	the	_
104-29	16146-16151	three	_
104-30	16152-16157	group	_
104-31	16158-16168	comparison	_
104-32	16169-16170	(	_
104-33	16170-16173	MDD	_
104-34	16173-16174	,	_
104-35	16175-16177	SZ	_
104-36	16177-16178	,	_
104-37	16179-16182	and	_
104-38	16183-16185	HC	_
104-39	16185-16186	)	_
104-40	16186-16187	.	_

#Text=Both the MDD and SZ groups demonstrated significant decreases in amygdala-DLPFC rsFC when compared to the HC group.
105-1	16188-16192	Both	_
105-2	16193-16196	the	_
105-3	16197-16200	MDD	_
105-4	16201-16204	and	_
105-5	16205-16207	SZ	_
105-6	16208-16214	groups	_
105-7	16215-16227	demonstrated	_
105-8	16228-16239	significant	_
105-9	16240-16249	decreases	_
105-10	16250-16252	in	_
105-11	16253-16267	amygdala-DLPFC	_
105-12	16268-16272	rsFC	_
105-13	16273-16277	when	_
105-14	16278-16286	compared	_
105-15	16287-16289	to	_
105-16	16290-16293	the	_
105-17	16294-16296	HC	_
105-18	16297-16302	group	_
105-19	16302-16303	.	_

#Text=Differences between the MDD and SZ group were observed in amygdala-VPFC and amygdala-dACC rs FC.
106-1	16304-16315	Differences	_
106-2	16316-16323	between	_
106-3	16324-16327	the	_
106-4	16328-16331	MDD	_
106-5	16332-16335	and	_
106-6	16336-16338	SZ	_
106-7	16339-16344	group	_
106-8	16345-16349	were	_
106-9	16350-16358	observed	_
106-10	16359-16361	in	_
106-11	16362-16375	amygdala-VPFC	_
106-12	16376-16379	and	_
106-13	16380-16393	amygdala-dACC	_
106-14	16394-16396	rs	_
106-15	16397-16399	FC	_
106-16	16399-16400	.	_

#Text=The MDD group had significantly decreased rsFC between the amygdala and VPFC, compared to the HC and SZ groups.
107-1	16401-16404	The	_
107-2	16405-16408	MDD	_
107-3	16409-16414	group	_
107-4	16415-16418	had	_
107-5	16419-16432	significantly	_
107-6	16433-16442	decreased	_
107-7	16443-16447	rsFC	_
107-8	16448-16455	between	_
107-9	16456-16459	the	_
107-10	16460-16468	amygdala	_
107-11	16469-16472	and	_
107-12	16473-16477	VPFC	_
107-13	16477-16478	,	_
107-14	16479-16487	compared	_
107-15	16488-16490	to	_
107-16	16491-16494	the	_
107-17	16495-16497	HC	_
107-18	16498-16501	and	_
107-19	16502-16504	SZ	_
107-20	16505-16511	groups	_
107-21	16511-16512	.	_

#Text=Significant decrease in amygdala-dACC rsFC was found only in the SZ group when compared to the HC group.
108-1	16513-16524	Significant	_
108-2	16525-16533	decrease	_
108-3	16534-16536	in	_
108-4	16537-16550	amygdala-dACC	_
108-5	16551-16555	rsFC	_
108-6	16556-16559	was	_
108-7	16560-16565	found	_
108-8	16566-16570	only	_
108-9	16571-16573	in	_
108-10	16574-16577	the	_
108-11	16578-16580	SZ	_
108-12	16581-16586	group	_
108-13	16587-16591	when	_
108-14	16592-16600	compared	_
108-15	16601-16603	to	_
108-16	16604-16607	the	_
108-17	16608-16610	HC	_
108-18	16611-16616	group	_
108-19	16616-16617	.	_

#Text=Results also suggest different effects of MDD and SZ on amygdala-dACC rsFC with the MDD group showing intermediate effects, although no significant difference in amygdala-dACC rsFC was observed between the MDD and SZ groups or the MDD and HC groups.
109-1	16618-16625	Results	_
109-2	16626-16630	also	_
109-3	16631-16638	suggest	_
109-4	16639-16648	different	_
109-5	16649-16656	effects	_
109-6	16657-16659	of	_
109-7	16660-16663	MDD	_
109-8	16664-16667	and	_
109-9	16668-16670	SZ	_
109-10	16671-16673	on	_
109-11	16674-16687	amygdala-dACC	_
109-12	16688-16692	rsFC	_
109-13	16693-16697	with	_
109-14	16698-16701	the	_
109-15	16702-16705	MDD	_
109-16	16706-16711	group	_
109-17	16712-16719	showing	_
109-18	16720-16732	intermediate	_
109-19	16733-16740	effects	_
109-20	16740-16741	,	_
109-21	16742-16750	although	_
109-22	16751-16753	no	_
109-23	16754-16765	significant	_
109-24	16766-16776	difference	_
109-25	16777-16779	in	_
109-26	16780-16793	amygdala-dACC	_
109-27	16794-16798	rsFC	_
109-28	16799-16802	was	_
109-29	16803-16811	observed	_
109-30	16812-16819	between	_
109-31	16820-16823	the	_
109-32	16824-16827	MDD	_
109-33	16828-16831	and	_
109-34	16832-16834	SZ	_
109-35	16835-16841	groups	_
109-36	16842-16844	or	_
109-37	16845-16848	the	_
109-38	16849-16852	MDD	_
109-39	16853-16856	and	_
109-40	16857-16859	HC	_
109-41	16860-16866	groups	_
109-42	16866-16867	.	_

#Text=The observed similarities and differences in amygdala-PFC rsFC may reflect neural mechanisms that underlie the clinical observations of symptom overlap during initial illness and divergence in longitudinal course in MDD and SZ.
110-1	16868-16871	The	_
110-2	16872-16880	observed	_
110-3	16881-16893	similarities	_
110-4	16894-16897	and	_
110-5	16898-16909	differences	_
110-6	16910-16912	in	_
110-7	16913-16925	amygdala-PFC	_
110-8	16926-16930	rsFC	_
110-9	16931-16934	may	_
110-10	16935-16942	reflect	_
110-11	16943-16949	neural	_
110-12	16950-16960	mechanisms	_
110-13	16961-16965	that	_
110-14	16966-16974	underlie	_
110-15	16975-16978	the	_
110-16	16979-16987	clinical	_
110-17	16988-17000	observations	_
110-18	17001-17003	of	_
110-19	17004-17011	symptom	_
110-20	17012-17019	overlap	_
110-21	17020-17026	during	_
110-22	17027-17034	initial	_
110-23	17035-17042	illness	_
110-24	17043-17046	and	_
110-25	17047-17057	divergence	_
110-26	17058-17060	in	_
110-27	17061-17073	longitudinal	_
110-28	17074-17080	course	_
110-29	17081-17083	in	_
110-30	17084-17087	MDD	_
110-31	17088-17091	and	_
110-32	17092-17094	SZ	_
110-33	17094-17095	.	_

#Text=However, we did not observe any significant correlation between amygdala-PFC rsFC and symptom measures using the HAMD, BPRS, or HAMA.
111-1	17096-17103	However	_
111-2	17103-17104	,	_
111-3	17105-17107	we	_
111-4	17108-17111	did	_
111-5	17112-17115	not	_
111-6	17116-17123	observe	_
111-7	17124-17127	any	_
111-8	17128-17139	significant	_
111-9	17140-17151	correlation	_
111-10	17152-17159	between	_
111-11	17160-17172	amygdala-PFC	_
111-12	17173-17177	rsFC	_
111-13	17178-17181	and	_
111-14	17182-17189	symptom	_
111-15	17190-17198	measures	_
111-16	17199-17204	using	_
111-17	17205-17208	the	_
111-18	17209-17213	HAMD	_
111-19	17213-17214	,	_
111-20	17215-17219	BPRS	_
111-21	17219-17220	,	_
111-22	17221-17223	or	_
111-23	17224-17228	HAMA	_
111-24	17228-17229	.	_

#Text=Interestingly, our findings seem to reflect general conceptualization and differentiation of MDD and SZ: MDD is a disorder of primarily emotional processing and regulation whereas cognitive deficits predominate in SZ.
112-1	17230-17243	Interestingly	_
112-2	17243-17244	,	_
112-3	17245-17248	our	_
112-4	17249-17257	findings	_
112-5	17258-17262	seem	_
112-6	17263-17265	to	_
112-7	17266-17273	reflect	_
112-8	17274-17281	general	_
112-9	17282-17299	conceptualization	_
112-10	17300-17303	and	_
112-11	17304-17319	differentiation	_
112-12	17320-17322	of	_
112-13	17323-17326	MDD	_
112-14	17327-17330	and	_
112-15	17331-17333	SZ	_
112-16	17333-17334	:	_
112-17	17335-17338	MDD	_
112-18	17339-17341	is	_
112-19	17342-17343	a	_
112-20	17344-17352	disorder	_
112-21	17353-17355	of	_
112-22	17356-17365	primarily	_
112-23	17366-17375	emotional	_
112-24	17376-17386	processing	_
112-25	17387-17390	and	_
112-26	17391-17401	regulation	_
112-27	17402-17409	whereas	_
112-28	17410-17419	cognitive	_
112-29	17420-17428	deficits	_
112-30	17429-17440	predominate	_
112-31	17441-17443	in	_
112-32	17444-17446	SZ	_
112-33	17446-17447	.	_

#Text=Previous studies implicate the VPFC and amygdala as core components of the cortico-limbic circuitry and interactions in emotional processing, especially in an affective disorder.
113-1	17448-17456	Previous	_
113-2	17457-17464	studies	_
113-3	17465-17474	implicate	_
113-4	17475-17478	the	_
113-5	17479-17483	VPFC	_
113-6	17484-17487	and	_
113-7	17488-17496	amygdala	_
113-8	17497-17499	as	_
113-9	17500-17504	core	_
113-10	17505-17515	components	_
113-11	17516-17518	of	_
113-12	17519-17522	the	_
113-13	17523-17537	cortico-limbic	_
113-14	17538-17547	circuitry	_
113-15	17548-17551	and	_
113-16	17552-17564	interactions	_
113-17	17565-17567	in	_
113-18	17568-17577	emotional	_
113-19	17578-17588	processing	_
113-20	17588-17589	,	_
113-21	17590-17600	especially	_
113-22	17601-17603	in	_
113-23	17604-17606	an	_
113-24	17607-17616	affective	_
113-25	17617-17625	disorder	_
113-26	17625-17626	.	_

#Text=For example, our previous study by Liu et al. reported decreased rsFC between the amygdala and the VPFC in BD, and our another resting-state fMRI study identified a negative correlation in VPFC-amygdala activity in BD.
114-1	17627-17630	For	_
114-2	17631-17638	example	_
114-3	17638-17639	,	_
114-4	17640-17643	our	_
114-5	17644-17652	previous	_
114-6	17653-17658	study	_
114-7	17659-17661	by	_
114-8	17662-17665	Liu	_
114-9	17666-17668	et	_
114-10	17669-17671	al	_
114-11	17671-17672	.	_
114-12	17673-17681	reported	_
114-13	17682-17691	decreased	_
114-14	17692-17696	rsFC	_
114-15	17697-17704	between	_
114-16	17705-17708	the	_
114-17	17709-17717	amygdala	_
114-18	17718-17721	and	_
114-19	17722-17725	the	_
114-20	17726-17730	VPFC	_
114-21	17731-17733	in	_
114-22	17734-17736	BD	_
114-23	17736-17737	,	_
114-24	17738-17741	and	_
114-25	17742-17745	our	_
114-26	17746-17753	another	_
114-27	17754-17767	resting-state	_
114-28	17768-17772	fMRI	_
114-29	17773-17778	study	_
114-30	17779-17789	identified	_
114-31	17790-17791	a	_
114-32	17792-17800	negative	_
114-33	17801-17812	correlation	_
114-34	17813-17815	in	_
114-35	17816-17829	VPFC-amygdala	_
114-36	17830-17838	activity	_
114-37	17839-17841	in	_
114-38	17842-17844	BD	_
114-39	17844-17845	.	_

#Text=In this study, decreased amygdala-VPFC rsFC in MDD was shown, consistent with our previous findings by Tang et al. and by Kong et al. of decreased functional connectivity amygdala-left VPFC and amygdala-left rostral PFC in treatment-naïve MDD.
115-1	17846-17848	In	_
115-2	17849-17853	this	_
115-3	17854-17859	study	_
115-4	17859-17860	,	_
115-5	17861-17870	decreased	_
115-6	17871-17884	amygdala-VPFC	_
115-7	17885-17889	rsFC	_
115-8	17890-17892	in	_
115-9	17893-17896	MDD	_
115-10	17897-17900	was	_
115-11	17901-17906	shown	_
115-12	17906-17907	,	_
115-13	17908-17918	consistent	_
115-14	17919-17923	with	_
115-15	17924-17927	our	_
115-16	17928-17936	previous	_
115-17	17937-17945	findings	_
115-18	17946-17948	by	_
115-19	17949-17953	Tang	_
115-20	17954-17956	et	_
115-21	17957-17959	al	_
115-22	17959-17960	.	_
115-23	17961-17964	and	_
115-24	17965-17967	by	_
115-25	17968-17972	Kong	_
115-26	17973-17975	et	_
115-27	17976-17978	al	_
115-28	17978-17979	.	_
115-29	17980-17982	of	_
115-30	17983-17992	decreased	_
115-31	17993-18003	functional	_
115-32	18004-18016	connectivity	_
115-33	18017-18030	amygdala-left	_
115-34	18031-18035	VPFC	_
115-35	18036-18039	and	_
115-36	18040-18053	amygdala-left	_
115-37	18054-18061	rostral	_
115-38	18062-18065	PFC	_
115-39	18066-18068	in	_
115-40	18069-18084	treatment-naïve	_
115-41	18085-18088	MDD	_
115-42	18088-18089	.	_

#Text=We did not observe similar findings in the SZ group.
116-1	18090-18092	We	_
116-2	18093-18096	did	_
116-3	18097-18100	not	_
116-4	18101-18108	observe	_
116-5	18109-18116	similar	_
116-6	18117-18125	findings	_
116-7	18126-18128	in	_
116-8	18129-18132	the	_
116-9	18133-18135	SZ	_
116-10	18136-18141	group	_
116-11	18141-18142	.	_

#Text=The dACC has been associated with various functions including conflict monitoring, reward processing and cognitive-motor functions and is also thought to be a critical component in the salience network in SZ.
117-1	18143-18146	The	_
117-2	18147-18151	dACC	_
117-3	18152-18155	has	_
117-4	18156-18160	been	_
117-5	18161-18171	associated	_
117-6	18172-18176	with	_
117-7	18177-18184	various	_
117-8	18185-18194	functions	_
117-9	18195-18204	including	_
117-10	18205-18213	conflict	_
117-11	18214-18224	monitoring	_
117-12	18224-18225	,	_
117-13	18226-18232	reward	_
117-14	18233-18243	processing	_
117-15	18244-18247	and	_
117-16	18248-18263	cognitive-motor	_
117-17	18264-18273	functions	_
117-18	18274-18277	and	_
117-19	18278-18280	is	_
117-20	18281-18285	also	_
117-21	18286-18293	thought	_
117-22	18294-18296	to	_
117-23	18297-18299	be	_
117-24	18300-18301	a	_
117-25	18302-18310	critical	_
117-26	18311-18320	component	_
117-27	18321-18323	in	_
117-28	18324-18327	the	_
117-29	18328-18336	salience	_
117-30	18337-18344	network	_
117-31	18345-18347	in	_
117-32	18348-18350	SZ	_
117-33	18350-18351	.	_

#Text=These functions may be relevant to the development of psychotic symptoms such as delusions and hallucinations.
118-1	18352-18357	These	_
118-2	18358-18367	functions	_
118-3	18368-18371	may	_
118-4	18372-18374	be	_
118-5	18375-18383	relevant	_
118-6	18384-18386	to	_
118-7	18387-18390	the	_
118-8	18391-18402	development	_
118-9	18403-18405	of	_
118-10	18406-18415	psychotic	_
118-11	18416-18424	symptoms	_
118-12	18425-18429	such	_
118-13	18430-18432	as	_
118-14	18433-18442	delusions	_
118-15	18443-18446	and	_
118-16	18447-18461	hallucinations	_
118-17	18461-18462	.	_

#Text=The ventral ACC is mainly activated within emotional process, whereas the dorsal ACC mostly engages in cognitive tasks.
119-1	18463-18466	The	_
119-2	18467-18474	ventral	_
119-3	18475-18478	ACC	_
119-4	18479-18481	is	_
119-5	18482-18488	mainly	_
119-6	18489-18498	activated	_
119-7	18499-18505	within	_
119-8	18506-18515	emotional	_
119-9	18516-18523	process	_
119-10	18523-18524	,	_
119-11	18525-18532	whereas	_
119-12	18533-18536	the	_
119-13	18537-18543	dorsal	_
119-14	18544-18547	ACC	_
119-15	18548-18554	mostly	_
119-16	18555-18562	engages	_
119-17	18563-18565	in	_
119-18	18566-18575	cognitive	_
119-19	18576-18581	tasks	_
119-20	18581-18582	.	_

#Text=For example, greater improvement in depressed bipolar adolescents was associated with baseline higher activity in ventral ACC to mild happy faces during emotion processing by fMRI.
120-1	18583-18586	For	_
120-2	18587-18594	example	_
120-3	18594-18595	,	_
120-4	18596-18603	greater	_
120-5	18604-18615	improvement	_
120-6	18616-18618	in	_
120-7	18619-18628	depressed	_
120-8	18629-18636	bipolar	_
120-9	18637-18648	adolescents	_
120-10	18649-18652	was	_
120-11	18653-18663	associated	_
120-12	18664-18668	with	_
120-13	18669-18677	baseline	_
120-14	18678-18684	higher	_
120-15	18685-18693	activity	_
120-16	18694-18696	in	_
120-17	18697-18704	ventral	_
120-18	18705-18708	ACC	_
120-19	18709-18711	to	_
120-20	18712-18716	mild	_
120-21	18717-18722	happy	_
120-22	18723-18728	faces	_
120-23	18729-18735	during	_
120-24	18736-18743	emotion	_
120-25	18744-18754	processing	_
120-26	18755-18757	by	_
120-27	18758-18762	fMRI	_
120-28	18762-18763	.	_

#Text=The patients with schizophrenia had abnormalities in activation of the dorsal ACC in cognitive functioning by fMRI.
121-1	18764-18767	The	_
121-2	18768-18776	patients	_
121-3	18777-18781	with	_
121-4	18782-18795	schizophrenia	_
121-5	18796-18799	had	_
121-6	18800-18813	abnormalities	_
121-7	18814-18816	in	_
121-8	18817-18827	activation	_
121-9	18828-18830	of	_
121-10	18831-18834	the	_
121-11	18835-18841	dorsal	_
121-12	18842-18845	ACC	_
121-13	18846-18848	in	_
121-14	18849-18858	cognitive	_
121-15	18859-18870	functioning	_
121-16	18871-18873	by	_
121-17	18874-18878	fMRI	_
121-18	18878-18879	.	_

#Text=We found significantly altered amygdala-dACC rsFC in the SZ group when compared to the HC group; this was not shown in the MDD group.
122-1	18880-18882	We	_
122-2	18883-18888	found	_
122-3	18889-18902	significantly	_
122-4	18903-18910	altered	_
122-5	18911-18924	amygdala-dACC	_
122-6	18925-18929	rsFC	_
122-7	18930-18932	in	_
122-8	18933-18936	the	_
122-9	18937-18939	SZ	_
122-10	18940-18945	group	_
122-11	18946-18950	when	_
122-12	18951-18959	compared	_
122-13	18960-18962	to	_
122-14	18963-18966	the	_
122-15	18967-18969	HC	_
122-16	18970-18975	group	_
122-17	18975-18976	;	_
122-18	18977-18981	this	_
122-19	18982-18985	was	_
122-20	18986-18989	not	_
122-21	18990-18995	shown	_
122-22	18996-18998	in	_
122-23	18999-19002	the	_
122-24	19003-19006	MDD	_
122-25	19007-19012	group	_
122-26	19012-19013	.	_

#Text=Our study results also suggest intermediate effects on amygdala-dACC rsFC in MDD, which would be consistent with the presence of more subtle cognitive impairments in MDD compared to SZ.
123-1	19014-19017	Our	_
123-2	19018-19023	study	_
123-3	19024-19031	results	_
123-4	19032-19036	also	_
123-5	19037-19044	suggest	_
123-6	19045-19057	intermediate	_
123-7	19058-19065	effects	_
123-8	19066-19068	on	_
123-9	19069-19082	amygdala-dACC	_
123-10	19083-19087	rsFC	_
123-11	19088-19090	in	_
123-12	19091-19094	MDD	_
123-13	19094-19095	,	_
123-14	19096-19101	which	_
123-15	19102-19107	would	_
123-16	19108-19110	be	_
123-17	19111-19121	consistent	_
123-18	19122-19126	with	_
123-19	19127-19130	the	_
123-20	19131-19139	presence	_
123-21	19140-19142	of	_
123-22	19143-19147	more	_
123-23	19148-19154	subtle	_
123-24	19155-19164	cognitive	_
123-25	19165-19176	impairments	_
123-26	19177-19179	in	_
123-27	19180-19183	MDD	_
123-28	19184-19192	compared	_
123-29	19193-19195	to	_
123-30	19196-19198	SZ	_
123-31	19198-19199	.	_

#Text=Decreased rsFC between the amygdala and DLPFC were found in both the MDD and SZ groups in this study, consistent with previous studies in MDD and SZ.
124-1	19200-19209	Decreased	_
124-2	19210-19214	rsFC	_
124-3	19215-19222	between	_
124-4	19223-19226	the	_
124-5	19227-19235	amygdala	_
124-6	19236-19239	and	_
124-7	19240-19245	DLPFC	_
124-8	19246-19250	were	_
124-9	19251-19256	found	_
124-10	19257-19259	in	_
124-11	19260-19264	both	_
124-12	19265-19268	the	_
124-13	19269-19272	MDD	_
124-14	19273-19276	and	_
124-15	19277-19279	SZ	_
124-16	19280-19286	groups	_
124-17	19287-19289	in	_
124-18	19290-19294	this	_
124-19	19295-19300	study	_
124-20	19300-19301	,	_
124-21	19302-19312	consistent	_
124-22	19313-19317	with	_
124-23	19318-19326	previous	_
124-24	19327-19334	studies	_
124-25	19335-19337	in	_
124-26	19338-19341	MDD	_
124-27	19342-19345	and	_
124-28	19346-19348	SZ	_
124-29	19348-19349	.	_

#Text=The DLPFC is thought to be involved in cognitive regulation of emotion, working memory, planning and cognitive flexibility.
125-1	19350-19353	The	_
125-2	19354-19359	DLPFC	_
125-3	19360-19362	is	_
125-4	19363-19370	thought	_
125-5	19371-19373	to	_
125-6	19374-19376	be	_
125-7	19377-19385	involved	_
125-8	19386-19388	in	_
125-9	19389-19398	cognitive	_
125-10	19399-19409	regulation	_
125-11	19410-19412	of	_
125-12	19413-19420	emotion	_
125-13	19420-19421	,	_
125-14	19422-19429	working	_
125-15	19430-19436	memory	_
125-16	19436-19437	,	_
125-17	19438-19446	planning	_
125-18	19447-19450	and	_
125-19	19451-19460	cognitive	_
125-20	19461-19472	flexibility	_
125-21	19472-19473	.	_

#Text=It may be necessary to translate information about value into goal representations and to maintain such information so that it can be implemented as action plans to achieve the desired outcome.
126-1	19474-19476	It	_
126-2	19477-19480	may	_
126-3	19481-19483	be	_
126-4	19484-19493	necessary	_
126-5	19494-19496	to	_
126-6	19497-19506	translate	_
126-7	19507-19518	information	_
126-8	19519-19524	about	_
126-9	19525-19530	value	_
126-10	19531-19535	into	_
126-11	19536-19540	goal	_
126-12	19541-19556	representations	_
126-13	19557-19560	and	_
126-14	19561-19563	to	_
126-15	19564-19572	maintain	_
126-16	19573-19577	such	_
126-17	19578-19589	information	_
126-18	19590-19592	so	_
126-19	19593-19597	that	_
126-20	19598-19600	it	_
126-21	19601-19604	can	_
126-22	19605-19607	be	_
126-23	19608-19619	implemented	_
126-24	19620-19622	as	_
126-25	19623-19629	action	_
126-26	19630-19635	plans	_
126-27	19636-19638	to	_
126-28	19639-19646	achieve	_
126-29	19647-19650	the	_
126-30	19651-19658	desired	_
126-31	19659-19666	outcome	_
126-32	19666-19667	.	_

#Text=The evidence indicated the involvement of the DLPFC in emotional processing and regulation and cognition abnormalities in the DLPFC in both MDD and SZ.
127-1	19668-19671	The	_
127-2	19672-19680	evidence	_
127-3	19681-19690	indicated	_
127-4	19691-19694	the	_
127-5	19695-19706	involvement	_
127-6	19707-19709	of	_
127-7	19710-19713	the	_
127-8	19714-19719	DLPFC	_
127-9	19720-19722	in	_
127-10	19723-19732	emotional	_
127-11	19733-19743	processing	_
127-12	19744-19747	and	_
127-13	19748-19758	regulation	_
127-14	19759-19762	and	_
127-15	19763-19772	cognition	_
127-16	19773-19786	abnormalities	_
127-17	19787-19789	in	_
127-18	19790-19793	the	_
127-19	19794-19799	DLPFC	_
127-20	19800-19802	in	_
127-21	19803-19807	both	_
127-22	19808-19811	MDD	_
127-23	19812-19815	and	_
127-24	19816-19818	SZ	_
127-25	19818-19819	.	_

#Text=For example, depressed subjects displayed decreased DLPFC activity in response to cognitive tasks, and patients with SZ reduced engagement of the DLPFC within the working memory network.
128-1	19820-19823	For	_
128-2	19824-19831	example	_
128-3	19831-19832	,	_
128-4	19833-19842	depressed	_
128-5	19843-19851	subjects	_
128-6	19852-19861	displayed	_
128-7	19862-19871	decreased	_
128-8	19872-19877	DLPFC	_
128-9	19878-19886	activity	_
128-10	19887-19889	in	_
128-11	19890-19898	response	_
128-12	19899-19901	to	_
128-13	19902-19911	cognitive	_
128-14	19912-19917	tasks	_
128-15	19917-19918	,	_
128-16	19919-19922	and	_
128-17	19923-19931	patients	_
128-18	19932-19936	with	_
128-19	19937-19939	SZ	_
128-20	19940-19947	reduced	_
128-21	19948-19958	engagement	_
128-22	19959-19961	of	_
128-23	19962-19965	the	_
128-24	19966-19971	DLPFC	_
128-25	19972-19978	within	_
128-26	19979-19982	the	_
128-27	19983-19990	working	_
128-28	19991-19997	memory	_
128-29	19998-20005	network	_
128-30	20005-20006	.	_

#Text=In addition, the meta-analytic results showed lower response in the dorsolateral prefrontal cortex in individuals with major depressive disorder than in healthy subjects and the review supported physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia.
129-1	20007-20009	In	_
129-2	20010-20018	addition	_
129-3	20018-20019	,	_
129-4	20020-20023	the	_
129-5	20024-20037	meta-analytic	_
129-6	20038-20045	results	_
129-7	20046-20052	showed	_
129-8	20053-20058	lower	_
129-9	20059-20067	response	_
129-10	20068-20070	in	_
129-11	20071-20074	the	_
129-12	20075-20087	dorsolateral	_
129-13	20088-20098	prefrontal	_
129-14	20099-20105	cortex	_
129-15	20106-20108	in	_
129-16	20109-20120	individuals	_
129-17	20121-20125	with	_
129-18	20126-20131	major	_
129-19	20132-20142	depressive	_
129-20	20143-20151	disorder	_
129-21	20152-20156	than	_
129-22	20157-20159	in	_
129-23	20160-20167	healthy	_
129-24	20168-20176	subjects	_
129-25	20177-20180	and	_
129-26	20181-20184	the	_
129-27	20185-20191	review	_
129-28	20192-20201	supported	_
129-29	20202-20215	physiological	_
129-30	20216-20227	dysfunction	_
129-31	20228-20230	of	_
129-32	20231-20243	dorsolateral	_
129-33	20244-20254	prefrontal	_
129-34	20255-20261	cortex	_
129-35	20262-20264	in	_
129-36	20265-20278	schizophrenia	_
129-37	20278-20279	.	_

#Text=Although the mechanism of interaction between DLPFC and amygdala remains unknown, our findings confirmed that the interaction of DLPFC-amygala could be closely associated with the pathophysiology of MDD and SZ.
130-1	20280-20288	Although	_
130-2	20289-20292	the	_
130-3	20293-20302	mechanism	_
130-4	20303-20305	of	_
130-5	20306-20317	interaction	_
130-6	20318-20325	between	_
130-7	20326-20331	DLPFC	_
130-8	20332-20335	and	_
130-9	20336-20344	amygdala	_
130-10	20345-20352	remains	_
130-11	20353-20360	unknown	_
130-12	20360-20361	,	_
130-13	20362-20365	our	_
130-14	20366-20374	findings	_
130-15	20375-20384	confirmed	_
130-16	20385-20389	that	_
130-17	20390-20393	the	_
130-18	20394-20405	interaction	_
130-19	20406-20408	of	_
130-20	20409-20422	DLPFC-amygala	_
130-21	20423-20428	could	_
130-22	20429-20431	be	_
130-23	20432-20439	closely	_
130-24	20440-20450	associated	_
130-25	20451-20455	with	_
130-26	20456-20459	the	_
130-27	20460-20475	pathophysiology	_
130-28	20476-20478	of	_
130-29	20479-20482	MDD	_
130-30	20483-20486	and	_
130-31	20487-20489	SZ	_
130-32	20489-20490	.	_

#Text=Exploratory analyses did not reveal any significant relationship between rsFC in regions showing significant group differences and symptom measures and WCST scores in MDD and SZ.
131-1	20491-20502	Exploratory	_
131-2	20503-20511	analyses	_
131-3	20512-20515	did	_
131-4	20516-20519	not	_
131-5	20520-20526	reveal	_
131-6	20527-20530	any	_
131-7	20531-20542	significant	_
131-8	20543-20555	relationship	_
131-9	20556-20563	between	_
131-10	20564-20568	rsFC	_
131-11	20569-20571	in	_
131-12	20572-20579	regions	_
131-13	20580-20587	showing	_
131-14	20588-20599	significant	_
131-15	20600-20605	group	_
131-16	20606-20617	differences	_
131-17	20618-20621	and	_
131-18	20622-20629	symptom	_
131-19	20630-20638	measures	_
131-20	20639-20642	and	_
131-21	20643-20647	WCST	_
131-22	20648-20654	scores	_
131-23	20655-20657	in	_
131-24	20658-20661	MDD	_
131-25	20662-20665	and	_
131-26	20666-20668	SZ	_
131-27	20668-20669	.	_

#Text=The reasons for this are unclear.
132-1	20670-20673	The	_
132-2	20674-20681	reasons	_
132-3	20682-20685	for	_
132-4	20686-20690	this	_
132-5	20691-20694	are	_
132-6	20695-20702	unclear	_
132-7	20702-20703	.	_

#Text=The measures used likely may not sufficiently capture the impairments in emotional processing and cognitive function related to the rsFC alterations observed herein as previously discussed.
133-1	20704-20707	The	_
133-2	20708-20716	measures	_
133-3	20717-20721	used	_
133-4	20722-20728	likely	_
133-5	20729-20732	may	_
133-6	20733-20736	not	_
133-7	20737-20749	sufficiently	_
133-8	20750-20757	capture	_
133-9	20758-20761	the	_
133-10	20762-20773	impairments	_
133-11	20774-20776	in	_
133-12	20777-20786	emotional	_
133-13	20787-20797	processing	_
133-14	20798-20801	and	_
133-15	20802-20811	cognitive	_
133-16	20812-20820	function	_
133-17	20821-20828	related	_
133-18	20829-20831	to	_
133-19	20832-20835	the	_
133-20	20836-20840	rsFC	_
133-21	20841-20852	alterations	_
133-22	20853-20861	observed	_
133-23	20862-20868	herein	_
133-24	20869-20871	as	_
133-25	20872-20882	previously	_
133-26	20883-20892	discussed	_
133-27	20892-20893	.	_

#Text=They may be too broad and overinclusive, and more targeted and refined approaches are needed to further examine the relationship between rsFC alterations and clinical symptoms and neuropsychological function.
134-1	20894-20898	They	_
134-2	20899-20902	may	_
134-3	20903-20905	be	_
134-4	20906-20909	too	_
134-5	20910-20915	broad	_
134-6	20916-20919	and	_
134-7	20920-20933	overinclusive	_
134-8	20933-20934	,	_
134-9	20935-20938	and	_
134-10	20939-20943	more	_
134-11	20944-20952	targeted	_
134-12	20953-20956	and	_
134-13	20957-20964	refined	_
134-14	20965-20975	approaches	_
134-15	20976-20979	are	_
134-16	20980-20986	needed	_
134-17	20987-20989	to	_
134-18	20990-20997	further	_
134-19	20998-21005	examine	_
134-20	21006-21009	the	_
134-21	21010-21022	relationship	_
134-22	21023-21030	between	_
134-23	21031-21035	rsFC	_
134-24	21036-21047	alterations	_
134-25	21048-21051	and	_
134-26	21052-21060	clinical	_
134-27	21061-21069	symptoms	_
134-28	21070-21073	and	_
134-29	21074-21092	neuropsychological	_
134-30	21093-21101	function	_
134-31	21101-21102	.	_

#Text=However, our findings implicate greater severity of impairments in SZ with given greater magnitude of rsFC alteration in SZ than MDD.
135-1	21103-21110	However	_
135-2	21110-21111	,	_
135-3	21112-21115	our	_
135-4	21116-21124	findings	_
135-5	21125-21134	implicate	_
135-6	21135-21142	greater	_
135-7	21143-21151	severity	_
135-8	21152-21154	of	_
135-9	21155-21166	impairments	_
135-10	21167-21169	in	_
135-11	21170-21172	SZ	_
135-12	21173-21177	with	_
135-13	21178-21183	given	_
135-14	21184-21191	greater	_
135-15	21192-21201	magnitude	_
135-16	21202-21204	of	_
135-17	21205-21209	rsFC	_
135-18	21210-21220	alteration	_
135-19	21221-21223	in	_
135-20	21224-21226	SZ	_
135-21	21227-21231	than	_
135-22	21232-21235	MDD	_
135-23	21235-21236	.	_

#Text=This is consistent with the predicted clinical course and outcome for these disorders.
136-1	21237-21241	This	_
136-2	21242-21244	is	_
136-3	21245-21255	consistent	_
136-4	21256-21260	with	_
136-5	21261-21264	the	_
136-6	21265-21274	predicted	_
136-7	21275-21283	clinical	_
136-8	21284-21290	course	_
136-9	21291-21294	and	_
136-10	21295-21302	outcome	_
136-11	21303-21306	for	_
136-12	21307-21312	these	_
136-13	21313-21322	disorders	_
136-14	21322-21323	.	_

#Text=Future studies should include more comprehensive and refined symptom and neuropsychological measurements to further understand the relationship between brain function and clinical and cognitive manifestations.
137-1	21324-21330	Future	_
137-2	21331-21338	studies	_
137-3	21339-21345	should	_
137-4	21346-21353	include	_
137-5	21354-21358	more	_
137-6	21359-21372	comprehensive	_
137-7	21373-21376	and	_
137-8	21377-21384	refined	_
137-9	21385-21392	symptom	_
137-10	21393-21396	and	_
137-11	21397-21415	neuropsychological	_
137-12	21416-21428	measurements	_
137-13	21429-21431	to	_
137-14	21432-21439	further	_
137-15	21440-21450	understand	_
137-16	21451-21454	the	_
137-17	21455-21467	relationship	_
137-18	21468-21475	between	_
137-19	21476-21481	brain	_
137-20	21482-21490	function	_
137-21	21491-21494	and	_
137-22	21495-21503	clinical	_
137-23	21504-21507	and	_
137-24	21508-21517	cognitive	_
137-25	21518-21532	manifestations	_
137-26	21532-21533	.	_

#Text=There are limitations in this study.
138-1	21534-21539	There	_
138-2	21540-21543	are	_
138-3	21544-21555	limitations	_
138-4	21556-21558	in	_
138-5	21559-21563	this	_
138-6	21564-21569	study	_
138-7	21569-21570	.	_

#Text=Educational level was marginally different among the three groups (p = 0.05), and it may have contributed to our findings.
139-1	21571-21582	Educational	_
139-2	21583-21588	level	_
139-3	21589-21592	was	_
139-4	21593-21603	marginally	_
139-5	21604-21613	different	_
139-6	21614-21619	among	_
139-7	21620-21623	the	_
139-8	21624-21629	three	_
139-9	21630-21636	groups	_
139-10	21637-21638	(	_
139-11	21638-21639	p	_
139-12	21640-21641	=	_
139-13	21642-21646	0.05	_
139-14	21646-21647	)	_
139-15	21647-21648	,	_
139-16	21649-21652	and	_
139-17	21653-21655	it	_
139-18	21656-21659	may	_
139-19	21660-21664	have	_
139-20	21665-21676	contributed	_
139-21	21677-21679	to	_
139-22	21680-21683	our	_
139-23	21684-21692	findings	_
139-24	21692-21693	.	_

#Text=Educational level has been previously shown to impact brain function.
140-1	21694-21705	Educational	_
140-2	21706-21711	level	_
140-3	21712-21715	has	_
140-4	21716-21720	been	_
140-5	21721-21731	previously	_
140-6	21732-21737	shown	_
140-7	21738-21740	to	_
140-8	21741-21747	impact	_
140-9	21748-21753	brain	_
140-10	21754-21762	function	_
140-11	21762-21763	.	_

#Text=Further, as the study included subjects early in the course of illness, the results herein should be interpreted with caution.
141-1	21764-21771	Further	_
141-2	21771-21772	,	_
141-3	21773-21775	as	_
141-4	21776-21779	the	_
141-5	21780-21785	study	_
141-6	21786-21794	included	_
141-7	21795-21803	subjects	_
141-8	21804-21809	early	_
141-9	21810-21812	in	_
141-10	21813-21816	the	_
141-11	21817-21823	course	_
141-12	21824-21826	of	_
141-13	21827-21834	illness	_
141-14	21834-21835	,	_
141-15	21836-21839	the	_
141-16	21840-21847	results	_
141-17	21848-21854	herein	_
141-18	21855-21861	should	_
141-19	21862-21864	be	_
141-20	21865-21876	interpreted	_
141-21	21877-21881	with	_
141-22	21882-21889	caution	_
141-23	21889-21890	.	_

#Text=Follow-up studies have found that 20 to 40% of adolescents with MDD develop BD within a period of 5 years after the onset of depression.
142-1	21891-21900	Follow-up	_
142-2	21901-21908	studies	_
142-3	21909-21913	have	_
142-4	21914-21919	found	_
142-5	21920-21924	that	_
142-6	21925-21927	20	_
142-7	21928-21930	to	_
142-8	21931-21934	40%	_
142-9	21935-21937	of	_
142-10	21938-21949	adolescents	_
142-11	21950-21954	with	_
142-12	21955-21958	MDD	_
142-13	21959-21966	develop	_
142-14	21967-21969	BD	_
142-15	21970-21976	within	_
142-16	21977-21978	a	_
142-17	21979-21985	period	_
142-18	21986-21988	of	_
142-19	21989-21990	5	_
142-20	21991-21996	years	_
142-21	21997-22002	after	_
142-22	22003-22006	the	_
142-23	22007-22012	onset	_
142-24	22013-22015	of	_
142-25	22016-22026	depression	_
142-26	22026-22027	.	_

#Text=The longitudinal diagnostic stability for these subjects remains to be seen with ongoing efforts for follow-up and diagnostic confirmation.
143-1	22028-22031	The	_
143-2	22032-22044	longitudinal	_
143-3	22045-22055	diagnostic	_
143-4	22056-22065	stability	_
143-5	22066-22069	for	_
143-6	22070-22075	these	_
143-7	22076-22084	subjects	_
143-8	22085-22092	remains	_
143-9	22093-22095	to	_
143-10	22096-22098	be	_
143-11	22099-22103	seen	_
143-12	22104-22108	with	_
143-13	22109-22116	ongoing	_
143-14	22117-22124	efforts	_
143-15	22125-22128	for	_
143-16	22129-22138	follow-up	_
143-17	22139-22142	and	_
143-18	22143-22153	diagnostic	_
143-19	22154-22166	confirmation	_
143-20	22166-22167	.	_

#Text=In summary, the findings of this study support our a prior hypotheses that there are abnormalities in amygdala-PFC rsFC in drug-naïve, first episode adolescent and young adult with MDD and SZ and that there are similarities and differences in these abnormalities between the two disorders.
144-1	22168-22170	In	_
144-2	22171-22178	summary	_
144-3	22178-22179	,	_
144-4	22180-22183	the	_
144-5	22184-22192	findings	_
144-6	22193-22195	of	_
144-7	22196-22200	this	_
144-8	22201-22206	study	_
144-9	22207-22214	support	_
144-10	22215-22218	our	_
144-11	22219-22220	a	_
144-12	22221-22226	prior	_
144-13	22227-22237	hypotheses	_
144-14	22238-22242	that	_
144-15	22243-22248	there	_
144-16	22249-22252	are	_
144-17	22253-22266	abnormalities	_
144-18	22267-22269	in	_
144-19	22270-22282	amygdala-PFC	_
144-20	22283-22287	rsFC	_
144-21	22288-22290	in	_
144-22	22291-22301	drug-naïve	_
144-23	22301-22302	,	_
144-24	22303-22308	first	_
144-25	22309-22316	episode	_
144-26	22317-22327	adolescent	_
144-27	22328-22331	and	_
144-28	22332-22337	young	_
144-29	22338-22343	adult	_
144-30	22344-22348	with	_
144-31	22349-22352	MDD	_
144-32	22353-22356	and	_
144-33	22357-22359	SZ	_
144-34	22360-22363	and	_
144-35	22364-22368	that	_
144-36	22369-22374	there	_
144-37	22375-22378	are	_
144-38	22379-22391	similarities	_
144-39	22392-22395	and	_
144-40	22396-22407	differences	_
144-41	22408-22410	in	_
144-42	22411-22416	these	_
144-43	22417-22430	abnormalities	_
144-44	22431-22438	between	_
144-45	22439-22442	the	_
144-46	22443-22446	two	_
144-47	22447-22456	disorders	_
144-48	22456-22457	.	_

#Text=Both MDD and SZ appear to have similar alterations in amygdala-DLPFC rsFC.
145-1	22458-22462	Both	_
145-2	22463-22466	MDD	_
145-3	22467-22470	and	_
145-4	22471-22473	SZ	_
145-5	22474-22480	appear	_
145-6	22481-22483	to	_
145-7	22484-22488	have	_
145-8	22489-22496	similar	_
145-9	22497-22508	alterations	_
145-10	22509-22511	in	_
145-11	22512-22526	amygdala-DLPFC	_
145-12	22527-22531	rsFC	_
145-13	22531-22532	.	_

#Text=Abnormalties amygdala-VPFC rsFC may be specific to MDD whereas those in amygdala-dACC rsFC may be more related to and severe in SZ.
146-1	22533-22545	Abnormalties	_
146-2	22546-22559	amygdala-VPFC	_
146-3	22560-22564	rsFC	_
146-4	22565-22568	may	_
146-5	22569-22571	be	_
146-6	22572-22580	specific	_
146-7	22581-22583	to	_
146-8	22584-22587	MDD	_
146-9	22588-22595	whereas	_
146-10	22596-22601	those	_
146-11	22602-22604	in	_
146-12	22605-22618	amygdala-dACC	_
146-13	22619-22623	rsFC	_
146-14	22624-22627	may	_
146-15	22628-22630	be	_
146-16	22631-22635	more	_
146-17	22636-22643	related	_
146-18	22644-22646	to	_
146-19	22647-22650	and	_
146-20	22651-22657	severe	_
146-21	22658-22660	in	_
146-22	22661-22663	SZ	_
146-23	22663-22664	.	_

#Text=These findings may reflect the neural mechanisms underlying the initial similarities and then divergence in clinical course in adolescent and young adult with MDD and SZ.
147-1	22665-22670	These	_
147-2	22671-22679	findings	_
147-3	22680-22683	may	_
147-4	22684-22691	reflect	_
147-5	22692-22695	the	_
147-6	22696-22702	neural	_
147-7	22703-22713	mechanisms	_
147-8	22714-22724	underlying	_
147-9	22725-22728	the	_
147-10	22729-22736	initial	_
147-11	22737-22749	similarities	_
147-12	22750-22753	and	_
147-13	22754-22758	then	_
147-14	22759-22769	divergence	_
147-15	22770-22772	in	_
147-16	22773-22781	clinical	_
147-17	22782-22788	course	_
147-18	22789-22791	in	_
147-19	22792-22802	adolescent	_
147-20	22803-22806	and	_
147-21	22807-22812	young	_
147-22	22813-22818	adult	_
147-23	22819-22823	with	_
147-24	22824-22827	MDD	_
147-25	22828-22831	and	_
147-26	22832-22834	SZ	_
147-27	22834-22835	.	_

#Text=Moreover, they may indicate potential differentiating markers at first-onset that may improve early diagnosis, intervention and treatment in adolescent and young adult with MDD and SZ.
148-1	22836-22844	Moreover	_
148-2	22844-22845	,	_
148-3	22846-22850	they	_
148-4	22851-22854	may	_
148-5	22855-22863	indicate	_
148-6	22864-22873	potential	_
148-7	22874-22889	differentiating	_
148-8	22890-22897	markers	_
148-9	22898-22900	at	_
148-10	22901-22912	first-onset	_
148-11	22913-22917	that	_
148-12	22918-22921	may	_
148-13	22922-22929	improve	_
148-14	22930-22935	early	_
148-15	22936-22945	diagnosis	_
148-16	22945-22946	,	_
148-17	22947-22959	intervention	_
148-18	22960-22963	and	_
148-19	22964-22973	treatment	_
148-20	22974-22976	in	_
148-21	22977-22987	adolescent	_
148-22	22988-22991	and	_
148-23	22992-22997	young	_
148-24	22998-23003	adult	_
148-25	23004-23008	with	_
148-26	23009-23012	MDD	_
148-27	23013-23016	and	_
148-28	23017-23019	SZ	_
148-29	23019-23020	.	_

#Text=And the clinicians could treat patients in the 2 disorders using physical therapy related brain regions.
149-1	23021-23024	And	_
149-2	23025-23028	the	_
149-3	23029-23039	clinicians	_
149-4	23040-23045	could	_
149-5	23046-23051	treat	_
149-6	23052-23060	patients	_
149-7	23061-23063	in	_
149-8	23064-23067	the	_
149-9	23068-23069	2	_
149-10	23070-23079	disorders	_
149-11	23080-23085	using	_
149-12	23086-23094	physical	_
149-13	23095-23102	therapy	_
149-14	23103-23110	related	_
149-15	23111-23116	brain	_
149-16	23117-23124	regions	_
149-17	23124-23125	.	_

#Text=Additional Information
#Text=How to cite this article: Wei, S. et al.
150-1	23126-23136	Additional	_
150-2	23137-23148	Information	_
150-3	23149-23152	How	_
150-4	23153-23155	to	_
150-5	23156-23160	cite	_
150-6	23161-23165	this	_
150-7	23166-23173	article	_
150-8	23173-23174	:	_
150-9	23175-23178	Wei	_
150-10	23178-23179	,	_
150-11	23180-23181	S	_
150-12	23181-23182	.	_
150-13	23183-23185	et	_
150-14	23186-23188	al	_
150-15	23188-23189	.	_

#Text=Similarities and differences of functional connectivity in drug-naïve, first-episode adolescent and young adult with major depressive disorder and schizophrenia.
151-1	23190-23202	Similarities	_
151-2	23203-23206	and	_
151-3	23207-23218	differences	_
151-4	23219-23221	of	_
151-5	23222-23232	functional	_
151-6	23233-23245	connectivity	_
151-7	23246-23248	in	_
151-8	23249-23259	drug-naïve	_
151-9	23259-23260	,	_
151-10	23261-23274	first-episode	_
151-11	23275-23285	adolescent	_
151-12	23286-23289	and	_
151-13	23290-23295	young	_
151-14	23296-23301	adult	_
151-15	23302-23306	with	_
151-16	23307-23312	major	_
151-17	23313-23323	depressive	_
151-18	23324-23332	disorder	_
151-19	23333-23336	and	_
151-20	23337-23350	schizophrenia	_
151-21	23350-23351	.	_

#Text=Sci.
152-1	23352-23355	Sci	_
152-2	23355-23356	.	_

#Text=Rep. 7, 44316; doi: 10.1038/srep44316 (2017).
153-1	23357-23360	Rep	_
153-2	23360-23361	.	_
153-3	23362-23363	7	_
153-4	23363-23364	,	_
153-5	23365-23370	44316	_
153-6	23370-23371	;	_
153-7	23372-23375	doi	_
153-8	23375-23376	:	_
153-9	23377-23384	10.1038	_
153-10	23384-23385	/	_
153-11	23385-23394	srep44316	_
153-12	23395-23396	(	_
153-13	23396-23400	2017	_
153-14	23400-23401	)	_
153-15	23401-23402	.	_

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
154-1	23403-23414	Publisher's	_
154-2	23415-23419	note	_
154-3	23419-23420	:	_
154-4	23421-23429	Springer	_
154-5	23430-23436	Nature	_
154-6	23437-23444	remains	_
154-7	23445-23452	neutral	_
154-8	23453-23457	with	_
154-9	23458-23464	regard	_
154-10	23465-23467	to	_
154-11	23468-23482	jurisdictional	_
154-12	23483-23489	claims	_
154-13	23490-23492	in	_
154-14	23493-23502	published	_
154-15	23503-23507	maps	_
154-16	23508-23511	and	_
154-17	23512-23525	institutional	_
154-18	23526-23538	affiliations	_
154-19	23538-23539	.	_

#Text=Associations between trait anhedonia and emotional memory deficits in females with schizophrenia versus major depression
#Text=Sleep-disordered breathing: in depression and schizophrenia
#Text=Prevalence of item level negative symptoms in first episode psychosis diagnoses
#Text=Phenomenology of first-episode psychosis in schizophrenia, bipolar disorder, and unipolar depression: a comparative analysis
#Text=First self-perceived signs and symptoms in emerging psychosis compared with depression
#Text=Depression and depressive symptoms in first episode psychosis
#Text=Schizophrenia and depression: challenging the paradigm of two separate diseases–a controlled study of schizophrenia, depression and healthy controls
#Text=Depression, neuroimaging and connectomics: a selective overview
#Text=A review of structural neuroimaging in schizophrenia: from connectivity to connectomics
#Text=A systematic review of brain frontal lobe parcellation techniques in magnetic resonance imaging
#Text=Functional brain imaging studies of youth depression: a systematic review
#Text=In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature
#Text=Prefrontal cortex and the dysconnectivity hypothesis of schizophrenia
#Text=Depression: perspectives from affective neuroscience
#Text=Working memory and prefrontal cortex dysfunction: specificity to schizophrenia compared with major depression
#Text=Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing
#Text=Decreased conflict- and error-related activity in the anterior cingulate cortex in subjects with schizophrenia
#Text=Anterior cingulate cortex activation during cognitive interference in schizophrenia
#Text=Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression
#Text=The human orbitofrontal cortex: linking reward to hedonic experience
#Text=Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study
#Text=Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression
#Text=Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone
#Text=Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia
#Text=Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder
#Text=Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells
#Text=GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder
#Text=Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms
#Text=Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia
#Text=Amygdala volume marks the acute state in the early course of depression
#Text=Abnormal size of the amygdala predicts impaired emotional memory in major depressive disorder
#Text=Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression
#Text=Reduced ventral anterior cingulate and amygdala volumes in medication-naive females with major depressive disorder: A voxel-based morphometric magnetic resonance imaging study
#Text=Demonstration of decreased gray matter concentration in the midbrain encompassing the dorsal raphe nucleus and the limbic subcortical regions in major depressive disorder: an optimized voxel-based morphometry study
#Text=Hippocampal, amygdala and nucleus accumbens volume in first-episode schizophrenia patients and individuals at high familial risk: A cross-sectional comparison
#Text=Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study
#Text=Impaired emotional learning and reduced amygdala size in schizophrenia: a 3-month follow-up
#Text=Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features
#Text=Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study
#Text=Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment
#Text=Increased amygdala response to shame in remitted major depressive disorder
#Text=Altered amygdala activation in schizophrenia patients during emotion processing
#Text=Evidence for altered amygdala activation in schizophrenia in an adaptive emotion recognition task
#Text=Structural MRI correlates for vulnerability and resilience to major depressive disorder
#Text=Differential spatiotemporal characteristics of the prefrontal hemodynamic response and their association with functional impairment in schizophrenia and major depression
#Text=Increased cognition connectivity network in major depression disorder: a FMRI study
#Text=The effect of body-mind relaxation meditation induction on major depressive disorder: A resting-state fMRI study
#Text=Abnormal anterior cingulate cortical activity during emotional n-back task performance distinguishes bipolar from unipolar depressed females
#Text=Brain structure in schizophrenia vs. psychotic bipolar I disorder: A VBM study
#Text=Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study
#Text=Association of stigma resistance with emotion regulation - functional magnetic resonance imaging and neuropsychological findings
#Text=Impaired prefrontal-amygdala effective connectivity is responsible for the dysfunction of emotion process in major depressive disorder: a dynamic causal modeling study on MEG
#Text=Decreased functional connectivity between the amygdala and the left ventral prefrontal cortex in treatment-naive patients with major depressive disorder: a resting-state functional magnetic resonance imaging study
#Text=Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder
#Text=Differentiating patterns of amygdala-frontal functional connectivity in schizophrenia and bipolar disorder
#Text=Maturation of human cerebrum observed in vivo during adolescence
#Text=Structural magnetic resonance imaging of the adolescent brain
#Text=Testing the hypothesis of accelerated cerebral white matter aging in schizophrenia and major depression
#Text=A comprehensive assessment of regional variation in the impact of head micromovements on functional connectomics
#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
#Text=Sequence of information processing for emotions based on the anatomic dialogue between prefrontal cortex and amygdala
#Text=Functional connectivity between ventral prefrontal cortex and amygdala at low frequency in the resting state in bipolar disorder
#Text=Aberrant salience network (bilateral insula and anterior cingulate cortex) connectivity during information processing in schizophrenia
#Text=Regional brain metabolism during auditory hallucinations in chronic schizophrenia
#Text=Cognitive and emotional influences in anterior cingulate cortex
#Text=Neural correlates of treatment response in depressed bipolar adolescents during emotion processing
#Text=Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia
#Text=Magnetic stimulation of the dorsolateral prefrontal cortex dissociates fragile visual short-term memory from visual working memory
#Text=Mechanisms Underlying Motivational Deficits in Psychopathology: Similarities and Differences in Depression and Schizophrenia
#Text=Abnormal functional activation and connectivity in the working memory network in early-onset schizophrenia
#Text=Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data
#Text=Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited
#Text=Neuropsychological test performance in Aruaco Indians: an exploratory study
#Text=Comparison of manic and depressive symptoms between children and adolescents with bipolar spectrum disorders
#Text=The authors declare no competing financial interests.
155-1	23541-23553	Associations	_
155-2	23554-23561	between	_
155-3	23562-23567	trait	_
155-4	23568-23577	anhedonia	_
155-5	23578-23581	and	_
155-6	23582-23591	emotional	_
155-7	23592-23598	memory	_
155-8	23599-23607	deficits	_
155-9	23608-23610	in	_
155-10	23611-23618	females	_
155-11	23619-23623	with	_
155-12	23624-23637	schizophrenia	_
155-13	23638-23644	versus	_
155-14	23645-23650	major	_
155-15	23651-23661	depression	_
155-16	23662-23678	Sleep-disordered	_
155-17	23679-23688	breathing	_
155-18	23688-23689	:	_
155-19	23690-23692	in	_
155-20	23693-23703	depression	_
155-21	23704-23707	and	_
155-22	23708-23721	schizophrenia	_
155-23	23722-23732	Prevalence	_
155-24	23733-23735	of	_
155-25	23736-23740	item	_
155-26	23741-23746	level	_
155-27	23747-23755	negative	_
155-28	23756-23764	symptoms	_
155-29	23765-23767	in	_
155-30	23768-23773	first	_
155-31	23774-23781	episode	_
155-32	23782-23791	psychosis	_
155-33	23792-23801	diagnoses	_
155-34	23802-23815	Phenomenology	_
155-35	23816-23818	of	_
155-36	23819-23832	first-episode	_
155-37	23833-23842	psychosis	_
155-38	23843-23845	in	_
155-39	23846-23859	schizophrenia	_
155-40	23859-23860	,	_
155-41	23861-23868	bipolar	_
155-42	23869-23877	disorder	_
155-43	23877-23878	,	_
155-44	23879-23882	and	_
155-45	23883-23891	unipolar	_
155-46	23892-23902	depression	_
155-47	23902-23903	:	_
155-48	23904-23905	a	_
155-49	23906-23917	comparative	_
155-50	23918-23926	analysis	_
155-51	23927-23932	First	_
155-52	23933-23947	self-perceived	_
155-53	23948-23953	signs	_
155-54	23954-23957	and	_
155-55	23958-23966	symptoms	_
155-56	23967-23969	in	_
155-57	23970-23978	emerging	_
155-58	23979-23988	psychosis	_
155-59	23989-23997	compared	_
155-60	23998-24002	with	_
155-61	24003-24013	depression	_
155-62	24014-24024	Depression	_
155-63	24025-24028	and	_
155-64	24029-24039	depressive	_
155-65	24040-24048	symptoms	_
155-66	24049-24051	in	_
155-67	24052-24057	first	_
155-68	24058-24065	episode	_
155-69	24066-24075	psychosis	_
155-70	24076-24089	Schizophrenia	_
155-71	24090-24093	and	_
155-72	24094-24104	depression	_
155-73	24104-24105	:	_
155-74	24106-24117	challenging	_
155-75	24118-24121	the	_
155-76	24122-24130	paradigm	_
155-77	24131-24133	of	_
155-78	24134-24137	two	_
155-79	24138-24146	separate	_
155-80	24147-24157	diseases–a	_
155-81	24158-24168	controlled	_
155-82	24169-24174	study	_
155-83	24175-24177	of	_
155-84	24178-24191	schizophrenia	_
155-85	24191-24192	,	_
155-86	24193-24203	depression	_
155-87	24204-24207	and	_
155-88	24208-24215	healthy	_
155-89	24216-24224	controls	_
155-90	24225-24235	Depression	_
155-91	24235-24236	,	_
155-92	24237-24249	neuroimaging	_
155-93	24250-24253	and	_
155-94	24254-24266	connectomics	_
155-95	24266-24267	:	_
155-96	24268-24269	a	_
155-97	24270-24279	selective	_
155-98	24280-24288	overview	_
155-99	24289-24290	A	_
155-100	24291-24297	review	_
155-101	24298-24300	of	_
155-102	24301-24311	structural	_
155-103	24312-24324	neuroimaging	_
155-104	24325-24327	in	_
155-105	24328-24341	schizophrenia	_
155-106	24341-24342	:	_
155-107	24343-24347	from	_
155-108	24348-24360	connectivity	_
155-109	24361-24363	to	_
155-110	24364-24376	connectomics	_
155-111	24377-24378	A	_
155-112	24379-24389	systematic	_
155-113	24390-24396	review	_
155-114	24397-24399	of	_
155-115	24400-24405	brain	_
155-116	24406-24413	frontal	_
155-117	24414-24418	lobe	_
155-118	24419-24431	parcellation	_
155-119	24432-24442	techniques	_
155-120	24443-24445	in	_
155-121	24446-24454	magnetic	_
155-122	24455-24464	resonance	_
155-123	24465-24472	imaging	_
155-124	24473-24483	Functional	_
155-125	24484-24489	brain	_
155-126	24490-24497	imaging	_
155-127	24498-24505	studies	_
155-128	24506-24508	of	_
155-129	24509-24514	youth	_
155-130	24515-24525	depression	_
155-131	24525-24526	:	_
155-132	24527-24528	a	_
155-133	24529-24539	systematic	_
155-134	24540-24546	review	_
155-135	24547-24549	In	_
155-136	24550-24557	pursuit	_
155-137	24558-24560	of	_
155-138	24561-24573	neuroimaging	_
155-139	24574-24584	biomarkers	_
155-140	24585-24587	to	_
155-141	24588-24593	guide	_
155-142	24594-24603	treatment	_
155-143	24604-24613	selection	_
155-144	24614-24616	in	_
155-145	24617-24622	major	_
155-146	24623-24633	depressive	_
155-147	24634-24642	disorder	_
155-148	24642-24643	:	_
155-149	24644-24645	a	_
155-150	24646-24652	review	_
155-151	24653-24655	of	_
155-152	24656-24659	the	_
155-153	24660-24670	literature	_
155-154	24671-24681	Prefrontal	_
155-155	24682-24688	cortex	_
155-156	24689-24692	and	_
155-157	24693-24696	the	_
155-158	24697-24712	dysconnectivity	_
155-159	24713-24723	hypothesis	_
155-160	24724-24726	of	_
155-161	24727-24740	schizophrenia	_
155-162	24741-24751	Depression	_
155-163	24751-24752	:	_
155-164	24753-24765	perspectives	_
155-165	24766-24770	from	_
155-166	24771-24780	affective	_
155-167	24781-24793	neuroscience	_
155-168	24794-24801	Working	_
155-169	24802-24808	memory	_
155-170	24809-24812	and	_
155-171	24813-24823	prefrontal	_
155-172	24824-24830	cortex	_
155-173	24831-24842	dysfunction	_
155-174	24842-24843	:	_
155-175	24844-24855	specificity	_
155-176	24856-24858	to	_
155-177	24859-24872	schizophrenia	_
155-178	24873-24881	compared	_
155-179	24882-24886	with	_
155-180	24887-24892	major	_
155-181	24893-24903	depression	_
155-182	24904-24912	Impaired	_
155-183	24913-24923	subjective	_
155-184	24924-24934	well-being	_
155-185	24935-24937	in	_
155-186	24938-24951	schizophrenia	_
155-187	24952-24954	is	_
155-188	24955-24965	associated	_
155-189	24966-24970	with	_
155-190	24971-24978	reduced	_
155-191	24979-24987	anterior	_
155-192	24988-24997	cingulate	_
155-193	24998-25006	activity	_
155-194	25007-25013	during	_
155-195	25014-25020	reward	_
155-196	25021-25031	processing	_
155-197	25032-25041	Decreased	_
155-198	25042-25050	conflict	_
155-199	25050-25051	-	_
155-200	25052-25055	and	_
155-201	25056-25069	error-related	_
155-202	25070-25078	activity	_
155-203	25079-25081	in	_
155-204	25082-25085	the	_
155-205	25086-25094	anterior	_
155-206	25095-25104	cingulate	_
155-207	25105-25111	cortex	_
155-208	25112-25114	in	_
155-209	25115-25123	subjects	_
155-210	25124-25128	with	_
155-211	25129-25142	schizophrenia	_
155-212	25143-25151	Anterior	_
155-213	25152-25161	cingulate	_
155-214	25162-25168	cortex	_
155-215	25169-25179	activation	_
155-216	25180-25186	during	_
155-217	25187-25196	cognitive	_
155-218	25197-25209	interference	_
155-219	25210-25212	in	_
155-220	25213-25226	schizophrenia	_
155-221	25227-25237	Functional	_
155-222	25238-25250	connectivity	_
155-223	25251-25255	bias	_
155-224	25256-25258	of	_
155-225	25259-25262	the	_
155-226	25263-25276	orbitofrontal	_
155-227	25277-25283	cortex	_
155-228	25284-25286	in	_
155-229	25287-25296	drug-free	_
155-230	25297-25305	patients	_
155-231	25306-25310	with	_
155-232	25311-25316	major	_
155-233	25317-25327	depression	_
155-234	25328-25331	The	_
155-235	25332-25337	human	_
155-236	25338-25351	orbitofrontal	_
155-237	25352-25358	cortex	_
155-238	25358-25359	:	_
155-239	25360-25367	linking	_
155-240	25368-25374	reward	_
155-241	25375-25377	to	_
155-242	25378-25385	hedonic	_
155-243	25386-25396	experience	_
155-244	25397-25408	Basolateral	_
155-245	25409-25417	amygdala	_
155-246	25418-25424	volume	_
155-247	25425-25428	and	_
155-248	25429-25433	cell	_
155-249	25434-25441	numbers	_
155-250	25442-25444	in	_
155-251	25445-25450	major	_
155-252	25451-25461	depressive	_
155-253	25462-25470	disorder	_
155-254	25470-25471	:	_
155-255	25472-25473	a	_
155-256	25474-25484	postmortem	_
155-257	25485-25498	stereological	_
155-258	25499-25504	study	_
155-259	25505-25512	Reduced	_
155-260	25513-25519	levels	_
155-261	25520-25522	of	_
155-262	25523-25527	NR2A	_
155-263	25528-25531	and	_
155-264	25532-25536	NR2B	_
155-265	25537-25545	subunits	_
155-266	25546-25548	of	_
155-267	25549-25553	NMDA	_
155-268	25554-25562	receptor	_
155-269	25563-25566	and	_
155-270	25567-25570	PSD	_
155-271	25570-25571	-	_
155-272	25571-25573	95	_
155-273	25574-25576	in	_
155-274	25577-25580	the	_
155-275	25581-25591	prefrontal	_
155-276	25592-25598	cortex	_
155-277	25599-25601	in	_
155-278	25602-25607	major	_
155-279	25608-25618	depression	_
155-280	25619-25626	Altered	_
155-281	25627-25631	gene	_
155-282	25632-25642	expression	_
155-283	25643-25645	in	_
155-284	25646-25649	the	_
155-285	25650-25658	amygdala	_
155-286	25659-25661	in	_
155-287	25662-25675	schizophrenia	_
155-288	25675-25676	:	_
155-289	25677-25690	up-regulation	_
155-290	25691-25693	of	_
155-291	25694-25699	genes	_
155-292	25700-25707	located	_
155-293	25708-25710	in	_
155-294	25711-25714	the	_
155-295	25715-25725	cytomatrix	_
155-296	25726-25732	active	_
155-297	25733-25737	zone	_
155-298	25738-25746	Impaired	_
155-299	25747-25757	kynurenine	_
155-300	25758-25765	pathway	_
155-301	25766-25776	metabolism	_
155-302	25777-25779	in	_
155-303	25780-25783	the	_
155-304	25784-25794	prefrontal	_
155-305	25795-25801	cortex	_
155-306	25802-25804	of	_
155-307	25805-25816	individuals	_
155-308	25817-25821	with	_
155-309	25822-25835	schizophrenia	_
155-310	25836-25844	Amygdala	_
155-311	25845-25854	astrocyte	_
155-312	25855-25864	reduction	_
155-313	25865-25867	in	_
155-314	25868-25876	subjects	_
155-315	25877-25881	with	_
155-316	25882-25887	major	_
155-317	25888-25898	depressive	_
155-318	25899-25907	disorder	_
155-319	25908-25911	but	_
155-320	25912-25915	not	_
155-321	25916-25923	bipolar	_
155-322	25924-25932	disorder	_
155-323	25933-25943	Postmortem	_
155-324	25944-25951	studies	_
155-325	25952-25954	in	_
155-326	25955-25959	mood	_
155-327	25960-25969	disorders	_
155-328	25970-25978	indicate	_
155-329	25979-25986	altered	_
155-330	25987-25994	numbers	_
155-331	25995-25997	of	_
155-332	25998-26005	neurons	_
155-333	26006-26009	and	_
155-334	26010-26015	glial	_
155-335	26016-26021	cells	_
155-336	26022-26031	GABAergic	_
155-337	26032-26044	interneurons	_
155-338	26044-26045	:	_
155-339	26046-26058	implications	_
155-340	26059-26062	for	_
155-341	26063-26076	understanding	_
155-342	26077-26090	schizophrenia	_
155-343	26091-26094	and	_
155-344	26095-26102	bipolar	_
155-345	26103-26111	disorder	_
155-346	26112-26121	Searching	_
155-347	26122-26125	for	_
155-348	26126-26132	unique	_
155-349	26133-26147	endophenotypes	_
155-350	26148-26151	for	_
155-351	26152-26165	schizophrenia	_
155-352	26166-26169	and	_
155-353	26170-26177	bipolar	_
155-354	26178-26186	disorder	_
155-355	26187-26193	within	_
155-356	26194-26200	neural	_
155-357	26201-26209	circuits	_
155-358	26210-26213	and	_
155-359	26214-26219	their	_
155-360	26220-26229	molecular	_
155-361	26230-26240	regulatory	_
155-362	26241-26251	mechanisms	_
155-363	26252-26261	Molecular	_
155-364	26262-26274	determinants	_
155-365	26275-26277	of	_
155-366	26278-26290	dysregulated	_
155-367	26291-26300	GABAergic	_
155-368	26301-26305	gene	_
155-369	26306-26316	expression	_
155-370	26317-26319	in	_
155-371	26320-26323	the	_
155-372	26324-26334	prefrontal	_
155-373	26335-26341	cortex	_
155-374	26342-26344	of	_
155-375	26345-26353	subjects	_
155-376	26354-26358	with	_
155-377	26359-26372	schizophrenia	_
155-378	26373-26381	Amygdala	_
155-379	26382-26388	volume	_
155-380	26389-26394	marks	_
155-381	26395-26398	the	_
155-382	26399-26404	acute	_
155-383	26405-26410	state	_
155-384	26411-26413	in	_
155-385	26414-26417	the	_
155-386	26418-26423	early	_
155-387	26424-26430	course	_
155-388	26431-26433	of	_
155-389	26434-26444	depression	_
155-390	26445-26453	Abnormal	_
155-391	26454-26458	size	_
155-392	26459-26461	of	_
155-393	26462-26465	the	_
155-394	26466-26474	amygdala	_
155-395	26475-26483	predicts	_
155-396	26484-26492	impaired	_
155-397	26493-26502	emotional	_
155-398	26503-26509	memory	_
155-399	26510-26512	in	_
155-400	26513-26518	major	_
155-401	26519-26529	depressive	_
155-402	26530-26538	disorder	_
155-403	26539-26546	Reduced	_
155-404	26547-26555	amygdala	_
155-405	26556-26562	volume	_
155-406	26563-26565	in	_
155-407	26566-26571	newly	_
155-408	26572-26580	admitted	_
155-409	26581-26592	psychiatric	_
155-410	26593-26604	in-patients	_
155-411	26605-26609	with	_
155-412	26610-26618	unipolar	_
155-413	26619-26624	major	_
155-414	26625-26635	depression	_
155-415	26636-26643	Reduced	_
155-416	26644-26651	ventral	_
155-417	26652-26660	anterior	_
155-418	26661-26670	cingulate	_
155-419	26671-26674	and	_
155-420	26675-26683	amygdala	_
155-421	26684-26691	volumes	_
155-422	26692-26694	in	_
155-423	26695-26711	medication-naive	_
155-424	26712-26719	females	_
155-425	26720-26724	with	_
155-426	26725-26730	major	_
155-427	26731-26741	depressive	_
155-428	26742-26750	disorder	_
155-429	26750-26751	:	_
155-430	26752-26753	A	_
155-431	26754-26765	voxel-based	_
155-432	26766-26778	morphometric	_
155-433	26779-26787	magnetic	_
155-434	26788-26797	resonance	_
155-435	26798-26805	imaging	_
155-436	26806-26811	study	_
155-437	26812-26825	Demonstration	_
155-438	26826-26828	of	_
155-439	26829-26838	decreased	_
155-440	26839-26843	gray	_
155-441	26844-26850	matter	_
155-442	26851-26864	concentration	_
155-443	26865-26867	in	_
155-444	26868-26871	the	_
155-445	26872-26880	midbrain	_
155-446	26881-26893	encompassing	_
155-447	26894-26897	the	_
155-448	26898-26904	dorsal	_
155-449	26905-26910	raphe	_
155-450	26911-26918	nucleus	_
155-451	26919-26922	and	_
155-452	26923-26926	the	_
155-453	26927-26933	limbic	_
155-454	26934-26945	subcortical	_
155-455	26946-26953	regions	_
155-456	26954-26956	in	_
155-457	26957-26962	major	_
155-458	26963-26973	depressive	_
155-459	26974-26982	disorder	_
155-460	26982-26983	:	_
155-461	26984-26986	an	_
155-462	26987-26996	optimized	_
155-463	26997-27008	voxel-based	_
155-464	27009-27020	morphometry	_
155-465	27021-27026	study	_
155-466	27027-27038	Hippocampal	_
155-467	27038-27039	,	_
155-468	27040-27048	amygdala	_
155-469	27049-27052	and	_
155-470	27053-27060	nucleus	_
155-471	27061-27070	accumbens	_
155-472	27071-27077	volume	_
155-473	27078-27080	in	_
155-474	27081-27094	first-episode	_
155-475	27095-27108	schizophrenia	_
155-476	27109-27117	patients	_
155-477	27118-27121	and	_
155-478	27122-27133	individuals	_
155-479	27134-27136	at	_
155-480	27137-27141	high	_
155-481	27142-27150	familial	_
155-482	27151-27155	risk	_
155-483	27155-27156	:	_
155-484	27157-27158	A	_
155-485	27159-27174	cross-sectional	_
155-486	27175-27185	comparison	_
155-487	27186-27196	Structural	_
155-488	27197-27202	brain	_
155-489	27203-27214	alterations	_
155-490	27215-27217	at	_
155-491	27218-27227	different	_
155-492	27228-27234	stages	_
155-493	27235-27237	of	_
155-494	27238-27251	schizophrenia	_
155-495	27251-27252	:	_
155-496	27253-27254	a	_
155-497	27255-27266	voxel-based	_
155-498	27267-27279	morphometric	_
155-499	27280-27285	study	_
155-500	27286-27294	Impaired	_
155-501	27295-27304	emotional	_
155-502	27305-27313	learning	_
155-503	27314-27317	and	_
155-504	27318-27325	reduced	_
155-505	27326-27334	amygdala	_
155-506	27335-27339	size	_
155-507	27340-27342	in	_
155-508	27343-27356	schizophrenia	_
155-509	27356-27357	:	_
155-510	27358-27359	a	_
155-511	27360-27361	3	_
155-512	27361-27362	-	_
155-513	27362-27367	month	_
155-514	27368-27377	follow-up	_
155-515	27378-27387	Increased	_
155-516	27388-27396	amygdala	_
155-517	27397-27400	and	_
155-518	27401-27410	decreased	_
155-519	27411-27423	dorsolateral	_
155-520	27424-27434	prefrontal	_
155-521	27435-27439	BOLD	_
155-522	27440-27449	responses	_
155-523	27450-27452	in	_
155-524	27453-27461	unipolar	_
155-525	27462-27472	depression	_
155-526	27472-27473	:	_
155-527	27474-27481	related	_
155-528	27482-27485	and	_
155-529	27486-27497	independent	_
155-530	27498-27506	features	_
155-531	27507-27515	Activity	_
155-532	27516-27519	and	_
155-533	27520-27532	connectivity	_
155-534	27533-27535	of	_
155-535	27536-27541	brain	_
155-536	27542-27546	mood	_
155-537	27547-27557	regulating	_
155-538	27558-27565	circuit	_
155-539	27566-27568	in	_
155-540	27569-27579	depression	_
155-541	27579-27580	:	_
155-542	27581-27582	a	_
155-543	27583-27593	functional	_
155-544	27594-27602	magnetic	_
155-545	27603-27612	resonance	_
155-546	27613-27618	study	_
155-547	27619-27628	Increased	_
155-548	27629-27637	amygdala	_
155-549	27638-27647	responses	_
155-550	27648-27650	to	_
155-551	27651-27654	sad	_
155-552	27655-27658	but	_
155-553	27659-27662	not	_
155-554	27663-27670	fearful	_
155-555	27671-27676	faces	_
155-556	27677-27679	in	_
155-557	27680-27685	major	_
155-558	27686-27696	depression	_
155-559	27696-27697	:	_
155-560	27698-27706	relation	_
155-561	27707-27709	to	_
155-562	27710-27714	mood	_
155-563	27715-27720	state	_
155-564	27721-27724	and	_
155-565	27725-27740	pharmacological	_
155-566	27741-27750	treatment	_
155-567	27751-27760	Increased	_
155-568	27761-27769	amygdala	_
155-569	27770-27778	response	_
155-570	27779-27781	to	_
155-571	27782-27787	shame	_
155-572	27788-27790	in	_
155-573	27791-27799	remitted	_
155-574	27800-27805	major	_
155-575	27806-27816	depressive	_
155-576	27817-27825	disorder	_
155-577	27826-27833	Altered	_
155-578	27834-27842	amygdala	_
155-579	27843-27853	activation	_
155-580	27854-27856	in	_
155-581	27857-27870	schizophrenia	_
155-582	27871-27879	patients	_
155-583	27880-27886	during	_
155-584	27887-27894	emotion	_
155-585	27895-27905	processing	_
155-586	27906-27914	Evidence	_
155-587	27915-27918	for	_
155-588	27919-27926	altered	_
155-589	27927-27935	amygdala	_
155-590	27936-27946	activation	_
155-591	27947-27949	in	_
155-592	27950-27963	schizophrenia	_
155-593	27964-27966	in	_
155-594	27967-27969	an	_
155-595	27970-27978	adaptive	_
155-596	27979-27986	emotion	_
155-597	27987-27998	recognition	_
155-598	27999-28003	task	_
155-599	28004-28014	Structural	_
155-600	28015-28018	MRI	_
155-601	28019-28029	correlates	_
155-602	28030-28033	for	_
155-603	28034-28047	vulnerability	_
155-604	28048-28051	and	_
155-605	28052-28062	resilience	_
155-606	28063-28065	to	_
155-607	28066-28071	major	_
155-608	28072-28082	depressive	_
155-609	28083-28091	disorder	_
155-610	28092-28104	Differential	_
155-611	28105-28119	spatiotemporal	_
155-612	28120-28135	characteristics	_
155-613	28136-28138	of	_
155-614	28139-28142	the	_
155-615	28143-28153	prefrontal	_
155-616	28154-28165	hemodynamic	_
155-617	28166-28174	response	_
155-618	28175-28178	and	_
155-619	28179-28184	their	_
155-620	28185-28196	association	_
155-621	28197-28201	with	_
155-622	28202-28212	functional	_
155-623	28213-28223	impairment	_
155-624	28224-28226	in	_
155-625	28227-28240	schizophrenia	_
155-626	28241-28244	and	_
155-627	28245-28250	major	_
155-628	28251-28261	depression	_
155-629	28262-28271	Increased	_
155-630	28272-28281	cognition	_
155-631	28282-28294	connectivity	_
155-632	28295-28302	network	_
155-633	28303-28305	in	_
155-634	28306-28311	major	_
155-635	28312-28322	depression	_
155-636	28323-28331	disorder	_
155-637	28331-28332	:	_
155-638	28333-28334	a	_
155-639	28335-28339	FMRI	_
155-640	28340-28345	study	_
155-641	28346-28349	The	_
155-642	28350-28356	effect	_
155-643	28357-28359	of	_
155-644	28360-28369	body-mind	_
155-645	28370-28380	relaxation	_
155-646	28381-28391	meditation	_
155-647	28392-28401	induction	_
155-648	28402-28404	on	_
155-649	28405-28410	major	_
155-650	28411-28421	depressive	_
155-651	28422-28430	disorder	_
155-652	28430-28431	:	_
155-653	28432-28433	A	_
155-654	28434-28447	resting-state	_
155-655	28448-28452	fMRI	_
155-656	28453-28458	study	_
155-657	28459-28467	Abnormal	_
155-658	28468-28476	anterior	_
155-659	28477-28486	cingulate	_
155-660	28487-28495	cortical	_
155-661	28496-28504	activity	_
155-662	28505-28511	during	_
155-663	28512-28521	emotional	_
155-664	28522-28528	n-back	_
155-665	28529-28533	task	_
155-666	28534-28545	performance	_
155-667	28546-28559	distinguishes	_
155-668	28560-28567	bipolar	_
155-669	28568-28572	from	_
155-670	28573-28581	unipolar	_
155-671	28582-28591	depressed	_
155-672	28592-28599	females	_
155-673	28600-28605	Brain	_
155-674	28606-28615	structure	_
155-675	28616-28618	in	_
155-676	28619-28632	schizophrenia	_
155-677	28633-28635	vs	_
155-678	28635-28636	.	_
155-679	28637-28646	psychotic	_
155-680	28647-28654	bipolar	_
155-681	28655-28656	I	_
155-682	28657-28665	disorder	_
155-683	28665-28666	:	_
155-684	28667-28668	A	_
155-685	28669-28672	VBM	_
155-686	28673-28678	study	_
155-687	28679-28687	Deficits	_
155-688	28688-28690	in	_
155-689	28691-28701	prefrontal	_
155-690	28702-28710	cortical	_
155-691	28711-28714	and	_
155-692	28715-28728	extrastriatal	_
155-693	28729-28737	dopamine	_
155-694	28738-28745	release	_
155-695	28746-28748	in	_
155-696	28749-28762	schizophrenia	_
155-697	28762-28763	:	_
155-698	28764-28765	a	_
155-699	28766-28774	positron	_
155-700	28775-28783	emission	_
155-701	28784-28795	tomographic	_
155-702	28796-28806	functional	_
155-703	28807-28815	magnetic	_
155-704	28816-28825	resonance	_
155-705	28826-28833	imaging	_
155-706	28834-28839	study	_
155-707	28840-28851	Association	_
155-708	28852-28854	of	_
155-709	28855-28861	stigma	_
155-710	28862-28872	resistance	_
155-711	28873-28877	with	_
155-712	28878-28885	emotion	_
155-713	28886-28896	regulation	_
155-714	28897-28898	-	_
155-715	28899-28909	functional	_
155-716	28910-28918	magnetic	_
155-717	28919-28928	resonance	_
155-718	28929-28936	imaging	_
155-719	28937-28940	and	_
155-720	28941-28959	neuropsychological	_
155-721	28960-28968	findings	_
155-722	28969-28977	Impaired	_
155-723	28978-28997	prefrontal-amygdala	_
155-724	28998-29007	effective	_
155-725	29008-29020	connectivity	_
155-726	29021-29023	is	_
155-727	29024-29035	responsible	_
155-728	29036-29039	for	_
155-729	29040-29043	the	_
155-730	29044-29055	dysfunction	_
155-731	29056-29058	of	_
155-732	29059-29066	emotion	_
155-733	29067-29074	process	_
155-734	29075-29077	in	_
155-735	29078-29083	major	_
155-736	29084-29094	depressive	_
155-737	29095-29103	disorder	_
155-738	29103-29104	:	_
155-739	29105-29106	a	_
155-740	29107-29114	dynamic	_
155-741	29115-29121	causal	_
155-742	29122-29130	modeling	_
155-743	29131-29136	study	_
155-744	29137-29139	on	_
155-745	29140-29143	MEG	_
155-746	29144-29153	Decreased	_
155-747	29154-29164	functional	_
155-748	29165-29177	connectivity	_
155-749	29178-29185	between	_
155-750	29186-29189	the	_
155-751	29190-29198	amygdala	_
155-752	29199-29202	and	_
155-753	29203-29206	the	_
155-754	29207-29211	left	_
155-755	29212-29219	ventral	_
155-756	29220-29230	prefrontal	_
155-757	29231-29237	cortex	_
155-758	29238-29240	in	_
155-759	29241-29256	treatment-naive	_
155-760	29257-29265	patients	_
155-761	29266-29270	with	_
155-762	29271-29276	major	_
155-763	29277-29287	depressive	_
155-764	29288-29296	disorder	_
155-765	29296-29297	:	_
155-766	29298-29299	a	_
155-767	29300-29313	resting-state	_
155-768	29314-29324	functional	_
155-769	29325-29333	magnetic	_
155-770	29334-29343	resonance	_
155-771	29344-29351	imaging	_
155-772	29352-29357	study	_
155-773	29358-29368	Functional	_
155-774	29369-29381	connectivity	_
155-775	29382-29389	between	_
155-776	29390-29393	the	_
155-777	29394-29402	amygdala	_
155-778	29403-29406	and	_
155-779	29407-29417	prefrontal	_
155-780	29418-29424	cortex	_
155-781	29425-29427	in	_
155-782	29428-29444	medication-naive	_
155-783	29445-29456	individuals	_
155-784	29457-29461	with	_
155-785	29462-29467	major	_
155-786	29468-29478	depressive	_
155-787	29479-29487	disorder	_
155-788	29488-29503	Differentiating	_
155-789	29504-29512	patterns	_
155-790	29513-29515	of	_
155-791	29516-29532	amygdala-frontal	_
155-792	29533-29543	functional	_
155-793	29544-29556	connectivity	_
155-794	29557-29559	in	_
155-795	29560-29573	schizophrenia	_
155-796	29574-29577	and	_
155-797	29578-29585	bipolar	_
155-798	29586-29594	disorder	_
155-799	29595-29605	Maturation	_
155-800	29606-29608	of	_
155-801	29609-29614	human	_
155-802	29615-29623	cerebrum	_
155-803	29624-29632	observed	_
155-804	29633-29635	in	_
155-805	29636-29640	vivo	_
155-806	29641-29647	during	_
155-807	29648-29659	adolescence	_
155-808	29660-29670	Structural	_
155-809	29671-29679	magnetic	_
155-810	29680-29689	resonance	_
155-811	29690-29697	imaging	_
155-812	29698-29700	of	_
155-813	29701-29704	the	_
155-814	29705-29715	adolescent	_
155-815	29716-29721	brain	_
155-816	29722-29729	Testing	_
155-817	29730-29733	the	_
155-818	29734-29744	hypothesis	_
155-819	29745-29747	of	_
155-820	29748-29759	accelerated	_
155-821	29760-29768	cerebral	_
155-822	29769-29774	white	_
155-823	29775-29781	matter	_
155-824	29782-29787	aging	_
155-825	29788-29790	in	_
155-826	29791-29804	schizophrenia	_
155-827	29805-29808	and	_
155-828	29809-29814	major	_
155-829	29815-29825	depression	_
155-830	29826-29827	A	_
155-831	29828-29841	comprehensive	_
155-832	29842-29852	assessment	_
155-833	29853-29855	of	_
155-834	29856-29864	regional	_
155-835	29865-29874	variation	_
155-836	29875-29877	in	_
155-837	29878-29881	the	_
155-838	29882-29888	impact	_
155-839	29889-29891	of	_
155-840	29892-29896	head	_
155-841	29897-29911	micromovements	_
155-842	29912-29914	on	_
155-843	29915-29925	functional	_
155-844	29926-29938	connectomics	_
155-845	29939-29948	Automated	_
155-846	29949-29959	anatomical	_
155-847	29960-29968	labeling	_
155-848	29969-29971	of	_
155-849	29972-29983	activations	_
155-850	29984-29986	in	_
155-851	29987-29990	SPM	_
155-852	29991-29996	using	_
155-853	29997-29998	a	_
155-854	29999-30010	macroscopic	_
155-855	30011-30021	anatomical	_
155-856	30022-30034	parcellation	_
155-857	30035-30037	of	_
155-858	30038-30041	the	_
155-859	30042-30045	MNI	_
155-860	30046-30049	MRI	_
155-861	30050-30064	single-subject	_
155-862	30065-30070	brain	_
155-863	30071-30079	Sequence	_
155-864	30080-30082	of	_
155-865	30083-30094	information	_
155-866	30095-30105	processing	_
155-867	30106-30109	for	_
155-868	30110-30118	emotions	_
155-869	30119-30124	based	_
155-870	30125-30127	on	_
155-871	30128-30131	the	_
155-872	30132-30140	anatomic	_
155-873	30141-30149	dialogue	_
155-874	30150-30157	between	_
155-875	30158-30168	prefrontal	_
155-876	30169-30175	cortex	_
155-877	30176-30179	and	_
155-878	30180-30188	amygdala	_
155-879	30189-30199	Functional	_
155-880	30200-30212	connectivity	_
155-881	30213-30220	between	_
155-882	30221-30228	ventral	_
155-883	30229-30239	prefrontal	_
155-884	30240-30246	cortex	_
155-885	30247-30250	and	_
155-886	30251-30259	amygdala	_
155-887	30260-30262	at	_
155-888	30263-30266	low	_
155-889	30267-30276	frequency	_
155-890	30277-30279	in	_
155-891	30280-30283	the	_
155-892	30284-30291	resting	_
155-893	30292-30297	state	_
155-894	30298-30300	in	_
155-895	30301-30308	bipolar	_
155-896	30309-30317	disorder	_
155-897	30318-30326	Aberrant	_
155-898	30327-30335	salience	_
155-899	30336-30343	network	_
155-900	30344-30345	(	_
155-901	30345-30354	bilateral	_
155-902	30355-30361	insula	_
155-903	30362-30365	and	_
155-904	30366-30374	anterior	_
155-905	30375-30384	cingulate	_
155-906	30385-30391	cortex	_
155-907	30391-30392	)	_
155-908	30393-30405	connectivity	_
155-909	30406-30412	during	_
155-910	30413-30424	information	_
155-911	30425-30435	processing	_
155-912	30436-30438	in	_
155-913	30439-30452	schizophrenia	_
155-914	30453-30461	Regional	_
155-915	30462-30467	brain	_
155-916	30468-30478	metabolism	_
155-917	30479-30485	during	_
155-918	30486-30494	auditory	_
155-919	30495-30509	hallucinations	_
155-920	30510-30512	in	_
155-921	30513-30520	chronic	_
155-922	30521-30534	schizophrenia	_
155-923	30535-30544	Cognitive	_
155-924	30545-30548	and	_
155-925	30549-30558	emotional	_
155-926	30559-30569	influences	_
155-927	30570-30572	in	_
155-928	30573-30581	anterior	_
155-929	30582-30591	cingulate	_
155-930	30592-30598	cortex	_
155-931	30599-30605	Neural	_
155-932	30606-30616	correlates	_
155-933	30617-30619	of	_
155-934	30620-30629	treatment	_
155-935	30630-30638	response	_
155-936	30639-30641	in	_
155-937	30642-30651	depressed	_
155-938	30652-30659	bipolar	_
155-939	30660-30671	adolescents	_
155-940	30672-30678	during	_
155-941	30679-30686	emotion	_
155-942	30687-30697	processing	_
155-943	30698-30707	Cognitive	_
155-944	30708-30711	and	_
155-945	30712-30718	neural	_
155-946	30719-30729	strategies	_
155-947	30730-30736	during	_
155-948	30737-30744	control	_
155-949	30745-30747	of	_
155-950	30748-30751	the	_
155-951	30752-30760	anterior	_
155-952	30761-30770	cingulate	_
155-953	30771-30777	cortex	_
155-954	30778-30780	by	_
155-955	30781-30785	fMRI	_
155-956	30786-30799	neurofeedback	_
155-957	30800-30802	in	_
155-958	30803-30811	patients	_
155-959	30812-30816	with	_
155-960	30817-30830	schizophrenia	_
155-961	30831-30839	Magnetic	_
155-962	30840-30851	stimulation	_
155-963	30852-30854	of	_
155-964	30855-30858	the	_
155-965	30859-30871	dorsolateral	_
155-966	30872-30882	prefrontal	_
155-967	30883-30889	cortex	_
155-968	30890-30901	dissociates	_
155-969	30902-30909	fragile	_
155-970	30910-30916	visual	_
155-971	30917-30927	short-term	_
155-972	30928-30934	memory	_
155-973	30935-30939	from	_
155-974	30940-30946	visual	_
155-975	30947-30954	working	_
155-976	30955-30961	memory	_
155-977	30962-30972	Mechanisms	_
155-978	30973-30983	Underlying	_
155-979	30984-30996	Motivational	_
155-980	30997-31005	Deficits	_
155-981	31006-31008	in	_
155-982	31009-31024	Psychopathology	_
155-983	31024-31025	:	_
155-984	31026-31038	Similarities	_
155-985	31039-31042	and	_
155-986	31043-31054	Differences	_
155-987	31055-31057	in	_
155-988	31058-31068	Depression	_
155-989	31069-31072	and	_
155-990	31073-31086	Schizophrenia	_
155-991	31087-31095	Abnormal	_
155-992	31096-31106	functional	_
155-993	31107-31117	activation	_
155-994	31118-31121	and	_
155-995	31122-31134	connectivity	_
155-996	31135-31137	in	_
155-997	31138-31141	the	_
155-998	31142-31149	working	_
155-999	31150-31156	memory	_
155-1000	31157-31164	network	_
155-1001	31165-31167	in	_
155-1002	31168-31179	early-onset	_
155-1003	31180-31193	schizophrenia	_
155-1004	31194-31204	Functional	_
155-1005	31205-31217	neuroimaging	_
155-1006	31218-31220	of	_
155-1007	31221-31226	major	_
155-1008	31227-31237	depressive	_
155-1009	31238-31246	disorder	_
155-1010	31246-31247	:	_
155-1011	31248-31249	a	_
155-1012	31250-31263	meta-analysis	_
155-1013	31264-31267	and	_
155-1014	31268-31271	new	_
155-1015	31272-31283	integration	_
155-1016	31284-31286	of	_
155-1017	31287-31291	base	_
155-1018	31292-31296	line	_
155-1019	31297-31307	activation	_
155-1020	31308-31311	and	_
155-1021	31312-31318	neural	_
155-1022	31319-31327	response	_
155-1023	31328-31332	data	_
155-1024	31333-31346	Physiological	_
155-1025	31347-31358	dysfunction	_
155-1026	31359-31361	of	_
155-1027	31362-31365	the	_
155-1028	31366-31378	dorsolateral	_
155-1029	31379-31389	prefrontal	_
155-1030	31390-31396	cortex	_
155-1031	31397-31399	in	_
155-1032	31400-31413	schizophrenia	_
155-1033	31414-31423	revisited	_
155-1034	31424-31442	Neuropsychological	_
155-1035	31443-31447	test	_
155-1036	31448-31459	performance	_
155-1037	31460-31462	in	_
155-1038	31463-31469	Aruaco	_
155-1039	31470-31477	Indians	_
155-1040	31477-31478	:	_
155-1041	31479-31481	an	_
155-1042	31482-31493	exploratory	_
155-1043	31494-31499	study	_
155-1044	31500-31510	Comparison	_
155-1045	31511-31513	of	_
155-1046	31514-31519	manic	_
155-1047	31520-31523	and	_
155-1048	31524-31534	depressive	_
155-1049	31535-31543	symptoms	_
155-1050	31544-31551	between	_
155-1051	31552-31560	children	_
155-1052	31561-31564	and	_
155-1053	31565-31576	adolescents	_
155-1054	31577-31581	with	_
155-1055	31582-31589	bipolar	_
155-1056	31590-31598	spectrum	_
155-1057	31599-31608	disorders	_
155-1058	31609-31612	The	_
155-1059	31613-31620	authors	_
155-1060	31621-31628	declare	_
155-1061	31629-31631	no	_
155-1062	31632-31641	competing	_
155-1063	31642-31651	financial	_
155-1064	31652-31661	interests	_
155-1065	31661-31662	.	_

#Text=Author Contributions F.W. and Y.T. designed the experiment.
156-1	31663-31669	Author	_
156-2	31670-31683	Contributions	_
156-3	31684-31687	F.W	_
156-4	31687-31688	.	_
156-5	31689-31692	and	_
156-6	31693-31696	Y.T	_
156-7	31696-31697	.	_
156-8	31698-31706	designed	_
156-9	31707-31710	the	_
156-10	31711-31721	experiment	_
156-11	31721-31722	.	_

#Text=H.G. and M.C. acquired the data.
157-1	31723-31726	H.G	_
157-2	31726-31727	.	_
157-3	31728-31731	and	_
157-4	31732-31735	M.C	_
157-5	31735-31736	.	_
157-6	31737-31745	acquired	_
157-7	31746-31749	the	_
157-8	31750-31754	data	_
157-9	31754-31755	.	_

#Text=S.W., H.G., M.C., Q.Z., Y.Z. and X.J. analyzed the data.
158-1	31756-31759	S.W	_
158-2	31759-31760	.	_
158-3	31760-31761	,	_
158-4	31762-31765	H.G	_
158-5	31765-31766	.	_
158-6	31766-31767	,	_
158-7	31768-31771	M.C	_
158-8	31771-31772	.	_
158-9	31772-31773	,	_
158-10	31774-31777	Q.Z	_
158-11	31777-31778	.	_
158-12	31778-31779	,	_
158-13	31780-31783	Y.Z	_
158-14	31783-31784	.	_
158-15	31785-31788	and	_
158-16	31789-31792	X.J	_
158-17	31792-31793	.	_
158-18	31794-31802	analyzed	_
158-19	31803-31806	the	_
158-20	31807-31811	data	_
158-21	31811-31812	.	_

#Text=S.W. and F.W. wrote the manuscript.
159-1	31813-31816	S.W	_
159-2	31816-31817	.	_
159-3	31818-31821	and	_
159-4	31822-31825	F.W	_
159-5	31825-31826	.	_
159-6	31827-31832	wrote	_
159-7	31833-31836	the	_
159-8	31837-31847	manuscript	_
159-9	31847-31848	.	_

#Text=All the authors discussed the results and reviewed the manuscript.
160-1	31849-31852	All	_
160-2	31853-31856	the	_
160-3	31857-31864	authors	_
160-4	31865-31874	discussed	_
160-5	31875-31878	the	_
160-6	31879-31886	results	_
160-7	31887-31890	and	_
160-8	31891-31899	reviewed	_
160-9	31900-31903	the	_
160-10	31904-31914	manuscript	_
160-11	31914-31915	.	_

#Text=The results of one-way ANOVA showing abnormalities in amygdala-VPFC, amygdala-DLPFC and amygdala-dACC resting-state functional connectivity in the three group comparison.
161-1	31916-31919	The	_
161-2	31920-31927	results	_
161-3	31928-31930	of	_
161-4	31931-31938	one-way	_
161-5	31939-31944	ANOVA	_
161-6	31945-31952	showing	_
161-7	31953-31966	abnormalities	_
161-8	31967-31969	in	_
161-9	31970-31983	amygdala-VPFC	_
161-10	31983-31984	,	_
161-11	31985-31999	amygdala-DLPFC	_
161-12	32000-32003	and	_
161-13	32004-32017	amygdala-dACC	_
161-14	32018-32031	resting-state	_
161-15	32032-32042	functional	_
161-16	32043-32055	connectivity	_
161-17	32056-32058	in	_
161-18	32059-32062	the	_
161-19	32063-32068	three	_
161-20	32069-32074	group	_
161-21	32075-32085	comparison	_
161-22	32085-32086	.	_

#Text=Post hoc comparison showing Z values differences at peak voxel between each pair group (HC vs.
162-1	32087-32091	Post	_
162-2	32092-32095	hoc	_
162-3	32096-32106	comparison	_
162-4	32107-32114	showing	_
162-5	32115-32116	Z	_
162-6	32117-32123	values	_
162-7	32124-32135	differences	_
162-8	32136-32138	at	_
162-9	32139-32143	peak	_
162-10	32144-32149	voxel	_
162-11	32150-32157	between	_
162-12	32158-32162	each	_
162-13	32163-32167	pair	_
162-14	32168-32173	group	_
162-15	32174-32175	(	_
162-16	32175-32177	HC	_
162-17	32178-32180	vs	_
162-18	32180-32181	.	_

#Text=MDD, HC vs.
163-1	32182-32185	MDD	_
163-2	32185-32186	,	_
163-3	32187-32189	HC	_
163-4	32190-32192	vs	_
163-5	32192-32193	.	_

#Text=SZ, MDD vs.
164-1	32194-32196	SZ	_
164-2	32196-32197	,	_
164-3	32198-32201	MDD	_
164-4	32202-32204	vs	_
164-5	32204-32205	.	_

#Text=SZ), *p < 0.01.
165-1	32206-32208	SZ	_
165-2	32208-32209	)	_
165-3	32209-32210	,	_
165-4	32211-32212	*	_
165-5	32212-32213	p	_
165-6	32214-32215	<	_
165-7	32216-32220	0.01	_
165-8	32220-32221	.	_

#Text=HC, Healthy control; MDD, Major depressive disorder; SZ, Schizophrenia.
166-1	32222-32224	HC	_
166-2	32224-32225	,	_
166-3	32226-32233	Healthy	_
166-4	32234-32241	control	_
166-5	32241-32242	;	_
166-6	32243-32246	MDD	_
166-7	32246-32247	,	_
166-8	32248-32253	Major	_
166-9	32254-32264	depressive	_
166-10	32265-32273	disorder	_
166-11	32273-32274	;	_
166-12	32275-32277	SZ	_
166-13	32277-32278	,	_
166-14	32279-32292	Schizophrenia	_
166-15	32292-32293	.	_

#Text=L.VPFC, left ventral prefrontal cortex, L.DLPFC, left dorsal lateral prefrontal cortex, Bil.dACC, bilateral dorsal anterior cingulated cortex.
167-1	32294-32300	L.VPFC	_
167-2	32300-32301	,	_
167-3	32302-32306	left	_
167-4	32307-32314	ventral	_
167-5	32315-32325	prefrontal	_
167-6	32326-32332	cortex	_
167-7	32332-32333	,	_
167-8	32334-32341	L.DLPFC	_
167-9	32341-32342	,	_
167-10	32343-32347	left	_
167-11	32348-32354	dorsal	_
167-12	32355-32362	lateral	_
167-13	32363-32373	prefrontal	_
167-14	32374-32380	cortex	_
167-15	32380-32381	,	_
167-16	32382-32390	Bil.dACC	_
167-17	32390-32391	,	_
167-18	32392-32401	bilateral	_
167-19	32402-32408	dorsal	_
167-20	32409-32417	anterior	_
167-21	32418-32428	cingulated	_
167-22	32429-32435	cortex	_
167-23	32435-32436	.	_

#Text=Demographics, clinical characteristics and cognitive function of participants.
168-1	32437-32449	Demographics	_
168-2	32449-32450	,	_
168-3	32451-32459	clinical	_
168-4	32460-32475	characteristics	_
168-5	32476-32479	and	_
168-6	32480-32489	cognitive	_
168-7	32490-32498	function	_
168-8	32499-32501	of	_
168-9	32502-32514	participants	_
168-10	32514-32515	.	_

#Text=Number (n)\tMDD\tSZ\tHC\t \tp\t \t49\t45\t50\t \tDemographic characteristic\t \tGender (male/female)\t17/32\t19/26\t17/33\tχ2 = 0.83\t0.66\t \tAge (years), mean ± SD\t19.35 ± 6.03\t18.42 ± 3.84\t18.18 ± 3.92\tF = 0.46\t0.63\t \tEducation (years), mean ± SD\t12.12 ± 3.77\t10.71 ± 2.43\t11.92 ± 2.60\tF = 2.94\t0.05\t \tClinical characteristic\t \tHAMD score, mean ± SD\t20.86 ± 8.70\t9.52 ± 11.41\t1.32 ± 1.65\tF = 78.64\t0.000\t \tBPRS score, mean ± SD\t23.08 ± 8.20\t40.00 ± 13.03\t18.26 ± 0.86\tF = 38.39\t0.000\t \tHAMA score, mean ± SD\t17.14 ± 8.81\t6.93 ± 8.45\t0.78 ± 2.16\tF = 62.35\t0.000\t \tDuration of illness (months), mean ± SD\t4.59 ± 6.28\t4.32 ± 10.46\t—\tT = 0.158\t0.88\t \tCognitive function\t \t \tWCST\t(n = 28)\t(n = 29)\t(n = 33)\t \t \t \tcorrect responses\t26.21 ± 10.78\t19.52 ± 12.90\t28.61 ± 12.80\tF = 4.48\t0.01\t \tcategories completed\t2.89 ± 1.75\t1.72 ± 1.89\t3.70 ± 2.08\tF = 8.17\t0.001\t \tTotal errors\t21.79 ± 10.78\t28.55 ± 13.01\t19.39 ± 12.80\tF = 4.52\t0.01\t \tPerseverative errors\t8.75 ± 7.27\t14.10 ± 14.05\t8.79 ± 9.54\tF = 2.47\t0.09\t \tNon-perseverative errors\t13.04 ± 5.19\t14.38 ± 8.50\t10.61 ± 5.12\tF = 2.77\t0.07\t \t
#Text=MDD, Major depressive disorder; SZ, Schizophrenia; HC, Healthy controls; SD, Standard Deviation; HAMD, Hamilton Depression Rating Scale; BPRS, Brief Psychiatric Rating Scale; HAMA, Hamilton Anxiety Rating Scale, WCST, Wisconsin Card Sorting Test.
169-1	32516-32522	Number	_
169-2	32523-32524	(	_
169-3	32524-32525	n	_
169-4	32525-32526	)	_
169-5	32527-32530	MDD	_
169-6	32531-32533	SZ	_
169-7	32534-32536	HC	_
169-8	32537-32538	 	_
169-9	32539-32540	p	_
169-10	32543-32545	49	_
169-11	32546-32548	45	_
169-12	32549-32551	50	_
169-13	32554-32565	Demographic	_
169-14	32566-32580	characteristic	_
169-15	32583-32589	Gender	_
169-16	32590-32591	(	_
169-17	32591-32595	male	_
169-18	32595-32596	/	_
169-19	32596-32602	female	_
169-20	32602-32603	)	_
169-21	32604-32606	17	_
169-22	32606-32607	/	_
169-23	32607-32609	32	_
169-24	32610-32612	19	_
169-25	32612-32613	/	_
169-26	32613-32615	26	_
169-27	32616-32618	17	_
169-28	32618-32619	/	_
169-29	32619-32621	33	_
169-30	32622-32624	χ2	_
169-31	32625-32626	=	_
169-32	32627-32631	0.83	_
169-33	32632-32636	0.66	_
169-34	32639-32642	Age	_
169-35	32643-32644	(	_
169-36	32644-32649	years	_
169-37	32649-32650	)	_
169-38	32650-32651	,	_
169-39	32652-32656	mean	_
169-40	32657-32658	±	_
169-41	32659-32661	SD	_
169-42	32662-32667	19.35	_
169-43	32668-32669	±	_
169-44	32670-32674	6.03	_
169-45	32675-32680	18.42	_
169-46	32681-32682	±	_
169-47	32683-32687	3.84	_
169-48	32688-32693	18.18	_
169-49	32694-32695	±	_
169-50	32696-32700	3.92	_
169-51	32701-32702	F	_
169-52	32703-32704	=	_
169-53	32705-32709	0.46	_
169-54	32710-32714	0.63	_
169-55	32717-32726	Education	_
169-56	32727-32728	(	_
169-57	32728-32733	years	_
169-58	32733-32734	)	_
169-59	32734-32735	,	_
169-60	32736-32740	mean	_
169-61	32741-32742	±	_
169-62	32743-32745	SD	_
169-63	32746-32751	12.12	_
169-64	32752-32753	±	_
169-65	32754-32758	3.77	_
169-66	32759-32764	10.71	_
169-67	32765-32766	±	_
169-68	32767-32771	2.43	_
169-69	32772-32777	11.92	_
169-70	32778-32779	±	_
169-71	32780-32784	2.60	_
169-72	32785-32786	F	_
169-73	32787-32788	=	_
169-74	32789-32793	2.94	_
169-75	32794-32798	0.05	_
169-76	32801-32809	Clinical	_
169-77	32810-32824	characteristic	_
169-78	32827-32831	HAMD	_
169-79	32832-32837	score	_
169-80	32837-32838	,	_
169-81	32839-32843	mean	_
169-82	32844-32845	±	_
169-83	32846-32848	SD	_
169-84	32849-32854	20.86	_
169-85	32855-32856	±	_
169-86	32857-32861	8.70	_
169-87	32862-32866	9.52	_
169-88	32867-32868	±	_
169-89	32869-32874	11.41	_
169-90	32875-32879	1.32	_
169-91	32880-32881	±	_
169-92	32882-32886	1.65	_
169-93	32887-32888	F	_
169-94	32889-32890	=	_
169-95	32891-32896	78.64	_
169-96	32897-32902	0.000	_
169-97	32905-32909	BPRS	_
169-98	32910-32915	score	_
169-99	32915-32916	,	_
169-100	32917-32921	mean	_
169-101	32922-32923	±	_
169-102	32924-32926	SD	_
169-103	32927-32932	23.08	_
169-104	32933-32934	±	_
169-105	32935-32939	8.20	_
169-106	32940-32945	40.00	_
169-107	32946-32947	±	_
169-108	32948-32953	13.03	_
169-109	32954-32959	18.26	_
169-110	32960-32961	±	_
169-111	32962-32966	0.86	_
169-112	32967-32968	F	_
169-113	32969-32970	=	_
169-114	32971-32976	38.39	_
169-115	32977-32982	0.000	_
169-116	32985-32989	HAMA	_
169-117	32990-32995	score	_
169-118	32995-32996	,	_
169-119	32997-33001	mean	_
169-120	33002-33003	±	_
169-121	33004-33006	SD	_
169-122	33007-33012	17.14	_
169-123	33013-33014	±	_
169-124	33015-33019	8.81	_
169-125	33020-33024	6.93	_
169-126	33025-33026	±	_
169-127	33027-33031	8.45	_
169-128	33032-33036	0.78	_
169-129	33037-33038	±	_
169-130	33039-33043	2.16	_
169-131	33044-33045	F	_
169-132	33046-33047	=	_
169-133	33048-33053	62.35	_
169-134	33054-33059	0.000	_
169-135	33062-33070	Duration	_
169-136	33071-33073	of	_
169-137	33074-33081	illness	_
169-138	33082-33083	(	_
169-139	33083-33089	months	_
169-140	33089-33090	)	_
169-141	33090-33091	,	_
169-142	33092-33096	mean	_
169-143	33097-33098	±	_
169-144	33099-33101	SD	_
169-145	33102-33106	4.59	_
169-146	33107-33108	±	_
169-147	33109-33113	6.28	_
169-148	33114-33118	4.32	_
169-149	33119-33120	±	_
169-150	33121-33126	10.46	_
169-151	33127-33128	—	_
169-152	33129-33130	T	_
169-153	33131-33132	=	_
169-154	33133-33138	0.158	_
169-155	33139-33143	0.88	_
169-156	33146-33155	Cognitive	_
169-157	33156-33164	function	_
169-158	33165-33166	 	_
169-159	33169-33173	WCST	_
169-160	33174-33175	(	_
169-161	33175-33176	n	_
169-162	33177-33178	=	_
169-163	33179-33181	28	_
169-164	33181-33182	)	_
169-165	33183-33184	(	_
169-166	33184-33185	n	_
169-167	33186-33187	=	_
169-168	33188-33190	29	_
169-169	33190-33191	)	_
169-170	33192-33193	(	_
169-171	33193-33194	n	_
169-172	33195-33196	=	_
169-173	33197-33199	33	_
169-174	33199-33200	)	_
169-175	33201-33204	 	 	_
169-176	33207-33214	correct	_
169-177	33215-33224	responses	_
169-178	33225-33230	26.21	_
169-179	33231-33232	±	_
169-180	33233-33238	10.78	_
169-181	33239-33244	19.52	_
169-182	33245-33246	±	_
169-183	33247-33252	12.90	_
169-184	33253-33258	28.61	_
169-185	33259-33260	±	_
169-186	33261-33266	12.80	_
169-187	33267-33268	F	_
169-188	33269-33270	=	_
169-189	33271-33275	4.48	_
169-190	33276-33280	0.01	_
169-191	33283-33293	categories	_
169-192	33294-33303	completed	_
169-193	33304-33308	2.89	_
169-194	33309-33310	±	_
169-195	33311-33315	1.75	_
169-196	33316-33320	1.72	_
169-197	33321-33322	±	_
169-198	33323-33327	1.89	_
169-199	33328-33332	3.70	_
169-200	33333-33334	±	_
169-201	33335-33339	2.08	_
169-202	33340-33341	F	_
169-203	33342-33343	=	_
169-204	33344-33348	8.17	_
169-205	33349-33354	0.001	_
169-206	33357-33362	Total	_
169-207	33363-33369	errors	_
169-208	33370-33375	21.79	_
169-209	33376-33377	±	_
169-210	33378-33383	10.78	_
169-211	33384-33389	28.55	_
169-212	33390-33391	±	_
169-213	33392-33397	13.01	_
169-214	33398-33403	19.39	_
169-215	33404-33405	±	_
169-216	33406-33411	12.80	_
169-217	33412-33413	F	_
169-218	33414-33415	=	_
169-219	33416-33420	4.52	_
169-220	33421-33425	0.01	_
169-221	33428-33441	Perseverative	_
169-222	33442-33448	errors	_
169-223	33449-33453	8.75	_
169-224	33454-33455	±	_
169-225	33456-33460	7.27	_
169-226	33461-33466	14.10	_
169-227	33467-33468	±	_
169-228	33469-33474	14.05	_
169-229	33475-33479	8.79	_
169-230	33480-33481	±	_
169-231	33482-33486	9.54	_
169-232	33487-33488	F	_
169-233	33489-33490	=	_
169-234	33491-33495	2.47	_
169-235	33496-33500	0.09	_
169-236	33503-33520	Non-perseverative	_
169-237	33521-33527	errors	_
169-238	33528-33533	13.04	_
169-239	33534-33535	±	_
169-240	33536-33540	5.19	_
169-241	33541-33546	14.38	_
169-242	33547-33548	±	_
169-243	33549-33553	8.50	_
169-244	33554-33559	10.61	_
169-245	33560-33561	±	_
169-246	33562-33566	5.12	_
169-247	33567-33568	F	_
169-248	33569-33570	=	_
169-249	33571-33575	2.77	_
169-250	33576-33580	0.07	_
169-251	33584-33587	MDD	_
169-252	33587-33588	,	_
169-253	33589-33594	Major	_
169-254	33595-33605	depressive	_
169-255	33606-33614	disorder	_
169-256	33614-33615	;	_
169-257	33616-33618	SZ	_
169-258	33618-33619	,	_
169-259	33620-33633	Schizophrenia	_
169-260	33633-33634	;	_
169-261	33635-33637	HC	_
169-262	33637-33638	,	_
169-263	33639-33646	Healthy	_
169-264	33647-33655	controls	_
169-265	33655-33656	;	_
169-266	33657-33659	SD	_
169-267	33659-33660	,	_
169-268	33661-33669	Standard	_
169-269	33670-33679	Deviation	_
169-270	33679-33680	;	_
169-271	33681-33685	HAMD	_
169-272	33685-33686	,	_
169-273	33687-33695	Hamilton	_
169-274	33696-33706	Depression	_
169-275	33707-33713	Rating	_
169-276	33714-33719	Scale	_
169-277	33719-33720	;	_
169-278	33721-33725	BPRS	_
169-279	33725-33726	,	_
169-280	33727-33732	Brief	_
169-281	33733-33744	Psychiatric	_
169-282	33745-33751	Rating	_
169-283	33752-33757	Scale	_
169-284	33757-33758	;	_
169-285	33759-33763	HAMA	_
169-286	33763-33764	,	_
169-287	33765-33773	Hamilton	_
169-288	33774-33781	Anxiety	_
169-289	33782-33788	Rating	_
169-290	33789-33794	Scale	_
169-291	33794-33795	,	_
169-292	33796-33800	WCST	_
169-293	33800-33801	,	_
169-294	33802-33811	Wisconsin	_
169-295	33812-33816	Card	_
169-296	33817-33824	Sorting	_
169-297	33825-33829	Test	_
169-298	33829-33830	.	_

#Text=Brain regions showing significant changes in the bilateral amygdala functional connectivity.
170-1	33831-33836	Brain	_
170-2	33837-33844	regions	_
170-3	33845-33852	showing	_
170-4	33853-33864	significant	_
170-5	33865-33872	changes	_
170-6	33873-33875	in	_
170-7	33876-33879	the	_
170-8	33880-33889	bilateral	_
170-9	33890-33898	amygdala	_
170-10	33899-33909	functional	_
170-11	33910-33922	connectivity	_
170-12	33922-33923	.	_

#Text=Cortical Regions (Brodmann Areas)\tMNI Coordinates\t \tCluster Size\tX\tY\tZ\tT valuesa\t \tLeft ventral prefrontal cortex (47)\t58\t−24\t15\t−21\t5.30\t \tLeft dorsal lateral prefrontal cortex (9/10)\t76\t−27\t54\t30\t8.03\t \tBilateral dorsal anterior cingulate cortex (24/32)\t165\t6\t12\t39\t7.45\t \t
#Text=aThese findings correspond to a corrected P < 0.05 by AlphaSim correction.
171-1	33924-33932	Cortical	_
171-2	33933-33940	Regions	_
171-3	33941-33942	(	_
171-4	33942-33950	Brodmann	_
171-5	33951-33956	Areas	_
171-6	33956-33957	)	_
171-7	33958-33961	MNI	_
171-8	33962-33973	Coordinates	_
171-9	33976-33983	Cluster	_
171-10	33984-33988	Size	_
171-11	33989-33990	X	_
171-12	33991-33992	Y	_
171-13	33993-33994	Z	_
171-14	33995-33996	T	_
171-15	33997-34004	valuesa	_
171-16	34007-34011	Left	_
171-17	34012-34019	ventral	_
171-18	34020-34030	prefrontal	_
171-19	34031-34037	cortex	_
171-20	34038-34039	(	_
171-21	34039-34041	47	_
171-22	34041-34042	)	_
171-23	34043-34045	58	_
171-24	34046-34047	−	_
171-25	34047-34049	24	_
171-26	34050-34052	15	_
171-27	34053-34054	−	_
171-28	34054-34056	21	_
171-29	34057-34061	5.30	_
171-30	34064-34068	Left	_
171-31	34069-34075	dorsal	_
171-32	34076-34083	lateral	_
171-33	34084-34094	prefrontal	_
171-34	34095-34101	cortex	_
171-35	34102-34103	(	_
171-36	34103-34104	9	_
171-37	34104-34105	/	_
171-38	34105-34107	10	_
171-39	34107-34108	)	_
171-40	34109-34111	76	_
171-41	34112-34113	−	_
171-42	34113-34115	27	_
171-43	34116-34118	54	_
171-44	34119-34121	30	_
171-45	34122-34126	8.03	_
171-46	34129-34138	Bilateral	_
171-47	34139-34145	dorsal	_
171-48	34146-34154	anterior	_
171-49	34155-34164	cingulate	_
171-50	34165-34171	cortex	_
171-51	34172-34173	(	_
171-52	34173-34175	24	_
171-53	34175-34176	/	_
171-54	34176-34178	32	_
171-55	34178-34179	)	_
171-56	34180-34183	165	_
171-57	34184-34185	6	_
171-58	34186-34188	12	_
171-59	34189-34191	39	_
171-60	34192-34196	7.45	_
171-61	34200-34206	aThese	_
171-62	34207-34215	findings	_
171-63	34216-34226	correspond	_
171-64	34227-34229	to	_
171-65	34230-34231	a	_
171-66	34232-34241	corrected	_
171-67	34242-34243	P	_
171-68	34244-34245	<	_
171-69	34246-34250	0.05	_
171-70	34251-34253	by	_
171-71	34254-34262	AlphaSim	_
171-72	34263-34273	correction	_
171-73	34273-34274	.	_
